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There is a clear and well-established need for new antibiotics. The biosynthesis of
the antibiotic mupirocin is an important model trans-AT polyketide synthase pathway.
A key tailoring step is the removal of a hydroxyl from the intermediate pseudomonic
acid B (PA-B), which generates active pseudomonic acid A (PA-A). This is proposed
to occur on discrete proteins after release from enzyme MmpB.
In this work, a systematic screen for genes required for this key step was devel-
oped, which implicated ten genes. On a multi-gene expression plasmid, these ten
genes encoded all functions necessary for conversion. This re-identified seven genes
from the existing proposed model. A novel requirement for MupM, MupN, and the
DNA sequence but not protein function of MupL was uncovered. This represents the
first identification of all genes required for this surprisingly convoluted pathway.
With the aim of re-engineering the location of these tailoring steps, domains
from thiomarinol enzyme TmpB were inserted into MmpB. Low-level conversion
to PA-A was achieved using thiomarinol tailoring enzymes. The TmpB KS0 domain
was used to load the normally free-standing MacpE, and high-level conversion was
achieved on the hybrid enzyme. This success opens the future path to further MmpB
modifications to generate mupirocin derivatives.
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1.1 The importance of natural products
1.1.1 Natural products have had a key historical role in drug dis-
covery
Natural products have had a key role in both the discovery and production of new
medicines throughout history. Drugs have been developed from natural products
in a wide variety of compound classes and functions. Different natural product
biosynthesis mechanisms combine to yield a large diversity of complex structures.
The diverse structures of the examples described in this section are displayed in
Figure 1.1.
A range of antibiotics have been identified and derived from natural products,
such as the iconic penicillin, discovered in Penicillium fungi by Fleming (1929), or
streptomycin discovered by Waksman (1953). Both of these discoveries were of huge
importance to the scientific and medical communities, and as such both won the
Nobel Prize in Physiology or Medicine, in 1945 and 1952 respectively. The first of the
aminoglycoside class discovered, streptomycin, is produced by Streptomyces griseus.
The Streptomyces genus has proved particularly fruitful in antibiotic discovery, with
more than 4500 antibiotics discovered in Streptomyces bacteria (Challinor and Bode,
2015).
Natural products are not limited to antibiotics or microorganisms. For example,
the household drug aspirin is named after the plant genus Spiraea, the source of
salicylic acid from which it is derived; marketed by Bayer AG in 1899 (Sneader, 1997).
Another example of high profile natural products are the cholesterol lowering statins,
such as lovastatin or simvastatin (Alberts et al., 1980; Mol et al., 1988). Both were
identified from the fungus Aspergillus terreus, and have become hugely successful
natural product derived drugs. Simvastatin was the most commonly prescribed NHS




















































































Figure 1.1: Examples of the diversity of natural product structures
Further to the relatively modern examples given so far, there are examples of
historical use of natural products for medicinal purposes, such as the anti-parasitic
artemisin. Artemisin is produced by the plant Artemisia annua, and the herb has been
used historically in traditional Chinese medicine for the treatment of malaria. The
compound Artemisin was discovered through a screen of more than 2000 Chinese
herb preparations, and together with semi-synthetic derivatives, is in current medic-
inal use (Tu, 2011). Youyou Tu was awarded a joint Nobel Prize in Physiology or
Medicine in 2015 for its discovery.
There are also natural product derived anti-cancer and anti-fungal drugs, such
as epothilones and caspofungin (Cragg and Newman, 2013). Secondary metabolites,
isolated from a variety of both prokaryotes and eukaryotes, have had a key role in
the historical development of a wide range of medical drugs.
3
1.1.2 The urgent need for new antibiotics
There has been a seemingly inexorable rise in antibiotic resistance over the last
century, with a positive correlation to antibiotic consumption (Bell et al., 2014). In
the classical example of penicillin, resistance was first observed in 1940, before its
clinical use (Abraham and Chain, 1940). This is understandable from an evolutionary
perspective, as there would be selective pressure on the development of resistance
for microbes growing in the same environment as an antibiotic producer. Further to
this, microbes that produce antibiotics need some method to avoid action against self,
which could provide a source of resistance genes for horizontal transfer. As clinical
use of penicillin and its derivatives increased, resistance became more widespread;
for example 40% of Streptococcus pneumoniae infections in Spain resistant by 1989
(Baquero et al., 1991).
Methicillin, a semi-synthetic derivative of penicillin, was developed by Beechams
in 1959. Whilst there was some expectation that its synthetic nature would limit the
development of resistance, resistant Staphyloccus infections were observed just two
years later (Jevons, 1961).
The case study of vancomycin demonstrates that resistance can and will develop
against antibiotics with alternative targets. Discovered in 1952, vancomycin was
targeted at treating β-lactam resistant Staphlococcus infections, although its use was
initially limited due to toxicity and more effective alternatives (Geraci et al., 1956;
Moellering, 2012). Vancomycin works by binding N-acetylmuramic acid (NAM) and
N-acetylglucosamine (NAG) of the gram positive cell wall, preventing cross-linking
of peptidoglycan (Barna and Williams, 1984). Following an increase in clinical use
in the 1980s, vancomycin resistance was observed in Enterococcus infections by 1986
(Leclercq et al., 1988). In 2002, highly vancomycin resistant Staphylococcus aureus was
clinically isolated, carrying resistance gene, vanA, presumably aquired by horizontal
gene transfer, which encodes an altered vancomycin cell wall binding site (Tenover,
2006).
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Under the selective pressure of antibiotic use, resistance can arise from a variety
of different mechanisms, some examples of which are summarised in Table 1.1 (Blair
et al., 2015). The unyielding advance in antibiotic resistance has led to an urgent
need for new effective compounds. Large pharmaceutical companies have spent
large amounts on drug development; for example GlaxoSmithKline spent £2.3 billion
on the search for new pharmaceuticals in 2015 (GlaxoSmithKline, 2016). However,
there are policy issues that limit the attractiveness of investment in new antibiotic
development by big pharmceutical companies (Piddock, 2012; Sinha and Kesselheim,
2016; Sciarretta et al., 2016). Antibiotics have a lifespan limited by resistance, and
are typically prescribed over short term periods, which yields less revenue than
long-term drugs such as statins. With the looming threat of resistance, effective new
compounds can be shelved by national healthcare providers to provide a last line of
defence. Unfortunately, this can allow patents to lapse before significant revenue is
achieved by the pharmaceutical company that developed it, which makes antibiotic
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drug discovery an unattractive financial prospect. Policy changes are needed to rem-
edy this; some have already been made such as the Generating Antibiotics Incentives
Now act in the USA, which guarantees market exclusivity for new antibiotics for 5
further years after the patent has lapsed (Bax and Green, 2014).
1.1.3 Antibiotic development strategies
The strategies used to develop antibiotics has evolved over the last century, largely
out of necessity due to antibiotic resistance . Broadly, in the early 20th Century,
unmodified natural products such as penicillin proved effective drugs. In the late
20th Century, medicinal chemistry took over, with the development of chemically
modified natural products that were often broadly effective natural products (Brown
and Wright, 2016). Worryingly, in recent years there has been little discovery of truly
novel antibiotics that are as broadly effective as the early generations. Therefore,
consideration of the avenues available for antibiotic discovery is of vital importance.
1.1.3.1 Synthetic compound generation
There are historical examples of outright fully synthetic antibiotics, such as nalidixic
acid, which was used in the 1960s and 1970s to treat urinary tract infections (Em-
merson and Jones, 2003). However, the largest impact chemical synthesis has had on
antibiotic development is through the semi-synthesis of derivatives of existing com-
pounds, which has improved the qualities and extended the life of existing classes of
antibiotics.
Small synthetic compound library screening
In the late 1990s, there was a push towards the development of small compound li-
braries through combinatorial chemistry termed combichem. Such libraries were then
tested against specific conditions, typically testing for the MIC against a pathogen
(Trias, 2001). Whilst results were initially optimistic, in the long term combichem
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has failed to have a significant impact on drug development (Lowe, 2014). This is
largely as the core chemical scaffolds of the libraries were quite limited, as large
natural product-like compounds typically take a large number of synthesis steps. For
example, total synthesis of erythromycin A was achieved in 52 steps with less than
0.01% yield (Woodward et al., 1981).
Synthetic library generation has since evolved towards Diversity Orientated Syn-
thesis (DOS), with a focus on generation of a wider range of scaffolds. DOS libraries
have not yet achieved wide-scale diversity equivalent to that seen in natural prod-
ucts (Galloway et al., 2009), although efforts are ongoing, such as the syntheses of
erythromycin-like macrocycles (Ciardiello et al., 2016; Seiple et al., 2016). A simi-
lar approach has been attempted using peptides, with libraries of diverse peptides
yielding some hits for antimicrobial activity against Escherichia coli (Hilpert et al.,
2005). Development of libraries of synthetic compounds, which mimic the diversity
of structures found in natural products, remains an attractive goal for future drug
development.
Semi-synthetic modification of existing structures
The synthetic modification of existing natural products has historically been
hugely successful, yielding new generations of a variety of different clinically impor-
tant antibiotics. An early example is the semi-synthesis of tetracycline from chlorote-
tracycline discovered at Pfizer (Wright et al., 2014). Synthetic modification of existing
scaffolds has produced new generations of different antibiotic classes, with various
potentially improved characteristics. Recently, synthetic modifications to vancomycin
have been reported to increase potency 200-fold against resistant pathogens (Okano
et al., 2017).
A fully-synthetic example is the quinolone antibiotics, where successive synthetic
modifications have been made to yield multiple generations of antibiotics (Figure 1.2).
Starting from the accidental generation of nalidixic acid in 1962 (Lesher et al., 1962),
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newer generations have some improved characteristics. For example, 3rd generation
quinolones such as levoflaxin are active against Streptococci, and the 4th generation



































Figure 1.2: The synthetic generations of quinolone antibiotics.
Each generation of the quinolone antibiotics has the core structure (in black). The
modifications (in red), have furthered the effectiveness of these antibiotics.
1.1.3.2 Identification of new antibiotic scaffolds
Whilst semi-synthetic approaches have been successful in further developing an-
tibiotics, there is a clear need for new antimicrobial scaffolds, which would essentially
open new avenues of modification by medicinal chemistry.
Screening new species
Historically, screening of different species for new antimicrobial compounds has
yielded a variety of antibiotics, such as penicillin, erythromycin and streptomycin.
However, identification of new antibiotics has faltered as the most accessible, easily
culturable, antibiotic producers have been identified. There are a large proportion of
organisms that are not conventially culturable in the lab, with estimates at approxi-
mately 1% or less of bacteria are lab-culturable (Bérdy, 2012; Clardy et al., 2006; Singh
and Pelaez, 2008). Screening still has the potential to provide new scaffolds, but a
more modern approach needs to be considered.
An example is the discovery of the non ribosomal peptide synthase (NRPS) de-
rived antibiotic teixobactin, representative of a new class of antibiotic (Ling et al.,
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2015). Teixobactin is produced by the previously unidentified gram negative, Eleft-
heria terrae, which was cultured using a modern technology called iChip. In this cul-
turing method, a soil sample is diluted and loaded to approximately one bacterium
per channel of the iChip, which is inserted back into the native soil. The device has
two semi-permeable membranes, which in effect allow the colony to grow separate
from other microbes, yet in its native environment. The screening of previously un-
culturable bacteria through techniques such as iChip, opens exciting possibilities of
the identification of novel natural products.
The authors infer that due to its multiple modes of action, resistance to teixobactin
and its future derivatives is unlikely to develop (Ling et al., 2015). Historically,
similar claims have proven false, and whilst it seems plausible resistance may develop
more slowly, it seems likely to arise eventually (Von Nussbaum and Süssmuth, 2015).
Logically, there will have been evolutionary selective pressure on the development
of resistance in microorganisms growing in proximity to the teixobactin producer,
E. terrae (Piddock, 2015). The gram negative E. terrae does not have a teixobactin
resistance gene, as the compound is only effective again gram positives, a limitation
on its potential use as a clinical antibiotic. Therefore, there is not a host resistance
gene that other organisms could aquire by horizontal gene transfer (Wright, 2015).
An alternative approach to finding new species, is to look in more niche environ-
ments. A recent example is the discovery of a human nose commensal, Staphylococcus
lugdunensis, which produces the antibiotic lugdunin (Zipperer et al., 2016). This
NRPS-derived antibiotic is able to prevent the colonisation of opportunistic pathogen
S. aureus, with the intriguing future possibility of preventative treatment with the
commensal (Lewis and Strandwitz, 2016).
Genomics based approaches
With the advent of successive high-throughput sequencing technologies, the
cost of whole genome sequencing has fallen, and there has been an increase in the
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volume of genomic data available. Bioinformatic technology has advanced, with
servers and algorithms such as antiSMASH facilitating the quick identification of
secondary metabolite genome clusters from these data (Medema et al., 2011). After
these genomics techniques identify potential silent biosynthetic clusters, molecular
approaches can then be undertaken with the aim of turning on the pathway, and
identifying new secondary metabolites (Zarins-Tutt et al., 2016).
One approach is to clone the identified biosynthetic clusters to heterologous hosts.
An example of this was performed in gram negative Photorhabdus luminescens, where
10 unknown biosynthetic gene clusters were cloned to plasmids and mobilised to
E. coli. This resulted in the discovery of several related new compounds, named
luminmycins (Bian et al., 2012).
An alternative is to modify the regulation of gene expression to turn on silent
clusters. One successful example of this was performed in the model fungus As-
pergillus nidulans (Bergmann et al., 2010). A silent NRPS cluster was identified in the
genome, flanked by gene encoding a putative regulator scpR. Over-expression of this
regulator from a plasmid activated expression of a second polyketide synthase (PKS)
gene cluster, producing the compound asperfuranone. Similar experiments have been
sucessful in turning on silent clusters in Streptomyces (Laureti et al., 2011).
Biosynthetic engineering
Biosynthetic engineering is the in vivo modification of biosynthesis pathways to
yield different secondary metabolites. Whilst knowledge of the mechanisms under-
pinning such pathways is required, engineering experiments also further that same
knowledge. Indeed, an important advantage to these approaches is that insights
gained in one pathway can be used to further the redesign of others. In cases such
as mupirocin (El-Sayed et al., 2003), where the natural product is industrially pro-
duced by fermentation of a producing microbe, re-engineered pathways could have
the advantage of being economically viable. Assuming a suitable yield is produced,
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the modified compounds could be industrially purified from fermentation broths in
a similar fashion to the parent compound.
Genetic engineering of PKS and NRPS biosynthetic pathways, through swapping
or mutagenesis of domains, has already yielded new derivative metabolites in a
variety of systems (Dunn and Khosla, 2013; Weissman, 2016). Examples include the
generation of a library of erythromycin analogs through feeding of fatty acids to a
strain containing a hybrid avermectin-erythromycin biosynthesis cluster (Pacey et al.,
1998), and the alteration of stereochemistry by KR swaps (Annaval et al., 2015). New
epothilone analogs have been generated by engineering of the growth media in a
heterologous host (Frykman et al., 2002).
Another example of such an approach was performed on anti-fungal amphotericin
B, produced by a PKS pathway in the soil bacterium Streptomyces nodosus (Caffrey
et al., 2001). When ketoreductase (KR) domain 16 was knocked out, a new ampho-
tericin B derivative also with anti-fungal activity was produced (Power et al., 2008).
A further example involved daptomycin biosynthesis, a lipopeptide antibiotic in
clinical use, developed by Cubist Pharmaceuticals. Daptomycin consists of a NRPS
produced peptide linked to a lipid and the biosynthesis cluster has been identified in
Steptomyces roseosporus (Miao et al., 2005). New daptomycin derivatives were isolated
following the expression of heterologous NRPS genes in a dptD (NRPS) knockout
(Table 1.2) (Miao et al., 2006). The heterologous genes expressed were lptD from
A54145 biosynthesis and cdaPS3 from calcium dependent antibiotic (CDA) biosynthe-
Table 1.2: Re-engineering daptomycin biosynthesis through expression of heterol-
ogous NRPS genes in S. roseosporus ∆dptD (Miao et al., 2006)
Amino acid position 12 Amino acid position 13 NRPS gene Gene source
MeGlu Trp dptD Daptomycin
Glu Trp cdaPS3 CDA
Glu Ile/Val lptD A54145
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sis, both are similar lipopeptide antibiotics produced by Streptomyces species. The new
derivative compounds demonstrated lower antimicrobial activity against S. aureus
and Enterococcus faecalis. Nevertheless, this remains an exciting demonstration that
new natural product derivatives can be generated from biosynthetically engineered
hybrid pathways.
1.2 The biosynthesis of natural products
1.2.1 Fatty acid biosynthesis
Describing fatty acid biosynthesis is a sensible prelude to polyketide biosynthesis,
as they share similar chemistries and enzymology. However, fatty acid biosynthesis
lacks the variety of extender units and non-essential modules seen in polyketide
biosynthesis.
1.2.1.1 Enzymology of fatty acid biosynthesis
The fatty acid biosynthesis cycle is summarised in Figure 1.3. Fatty acid biosyn-
thesis begins with the loading of an acetate starter unit from acetyl-CoA onto the
ketosynthase (KS) via an acyl carrier protein (ACP), catalysed by a malonyl-acetyl
transferase (MAT). This acetate is attached as a thiol to a conserved cysteine on the
KS. The ACP is post-translationally modified with a prosthetic flexible phosphopan-
tetheine (PP) arm from CoA, which is held on a conserved serine residue. The PP
arm is long and flexible, which aids the ACP in the delivery of intermediates to the
various domains. A malonate extender unit is loaded from malonyl-CoA onto the
PP arm of the ACP as a thiol, catalysed by the MAT. The ketosynthase catalyses
a condensation between the starter and extender unit, adding two carbons with a
β-keto group to the starter unit, and leaving the chain on the ACP.
The added β-keto group is then reduced to a hydroxyl catalysed by a ketoreduc-
tase (KR) domain, dehydrated by a dehydratase (DH), and further reduced by an
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Figure 1.3: The fatty acid biosynthetic pathway.
After 7 cycles of addition and reduction of a β-keto group, the palmitic acid (16 car-
bons) is released, catalysed by the TE domain. Other length fatty acids are produced
by variation in the number of cycles, for example, 8 cycles would generate stearic
acid (18 carbons).
Initially, R=CH3, but it is then increased by two carbons for each biosynthetic cycle.
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enoyl reductase (ER). This results in the fully reduced, saturated extension of the
fatty acid by two carbons.
The growing chain is transferred to the KS, and a new malonate extender unit
loaded onto the ACP by the MAT. Again the KS catalyses a condensation, extending
the chain by two carbons, and the KR, DH and ER domains reduce the added β-
keto group. After successive cycles, the thioester is cleaved by the thioesterase (TE),
releasing the fatty acid product (Staunton and Weissman, 2001; Magnuson et al.,
1993).
There are several factors that influence the chain length produced. The MAT can
catalyse the transfer between CoA and the ACP/KS in both directions, but favours
two and four carbon chains. This prevents the release of the longer FAS-derived acids
through transfer to CoA. The rate of elongation rapidly reduces at more than 16
carbons, and the TE domain demonstrates specificity towards fatty acids with 16 or
more carbons. The combination of these factors control chain length (Smith et al.,
2003).
1.2.1.2 Structural organisation of fatty acid synthases
All these enzymatic domains (KS, MAT, ACP, KR, DH, ER, TE) together form
fatty acid synthases (FAS). The organisations of these domains can be classified into
two types. In type I FAS, as seen in mammals, these domains are all present on a
single polypeptide. In type II FAS, as seen in bacteria, the domains are on separate
polypeptides that complex to give the FAS holoenzyme (Campbell and Cronan Jr.,
2001).
The structure of the mammalian type I FAS has been solved (Figure 1.4) (Maier
et al., 2008). The FAS forms a dimer, with the KS and MAT at the bottom, and the
modifying domains (KR, DH, ER) at the top. The ACP and TE domains were not
solved in the X-ray structure. This is likely because the ACP domain is allowed to
flex by a linker, and therefore shuttle the fatty acid intermediates between the various
14
domains.
Figure 1.4: The structure of a mammalian type I FAS.
Two non-enzymatic pseudo domains were identified, pseudo-methyltransferase
(ΨME) and pseudo-ketoreductase (ΨKR). The ACP and TE domains were not solved
in the X-ray structure. The dehydratase domain was discovered to form a dimer of
two hot dog folds, labelled DH1 and DH2. Reproduced from Maier et al. (2008).
1.2.2 Polyketide biosynthesis
Polyketide synthase (PKS) enzymes function in a very similar fashion to fatty
acid synthases. The core PKS module has an ACP, which holds the extender unit
and growing chain, an AT, which loads the ACP, and a KS, which catalyses the
condensation. Whereas in fatty acid biosynthesis a KR, DH and ER are always
present, in PKS enzymes some or all of these are often missing. PKSs can incorporate
a range of starter and extender units, whereas FAS typically only use acetate and
malonate respectively. Polyketide pathways often include tailoring enzymes, which
further modify the polyketide, before the final compound is produced.
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1.2.2.1 The types of polyketide synthase enzymes
There are three broad classes of PKS enzymes. Type I have all their domains cova-
lently linked, such that they are on the same peptide. These can be modular, where
there is one module to catalyse each Claisen condensation, as is seen in rapamycin
biosynthesis for example (Staunton and Wilkinson, 1997). Type I PKSs can also be iter-
ative, where one ketosynthase catalyses multiple condensations; an example of this is
lovastatin biosynthesis, also known for being one of the first natural Diels-Alderases
identified (Auclair et al., 2000). Both type I modular and iterative PKSs are used in
mupirocin and thiomarinol biosynthesis, the focus of this work. In type II PKSs, each
domain is on a discrete peptide, such as in actinorhodin biosynthesis. Finally, type III
PKSs lack ACPs, and function iteratively; an example is flavolin biosynthesis (Shen
et al., 2002).
Type I PKSs can be further divided into cis-AT, where the acyl transferase (AT)
domain is positioned behind the KS on the same peptide, and trans-AT where the AT
is on a separate peptide to the remaining PKS domains (Piel, 2010).
1.2.2.2 Erythromycin biosynthesis
Erythromycin biosynthesis is the best-studied type I modular PKS pathway. The
biosynthesis genes were located in 1989 by genomic mapping of non-producer Sac-
charopolyspora erythraea mutants (Vara et al., 1989), and partially sequenced in 1990 by
“walking along the chromosome” from the resistance gene ermE (Cortes et al., 1990).
Three large genes were identified, eryAI, eryAII, and eryAIII; these encode the cis-AT
PKS enzymes named DEBS1, DEBS2, and DEBS3 respectively. Each protein has two
modules, to give six in total (Figure 1.5) (Bevitt et al., 1992; Donadio et al., 1991).
Interaction between the three peptides is governed by N and C terminal docking
domains (Weissman, 2006).
DEBS1 begins with a loading module, consisting of an acyl transferase (AT) and
an ACP domain. The ACP is activated through the transfer of a phosphopantetheine
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Post – PKS processing
6 – Deoxyerythronolide BErythromycin - A
DEBS 1 DEBS 2 DEBS 3
Figure 1.5: The erythromycin biosynthesis pathway.
The PKS pathway consists of six modules spread over three peptides. Each mod-
ule catalyses a successive Claisen condensation, and the KR, DH and ER domains
modify the β-keto groups where present. The thioesterase domain both releases the
polyketide and catalyses cyclisation, yielding 6-Deoxyerythronolide B. This is then
processed by tailoring enzymes to give erythromycin (Bevitt et al., 1992; Donadio
et al., 1991).
(PP) arm from CoA onto a conserved serine on the ACP, catalysed by a phosphopan-
tetheinyltransferase, giving the holoenzyme (Chan et al., 2009). A propionate starter
unit is loaded onto the PP arm of the first ACP by the AT domain. In each of the
six modules, the KS catalyses the condensation of the growing polyketide with a
methylmalonate extender unit.
Each additional β-keto group is modified as dictated by the presence of the op-
tional modules. Module 1 has a KR domain, and therefore the β-keto is reduced to
a hydroxy group. Module 3 has none of the optional domains, and therefore the
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β-keto is not modified, whereas module 4 has a KR, DH, and ER, and the group
is therefore fully reduced, like in fatty acid biosynthesis. After the six condensa-
tions, the TE domain catalyses release and cyclisation of the polyketide. As is typical
for polyketide natural products, the polyketide released by the PKS is not the final
secondary metabolite (Staunton and Weissman, 2001). Tailoring enzymes catalyse
further modifications to give the final product, erythromycin.
1.2.2.3 The structure of a type I PKS enzyme
Historically, solving of the structure of a complete PKS has proven difficult due
to their large size (Weissman, 2015), although the structure of PKS PikAIII from
pikromycin has been solved relatively recently (Dutta et al., 2014). Pikromycin is a
macrolide antibiotic produced by Streptomyces venezuelae. The biosynthetic cluster
was identified in 1998 (Xue et al., 1998); four genes encode four type I modular PKS
enzymes with six modules in total. The structure was obtained for PikAIII, which
has one module consisting of KS, AT, KR and ACP (Figure 1.6).
Like mammalian FAS, PikAIII forms a dimer, although the organisation of the
domains is clearly different. The AT and KR domains are close together, whereas the
MAT and KR domains in mammalian FAS are further apart (Figure 1.4). However,
some differences are to be expected given the lack of DH and ER domains in PikAIII.
The ACP domains were observed to occupy two positions, one near the KR and
one near the KS. Mirroring the assigned role in fatty acid biosynthesis, the ACP is
positioned to shuttle intermediates around the catalytic domains.
Whilst the insight into a complete PKS enzyme is extremely valuable, there is
significant variability in the domain composition of PKS enzymes. As previously
discussed, PKS enzymes can have all, some of, or none of the KR, DH, ER domains.
Trans-AT systems exist where the AT domain is on a separate peptide (Piel, 2010);
indeed mupirocin (Section 1.3) and thiomarinol (Section 1.4) are example trans-AT
PKS systems. With this variability in the make up of modules in PKS enzymes,
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Figure 1.6: The structure of type I modular PKS PikAIII.
In a similar fashion to mammalian FAS, PikAIII was observed as a dimer. However,
the AT domains appear closer to the KR side than the equivalent MAT in FAS. The
ACP localised in two positions, the one near the KR and one near the KS. This is
evidence of the flexibility that would allow the ACP to shuttle intermediates around
the various domains. Modified from Dutta et al. (2014).
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structural diversity could still be expected. Indeed functionality of PikAIII seems
tied to conformational changes of the KR, which could not happen if the KR is not
present.
1.2.3 Nonribosomal peptide synthases
Nonribosomal peptides (NRP) are another important class of secondary metabo-
lites, that includes vancomycin. They are synthesised by nonribosomal peptide syn-
thases (NRPS), which are very large enzymes; for example cyclosporin A is 1.6 MDa
(Weber et al., 2015). The core NRPS module consists of three domains, adenylation
(A), peptidyl carrier protein (PCP) and condensation (C) (Figure 1.7).
Figure 1.7: Nonribosomal peptide biosynthesis.
The diagram represents a minimal NRPS protein. The adenylation domains specif-
ically select and activates amino acids. These are transferred onto the PP arm of
the following PCP domains, where the condensation domain catalyses peptide bond
formation. Typically NRPS proteins will have multiple modules, and the growing
peptide will be synthesised by successive condensation domains.
Typically, NRP biosynthesis begins with an adenylation domain, which selects the
amino acid to be activated. There is a region of approximately 10 amino acids on the
A domain responsible for substrate specificity (Schwarzer et al., 2003). This is then
transferred onto the following PCP. The PCP holds the peptide on a PP arm taken
from CoA, in a similar fashion to the ACP in fatty acid and polyketide biosynthesis.
The extending amino acid is selected by the next A domain, adenylated and
loaded onto the next PCP. The condensation domain then catalyses the formation of
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the peptide bond. Typically, NRPS pathways include multiple modules, accounting
for the large size the enzymes can reach. A TE domain is often present, that catalyses
the release of generated peptide. In a similar fashion to polyketides, NRP pathways
can include post-NRPS tailoring steps before the final product is generated.
NRPS pathways can be fused with other biosynthesis mechanisms, such as with
a PKS in bleomycin or andrimid (Shen et al., 2002; Jin et al., 2006; Magarvey et al.,

































































































Figure 1.8: Examples of hybrid natural products.
The biosynthesis pathway for the lipopeptide antibiotic daptomycin joins a lipid to
a cyclic nonribosomal peptide (Miao et al., 2005). Bleomycin is an anti-cancer drug














DptA CIIIATrp1T CAAsn2TE CIIAAsp3T CAThr4T CAGly5T
DptBC CIIAOrn6T CAAsp7T CAAsp7Tla8 E CAAsp7TII Asp9T CAAsp7TGly10T CAAsp7TSer11TE
CIIAmGlu12TDptD CAKyn13T Te
Figure 1.9: Overview of the biosynthesis of the lipopeptide antibiotic, daptomycin.
Three NRPS proteins hold the 13 modules between them to generate the daptomycin
NRP. DptA lacks an N-terminal adenylation domain. Instead of beginning with an
amino acid, daptomycin biosynthesis is thought to begin with a lipid provided on an
ACP, DptF (Miao et al., 2005; Wittmann et al., 2008; Robbel and Marahiel, 2010).
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1.3 Mupirocin
1.3.1 The characteristics of mupirocin
The antibiotic mupirocin was discovered in 1971 as a natural product of Pseu-
domonas fluorescens NCIMB10586 (Fuller et al., 1971). P. fluorescens is a soil bacterium,
that forms part of the rhizosphere around plant roots. Mupirocin is a mixture of
pseudomonic acids (Figure 1.10), which consist of monic acid linked by an ester to
9-hydroxynonanoic acid. Pseudomonic acid A (PA-A) makes up approximately 90%
of the mixture, and is the primary active form.
Mupirocin is in clinical use, as a topical agent against MRSA, marketed as Bac-
troban by GlaxoSmithKline. The NHS spent approximately £1.0m on mupirocin
prescriptions in England in 2016 (NHS, 2016). Mupirocin is limited to topical use due
to hydrolysis of the ester in bodily fluids, and binding to blood albumin (Thomas
et al., 2010).
1.3.1.1 Mode of action
The target of mupirocin was identified as isoleucyl tRNA synthetase (IRS); feeding
E. coli with excess isoleucine was found to alleviate mupirocin inhibition (Hughes
and Mellows, 1978). This mode of action was confirmed by the co-crystallisation
of mupirocin with its target enzyme (Silvian et al., 1999; Nakama et al., 2001). The
monic acid end (C14) of mupirocin appears to mimic the isoleucine side chain; the
pyran ring and region of monic acid near the ester fit the ATP binding pocket (Figure
1.11). The 9-hydroxynonanoic acid may stabilise the binding of mupirocin to its target
through hydrophobic interactions.
1.3.1.2 Resistance
Relatively low level mupirocin resistance can arise through single point mutations























































Figure 1.10: The chemical structures of pseudomonic acids.
Pseudomonic acids are comprised of monic acid linked by an ester to 9-
hydroxynonanoic acid. The primary active form in mupirocin, pseudomonic acid A
(PA-A), has C8-H, where pseudomonic acid B (PA-B) has C8-OH. The differences
between the other pseudomonic acids from PA-A are highlighted in red.
to a maximum of 16 µg ml−1. Further secondary point mutations were observed to
increase resistance further, reaching up to 128 µg ml−1; however these tripled the
doubling time, suggesting a significant fitness cost (Hurdle et al., 2004).
Perhaps more concerning for its clinical use, high level resistance in MRSA and
Staphyloccus epidermis can arise through acquisition of the eukaryotic like IRS encoded
by mupA, a gene that has been found on a conjugative plasmid. Note that mupA shares






























































































Figure 1.11: Interactions between mupirocin and its target enzyme isoleucyl tRNA
synthetase.
Generated by Ligplot for PDB structure 1FFY (Silvian et al., 1999)
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1.3.2 The mupirocin biosynthesis gene cluster
Transposon mutagenesis identified a 60 kb region of the P. fluorescens NCIMB10586
chromosome required for mupirocin biosynthesis (Whatling et al., 1995). The cluster
was later sequenced, with 36 coding DNA sequences (CDS) identified over a 74 kb
region (El-Sayed et al., 2003) (Figure 1.12). Genes encoding six large peptides with
multiple domains were identified, and these were named mmpA through to mmpF.
The remaining genes were named mupA through to mupW in chromosome order,
with the exception of regulatory genes mupI, mupR, mupX, which were named for
their homologs in the model lux regulon (El-Sayed et al., 2001). A further putative
gene at the start of the cluster was later identified, named mupZ. The predicted
functions based on bioinformatic homology and the assigned pathway role based on
accumulated knowledge, are listed in Table 1.3.
Two large type I modular PKSs are encoded by mmpA and mmpD. Analysis of the
domains reveals four modules in MmpD and two, excluding a loading module, in
MmpA. A type I iterative PKS is encoded by mmpB, which like MmpD and MmpA,
lacks functional AT domains. The AT domains are instead encoded on a separate
gene mmpC. The remaining 30 genes include mupM, which encodes a eukaryotic-like
IRS to prevent self action, and regulators mupI, mupR and mupX. The remaining
genes either encode proteins accessory to the PKSs, or tailoring enzymes.
The mupirocin cluster is not unique to NCIMB10586, as a near identical cluster was
sequenced in Pseudomonas sp. BRG-100, and a more divergent cluster with around 60
to 80% amino acid similarity was sequenced in Pseudomonas pyschrotolerans. The mup
genes also share between 35% and 56% similarity with the thiomarinol biosynthesis
genes (Section 1.4). A PCR screen of 195 Pseudomonas strains for an mmpD DNA
fragment, identified 5 further strains carrying the cluster (Matthijs et al., 2014).
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Table 1.3: Functions of mupirocin biosynthesis cluster genes
Gene Bioinformatically predicted
function
Putative function in pathway
mupZ Hypothetical protein Unknown
mupA Reduced flavin mononucleotide
oxygenase
Unknown
mmpA Type I modular PKS Monic acid biosynthesis
mupB 3-oxo-ACP-synthase Unknown
mmpB Type I iterative PKS 9-hydroxynonanoic acid
biosynthesis
mmpC AT and ER AT activity for PKSs
mmpD Type I modular PKS Monic acid biosynthesis
mupC NADH oxidase Pyran ring oxidation state tailoring
macpA ACP Unknown
mupD 3-oxo-ACP-synthase Unknown
mupE ER In trans reduction at MmpB
macpB ACP Unknown
mupF KR Pyran ring oxidation state tailoring
macpC ACP Site of β branching
mupG 3-oxo-ACP-synthase HCS cassette (β branching)
mupH HMG CoA synthase HCS cassette (β branching)
mupJ Enoyl CoA hydratase HCS cassette (β branching)
mupK Enoyl CoA hydratase HCS cassette (β branching)
mmpE KS0, ACP and oxidoreductase Formation of C10,11 epoxide
mupL Hydrolase Unknown
mupM Isoleucyl-tRNA synthetase Mupirocin resistance
mupN Phosphopantetheinyl transferase Transfer of PP arms to ACPs
mupO Cytochrome P450 Removal of the C8-OH
mupP Dehydratase Removal of the C8-OH
mupQ Acyl CoA synthase 3-HP starter unit loading
mupS 3-oxo-ACP reductase 3-HP starter unit loading
macpD ACP Holds 3-HP starter unit for MmpB
mmpF KS Unknown
macpE ACP Site of C8-OH removal
mupT (2Fe-2S) ferredoxin Electron transport to MupW
mupU Acyl CoA synthase Loading onto MacpE
mupV Oxidoreductase and TE Release from MacpE
mupW Rieske dioxygenase Closure of pyran ring
mupR Transcriptional activator Gene expression regulation
mupX Amidase Degradation of the lactone
mupI N-acyl homoserine lactone synthase Production of quorum sensing
molecule
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Figure 1.12: Genetic organisation of the mupirocin biosynthetic cluster.
The blue arrows represent the mupirocin biosynthesis genes over the 74 kb region of the chromosome. PKS domains are
coloured as follows: red = KS, green = ACP, yellow = KR, blue = DH, grey = TE, orange = OR, pink = AT, peach = MT. Diagram
produced by Anthony Haines, University of Birmingham.
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1.3.2.1 Gene regulation
Expression of the mupirocin cluster is turned on at late exponential or early sta-
tionary phase, based on fusions of mupA with the reporter gene xylE (El-Sayed et al.,
2001). This supports the observation that a significant yield of PA-A is produced after
20 hours (Mantle et al., 2001). Gene expression in the mupirocin cluster is regulated
by a quorum sensing system, where small diffusible compounds produced by the
organism give a measure of self cell concentration (El-Sayed et al., 2001).
The signalling molecule is homoserine lactone, produced by the homoserine lac-
tone synthase encoded by mupI. This molecule is thought to activate the transcription
factor MupR, which induces mupirocin gene expression. However, addition of the
homoserine lactone or induction of mupI expression was not observed to increase
mupirocin gene expression (Hothersall et al., 2011). Expression of the putative tran-
scriptional activator MupR increased the expression of the cluster significantly. Finally,
mupX encodes an amidase, thought responsible for degradation of the signalling lac-
tone.
1.3.3 The mupirocin biosynthesis pathway
Mupirocin biosynthesis can be divided into two broad sections, synthesis of the
polyketide backbone by the PKS enzymes, and tailoring of these compounds to yield
mupirocin.
1.3.3.1 Synthesis of the polyketide backbone
The monic acid precursor is synthesised by type I modular PKSs, MmpD and
MmpA. Before biosynthesis can occur, PP arms are transferred onto the ACP do-
mains, catalysed by phosphopantetheinyl transferase MupN (Shields et al., 2010).






















































































Figure 1.13: Biosynthesis of the mupirocin polyketide backbone.
Type I modular PKS enzymes MmpD and MmpA generate the monic acid precursor. Type I iterative PKS MmpB is thought
responsible for 9-HN biosynthesis. The MmpB starter unit, 3-hydroxyhydroxypropionate, is shown joined by an ester bond to
the monic acid precursor. This represents the current working hypothesis, although the exact timing and mechanism of ester
bond formation has not been determined (El-Sayed et al., 2003; Thomas et al., 2010).
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Polyketide biosynthesis begins with loading from acetyl-CoA onto the module 1
KS on MmpD, potentially via the module 1 ACP. The extender unit, malonate, is
loaded onto the module 1 ACP. Loading of these units is catalysed by AT domains
provided in trans on MmpC. The first KS catalyses a Claisen condensation (Heath
and Rock, 2002), extending the acetate starter unit by a β-keto group. This is reduced
by the KR domain, and an α-methyl group added by the MT.
The growing polyketide is passed along the modules, with each performing
a Claisen condensation and modifications where the domains are present. The
MmpD modules perform four condensations, before loading the polyketide chain
onto MmpA. The first module of MmpA has a non-elongating KS0, which does
not catalyse a condensation, but instead is thought to load the output from MmpD
onto MmpA. Two further condensations are performed on MmpA to give the monic
acid precursor. The proposed scheme logically fits the bioinformatically predicted
domains on the PKS enzymes.
No mupirocin production was observed in mutant strains lacking of the MmpA
KR and KS0 domains, confirming that they are essential to mupirocin biosynthesis (El-
Sayed et al., 2003). The nature of the formation of the ester bond between monic acid
and 9-HN is not yet clear. The most likely possibility is that monic acid is esterified to
the 9-HN starter unit, and the 9-HN is synthesised on monic acid. Another possibility
is that the monic acid and 9-HN are produced separately and linked later. However,
this seems unlikely, as knockouts of the majority of mupirocin cluster genes have
been generated and tested, and no accumulation of individual monic acid and 9-HN
has been observed.
The iterative PKS MmpB is proposed responsible for 9-HN biosynthesis. No
mupirocin production was observed in a strain lacking the MmpB TE domain (El-
Sayed et al., 2003), demonstrating that it is required for mupirocin biosynthesis. Induc-
tion of expression of the CoA ligase TmlU in the mupirocin producer NCIMB10586
yielded pseudomonic acids with truncated 9-HN (Omer-Bali, 2013). This suggests
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that TmlU interacts with the components responsible for 9-HN biosynthesis in the
pathway. An interaction between TmlU and the TE domain of MmpB was detected
by the Bacterial Two Hybrid system (Alsammarraie, 2016). Together, this strengthens
the logical hypothesis, that MmpB is responsible for 9-HN biosynthesis.
MmpB functions in a iterative fashion, where the KS catalyses three condensations
to give the 9-HN product. The starter unit is thought to be 3-hydroxypropionate, and
the extender unit malonate. In a similar fashion to MmpA and MmpD, MmpB lack
an AT domain, and this is thought to be provided in trans by MmpC. MmpB lacks
an ER domain, which is required for full reduction of the fatty acid. This could also
be provided in trans, potentially by ER domains on MupE or MmpC.
MmpB has three ACPs, the need for which is not yet entirely clear. In-frame
deletion of each of the ACPs had no significant impact on mupirocin production,
deletion of two domains decreased production, whereas deletion of all three abolished
production (Rahman et al., 2005). However, no mupirocin production was detected
in a strain with a point mutation inactivating ACP5. It seems that the ACP triplet
provide a function in parallel, rather than they are all strictly required.
1.3.3.2 Tailoring steps
As is typical in polyketide natural products, there are several tailoring steps
that occur before production of the final metabolite mupirocin (Figure 1.14). After
biosynthesis of the monic acid precursor by MmpA and MmpD, β-branching is
thought to occur, which is the addition of a β-methyl group. The components required
have been identified as MupG, MupH, MupJ, MupK and MacpC (Wu et al., 2008;
Haines et al., 2013).
MupW and MupT are thought responsible for closure of the pyran ring. No PA-A
was produced by strains with deletions of either mupW or mupT (El-Sayed et al., 2003;
Cooper et al., 2005). Production of pseudomonic acids without a closed pyran ring







































































































Figure 1.14: The proposed mupirocin tailoring pathway.
Modifications at each step are highlighted in red (Cooper et al., 2005; Hothersall et al.,
2007; Gao et al., 2014, 2017).
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Figure 1.15: Proposed functions of MupT and MupW.
MupT and MupW may form an electron transport chain starting with an unidentified
reductase enzyme. This provides an electron, reducing MupT, which in turn reduces
the [2Fe-2S] of MupW, which then reduces the catalytic non-heme iron.
MupT is a Rieske ferredoxin, a small protein that contains an [2Fe-2S] cluster. It
is likely that MupT and MupW function like the characterised Rieske dioxygenases
they show homology to (Ferraro et al., 2005; Barry and Challis, 2013). These form
an electron transport chain, which begins with the reduction of the [2Fe-2S] cluster
of MupT by an unidentified reductase (Figure 1.15). MupT acts as a shuttle, in
turn reducing the [2Fe-2S] of the Rieske dioxygenase, MupW. MupW likely forms
a homotrimer, such that the [2Fe-2S] is placed in close proximity to the active site
mononuclear iron. MupW can then catalyse pyran ring closure, though the exact
chemical mechanism of this is not yet clear.
There are also tailoring steps thought to occur after 9-HN biosynthesis on MmpB.
A switch to PA-B production was observed in strains with deletions to either mupO,
mupU, mupV, and macpE (Cooper et al., 2005). PA-B, which is inactive, has C8-OH,
whereas the highly active PA-A has C8-H, this step is explored in more detail in
Section 3.1. Strains with deletions of mupC and mupF were observed to generate
compounds where the tailoring of the oxidation state of the pyran ring had not been
completed (Scott et al., 2011; Gao et al., 2014).
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1.4 Thiomarinol
Thiomarinol was discovered in 1993, as a secondary metabolite produced by Pseu-
doalteromonas sp. SANK73390, which was cultured from Japanese seawater (Shiozawa
et al., 1993). The chemical structure of thiomarinol is similar to mupirocin, and in
particular to PA-C (Figure 1.16). Thiomarinol, like PA-C, does not have the C-10,11
epoxide. Thomarinol also has one less carbon in the fatty acid, and C4-OH not found
on PA-A.
The biosynthesis cluster has been sequenced, and is found on a 98 kb plasmid
name pTML1 (Fukuda et al., 2011) (Figure 1.17). The largest difference between the
mupirocin and thiomarinol clusters is the presence of the 12 kb NRPS hol genes on
pTML1, thought responsible for pyrrothine biosynthesis. Otherwise, the two clusters
share strong homology, with the thiomarinol cluster having homologs to all of the
mmp genes present (named tmp).
Figure 1.16: The structures of pseudomonic acid A and thiomarinol.
Thiomarinol is comprised of marinolic acid joined by an amide to pyrrothine. Mari-
nolic acid is similar to pseudomonic acid; however marinolic acid lacks the C-10,11
epoxide, has an additional hydroxyl at C-4, and has one less carbon in the fatty acid.
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Figure 1.17: The genetic organisation of the thiomarinol cluster.
Approximately 88 kb of the 98 kb pTML1 encodes biosynthesis genes, which includes the 12 kb NRPS cluster thought responsible
for holomycin (pyrrothine) biosynthesis. The plasmid replicon occupies approximately 5.3 kb, and the remaining 3.5 kb region
seems to be the remnants of a transposon. Reproduced from Fukuda et al. (2011).
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Figure 1.18: Proposed thiomarinol PKS-NRPS biosynthesis pathway.
TmpD and TmpA are type I module PKS enzymes proposed responsible for monic
acid biosynthesis. TmpB is an iterative type I PKS that is proposed responsible for
8-hydroxyoctanoic acid. HolA is proposed to be an iterative NRPS that, together
with HolB, C, D, F-H, is responsible for pyrrothine biosynthesis. Reproduced from
Fukuda et al. (2011).
Biosynthesis of thiomarinol is thought to occur in a similar manner to mupirocin
biosynthesis (Figure (1.18). Six modules across type I trans-AT modular PKS enzymes
TmpD and TmpA are proposed responsible for biosynthesis of monic acid. The
tailoring of the monic acid precursor in thiomarinol is different to in mupirocin, as
the former has C10,11-alkene where the latter has C10,11-epoxide. Installation of this
epoxide is proposed to be catalysed by the oxidoreductase (OR) domain of MmpE of
mupirocin biosynthesis, which is bioinformatically predicted to hold a non-elongating
KS0, ACP and OR domains (Gao et al., 2014). Intriguingly, thiomarinol has a homolog
to this enzyme, TmpE, despite the epoxide not being present in thiomarinol. TmpE
also has an extra predicted hydratase domain at the N-terminal side.
The fatty acid component, 8-hydroxyoctanoic acid (8-HO), is proposed to be syn-
thesised by the type I iterative PKS TmpB. This has an additional ACP in module
1 and an additional second module compared with its mupirocin homolog, MmpB.
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A logical route to biosynthesis of 8-HO would be an acetate starter unit with three
condensations of malonate extender units, similarly to fatty acid biosynthesis. How-
ever, radiolabelling experiments indicated the starter unit is 4C, and proposed to be
4-hydroxybutyrate, with two condensations to give the 8C fatty acid (Murphy et al.,
2014). TmpB is discussed in more detail in Section 4.1.
There are some additional genes on pTML1 with no homolog present in the
mupirocin cluster: tmlY, tmuA, tmuB. The function of tmlY is unknown, tmuA appears
to encode a DNA binding protein, and the tmuB product has been implicated in C4-
OH formation (Mohammad, 2017). TmlU has been demonstrated to have a different
function to its mupirocin homolog, MupU. In mupirocin biosynthesis, a switch to
PA-B production was observed with deletion of mupU (Cooper et al., 2005). However,
in thiomarinol, mutation of tmlU caused the buildup of marinolic acid and pyrrothine
(Fukuda et al., 2011). TmlU was therefore first assigned as an amide ligase; however
in vitro studies have since demonstrated it is a CoA ligase that activates marinolic
acid as a CoA thioester (Dunn et al., 2015). The formation of the amide bond between
marinolic acid-CoA and holomycin is then thought to be catalysed by HolE.
The similarities between the mupirocin and thiomarinol clusters could facilitate
the fusion of elements from both pathways. A mupirocin-pyrrothine derivative has
been generated by feeding PA-A to a Pks- SANK73390 mutant, although the com-
pound demonstrated reduced activity compared to both mupirocin and thiomarinol
(Murphy et al., 2011). However, reverse genetic investigations of the thiomarinol
pathway have been hindered by the high failure rate of mutagenesis methods on
pTML1 in SANK73390.
Investigations of mupirocin biosynthesis in P. fluorescens NCIMB10586 have made
extensive use of pAKE604 for the generation of scar-less chromosomal mutations,
such as in-frame deletions (Cooper et al., 2005; Hothersall et al., 2007; Gao et al., 2014,
2017) or point mutations (Alsammarraie, 2016; Mohammad, 2017). Further examples
of both are included in this thesis (Sections 3.2.1.2, 3.2.4.1, 4.2.4.2, 4.2.5.3), using an
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improved pAKE604 generated in this work, pJC70. Both plasmids have an E. coli
pMB1 origin of replication from pUC18, which does not function in Psuedoalteromonas
or P. fluorescens. For generation of scar-less mutations, two arms of typically 500 bp
DNA are designed flanking the desired mutational sequence in pAKE604. Forma-
tion of a cross-over between one of these arms and the homologous region of the
10586 chromosome, mediates insertion of the plasmid into the desired chromosomal
sequence. Excision of the plasmid mediated by a second cross-over, which can occur
with equal frequency in the same arm causing a reversion to WT, or in the other arm,
which removes the plasmid sequence leaving the desired mutation.
Despite the wide-spread successful use of this method in 10586, it has largely
failed in mutagensis of pTML1 in SANK73390, with multiple unsuccessful unpub-
lished mutagenesis attempts made by the Thomas group. A tmuB mutant was suc-
cessfully generated, although required much replication and additional screening
compared with the relative ease in 10586 (Mohammad, 2017). The three mutants
described in Fukuda et al. (2011) as PKS-, NRPS- and TmlU-, are actually all inser-
tion mutants. These were generated using a single homologous DNA arm, which
allowed for insertion of the mutagenesis plasmid into the targeted gene, disrupting
its function. However, with no excision method, this leaves the entire plasmid of
approximately 8 kb inside the mutated gene. This is likely to have polar effects on
neighbouring genes on pTML1, and as such it is not surprising that complementation
of the TmlU- mutant failed (Alsammarraie, 2016). The cause for the high failure rate
of double recombination style mutants in 73390 remains cryptic, especially as the
same technique using plasmids carrying the same core features has been reported
successful in other Pseudoalteromonas strains (Wang et al., 2014).
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1.5 Context and objectives of this work
1.5.1 General Context
As discussed in Section 1.1, there is a clear and immediate need for new antibiotics,
in particular new chemical scaffolds. One avenue towards discovering and generating
these scaffolds is the modification of existing natural products to generate new deriva-
tives. Development of a mupirocin derivative conjugated to a non-ribosomal peptide
(NRP) could provide immediately useful clinical compounds. Furthermore, the meth-
ods used to develop such a derivative would add to the ”toolbox” of technologies
available for engineering polyketide and NRP natural products in general.
The antibiotic thiomarinol consists of marinolic acid, which is similar to pseu-
domonic acid C, conjugated to pyrrothine (Section 1.4). As thiomarinol is a polyke-
tide conjugated to NRP already, it provided a sensible starting point for considering
how mupirocin NRP derivatives could be generated.
1.5.1.1 The generation of mupirocin pyrrothine derivatives catalysed by thiomari-
nol enzymes
Unlike P. fluorescens, the thiomarinol producing organism Pseudoalteromonas sp.
SANK73390 is not readily genetically tractable, although three mutants were achieved
in Fukuda et al. (2011). One was an insertion mutation to the first KS domain of
TmpD, which is the equivalent type I modular PKS to MmpD. The thiomarinol pro-
ducer carrying this tmpD mutation, SANK73390 PKS−, did not produce the polyke-
tide component of thiomarinol, marinolic acid. Mupirocin conjugated to pyrrothine
was generated by mutasynthesis with this strain, through the feeding of PA-A to
SANK73390 PKS- (Figure 1.19) (Murphy et al., 2011). Unfortunately, this derivative
proved less active against B. subtilis than mupirocin or thiomarinol, with plate bioas-
say zone of inhibition diameters of 70 and 68% respectively. However, activity against






























Figure 1.19: Generation of a PA-A-pyrrothine derivative by mutasynthesis (Mur-
phy et al., 2011)
Encouragingly, these mutasynthesis experiments demonstrated that the thiomari-
nol enzymes responsible for conjugation of marinolic acid to pyrrothine are able to
process PA-A. This suggested there was scope for introducing these thiomarinol
enzymes into the mupirocin producer P. fluorescens NCIMB10586, and generating
such derivatives in vivo. Catalysis of the amidation of marinolic acid and pyrrothine
was originally attributed to TmlU, based on the lack of amide bond formation in
SANK73390 ∆tmlU (Fukuda et al., 2011). However, the elegant in vitro experiments
reported in Dunn et al. (2015) demonstrated that TmlU acts as a CoA ligase, which
generates a marinolic acid-CoA thioester, prior to amide bond formation catalysed
by a second enzyme, HolE (acetyl transferase).
Before the discovery of the requirement of HolE, tmlU was introduced on an
expression plasmid into the mupirocin producer 10586, with the goal of later gen-
erating in vivo mupirocin derivatives (Omer-Bali, 2013). Surprisingly, induction of
tmlU expression in 10586 proved inhibitory to mupirocin biosynthesis, and inactive
metabolites were produced with truncated fatty acid and C8-OH (as in PA-B). In the
same work, relief of this inhibition was reported in a strain with ACP6 of MmpB
deleted; however this effect proved unreproducible (Alsammarraie, 2016).
The inhibition of mupirocin biosynthesis by TmlU represents a significant bar-
rier to its use for generation of in vivo derivatives. In vitro experiments with HolE
indicated it is fairly selective as to which amines it will accept. Therefore, even if
the problem of TmlU inhibition were solved, it is likely that its use in mupirocin
biosynthesis could only yield mupirocin conjugated to pyrrothine, which has already
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been generated by mutasynthesis and demonstrated to be less active (Murphy et al.,
2011).
1.5.1.2 The long term ambition of generating a library of mupirocin nonriboso-
mal peptide derivatives
With the various problems associated with use of thiomarinol enzymes TmlU and
HolE, an alternative objective was conceived where mupirocin derivatives would be
generated in vivo through the splicing of NRPS from other systems to a mupirocin
PKS.
The designated PKS was MmpB, as MmpB is proposed to offload pseudomonic
acid B, having undergone all necessary Claisen condensations. Many PKS/NRPS hy-
brid natural products exist in nature, such as bleomycin (Shen et al., 2001), haliamide
(Sun et al., 2016) and andrimid (Jin et al., 2006). Daptomycin (Miao et al., 2005) and
the similar calcium dependent antibiotic (Hojati et al., 2002) were primary consider-
ations, largely due to their relatively well studied coupling of fatty acids into NRPS
biosynthesis (Bloudoff et al., 2013; Kraas et al., 2012). The daptomycin freestanding
ACP, DptF, is proposed to hold decanoic fatty acid, prior to condensation with the
first amino acid (Trp) by the first condensase on DptA (Wittmann et al., 2008). One
possibility for generation of an in vivo mupirocin-NRP hybrid would be to load an
ACP such as DptF fused to the mupirocin PKS MmpB, after which the daptomycin
NRPS modules could potentially add amino acids.
There are significant hurdles to be overcome before a successful in vivo mupirocin
daptomycin hybrid could be achieved, including the need for a mechanism to load
DptF on MmpB without disrupting normal MmpB function. Also, the daptomycin
NRPS enzymes need to show sufficiently relaxed specificity to accept this substrate,
and in particular the first condensation domain of DptA. Instead it seems sensible
to attempt to load a variety of ACPs from PKS (or fatty acid) NRPS hybrid systems.
Hopefully, a library of mupirocin NRP derivatives could be generated, which could
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then be screened for any potential clinical usefulness. More importantly, this accom-
plishment would add to our understanding of how to re-engineer PKS and NRPS
systems in general, some examples of which were discussed in Section 1.1.3.2.
Regardless of the specific NRPS enzymes used, the proposed site of fusion to
mupirocin biosynthesis is the iterative PKS MmpB. However, at the point of release
from MmpB, the intermediate is proposed to be the inactive PA-B, with tailoring
to PA-A only occurring after release (Figure 1.14). Therefore any derivatives would
likely be generated with the inactive PA-B form.
1.5.2 Objectives
The core objective of the work described in this thesis was to re-engineer mupirocin
biosynthesis so that PA-B to PA-A conversion occurs on MmpB. As covered in more
detail in Section 3.1, the inactive PA-B is proposed to be released from MmpB, before
loading to freestanding MacpE and conversion to the active PA-A. Conversion of
PA-B to PA-A requires removal of the C8 hydroxl, and occurs by a surprisingly com-
plicated process, with six proposed enzymatic steps (Gao et al., 2017). The successful
re-engineering of this conversion process, to occur on the PKS MmpB, could unlock
the possibility for generation of PA-A NRP in vivo derivatives through MmpB-NRPS
hybrids in the future.
The main aim of the work presented in Chapter 3 was to characterise what genes
are required for conversion of PA-B to PA-A in mupirocin biosynthesis. This was to be
accomplished in two parts: firstly the systematic screening of mutants of all mupirocin
tailoring genes for ability to convert PA-B to PA-A, followed by cloning of a set of
genes to generate an expression plasmid that encodes all necessary functions. Our
understanding of how this complicated conversion occurs has historically become
more complex (Section 3.1.1), and this work aimed to comprehensively demonstrate
what functions are required. Understanding how PA-B to PA-A conversion works is
an important prelude to designing MmpB modifications to re-engineer how it occurs.
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Chapter 4 then covers the core objective: re-engineering the timing or position
of PA-B to PA-A conversion such that it occurs on the PKS MmpB. This was to be
accomplished through fusions with a non-elongating KS0 domain from thiomarinol
biosynthesis, and initially through provision of thiomarinol tailoring enzymes in trans.
However, later this transitioned into use of the thiomarinol KS0 domain to load the
normally freestanding MacpE whilst fused to MmpB. This would also establish the
usefulness of this KS0 domain for loading foreign ACPs, which in the future could
be a potential method for loading DptF.
This work should hopefully add to the knowledge pool for engineering of polyke-
tide biosynthesis in general, and could unlock the generation of in vivo mupirocin-
NRP hybrids in the future.
Whilst undertaking these objectives, the methods used historically to investigate
mupirocin biosynthesis in P. fluorescens NCIMB10586 have been appraised, and where
possible improved. An alternative transconjugant selection procedure was developed
that saves 8-12 days on the minimal media selection procedure used previously (Omer-
Bali, 2013; Alsammarraie, 2016; Gurney, 2012). The suicide mutagenesis vector pJC70






2.1 Bacterial strains, plasmids and growth conditions
2.1.1 Bacterial strains and plasmids
Table 2.1: Bacterial strains used and generated in this study
Strain Description and genotype Source /
reference
Bacillus subtilis 1604 Used as a gram positive test organism
for mupirocin activity, trpC2
Moir et al. (1979)
Escherichia coli DH5α Used for cloning and DNA propagation.
F- endAI thi-1 lacZ∆M15
Gibco BRL
Hanahan (1985)
E. coli ER2925 MG1655 endA1 derivative. Dam- Dcm-




E. coli S17-1 Used for RP4 mediated conjugation.












Reference strain without a mupirocin





The wild type mupirocin producer Fuller et al.
(1971)
P. fluorescens ∆mup-cluster 10586 with a deletion of all mupirocin






10586 with an in-frame deletion of mupI
and reporter gene xylE fused to mupA
El-Sayed et al.
(2001)
P. fluorescens ∆macpA 10586 with an in-frame deletion of macpA Hothersall et al.
(2007)
P. fluorescens ∆macpB 10586 with an in-frame deletion of macpB Hothersall et al.
(2007)
P. fluorescens ∆macpC 10586 with an in-frame deletion of macpC Hothersall et al.
(2007)
Continued on next page
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Table 2.1 – Continued
Strain Description and genotype Source /
reference




P. fluorescens ∆macpE 10586 with an in-frame deletion of macpE Hothersall et al.
(2007)
P. fluorescens ∆mmpA 10586 with an in-frame deletion of mmpA El-Sayed et al.
(2003)












P. fluorescens mmpE∆OR 10586 with an in-frame deletion of the
oxidoreductase domain of mmpE
Gao et al. (2014)
P. fluorescens ∆mupA 10586 with an in-frame deletion of mupA Hothersall, J.
(unpublished)
P. fluorescens ∆mupB 10586 with an in-frame deletion of mupB Hothersall, J.
(unpublished)
P. fluorescens ∆mupC 10586 with an in-frame deletion of mupC Hothersall et al.
(2007)
P. fluorescens ∆mupD 10586 with an in-frame deletion of mupD Hothersall et al.
(2007)
P. fluorescens ∆mupE 10586 with an in-frame deletion of mupE Hothersall et al.
(2007)
P. fluorescens ∆mupF 10586 with an in-frame deletion of mupF Hothersall et al.
(2007)
P. fluorescens ∆mupG 10586 with an in-frame deletion of mupG Hothersall et al.
(2007)
P. fluorescens ∆mupH 10586 with an in-frame deletion of mupH Hothersall et al.
(2007)
P. fluorescens ∆mupI 10586 with an in-frame deletion of mupI El-Sayed et al.
(2001)
Continued on next page
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Table 2.1 – Continued
Strain Description and genotype Source /
reference
P. fluorescens ∆mupJ 10586 with an in-frame deletion of mupJ Hothersall et al.
(2007)
P. fluorescens ∆mupK 10586 with an in-frame deletion of mupK Hothersall et al.
(2007)
P. fluorescens ∆mupL 10586 with an in-frame deletion of mupL Hothersall et al.
(2007)
P. fluorescens ∆mupM 10586 with an in-frame deletion of mupM Hothersall et al.
(2007)
P. fluorescens ∆mupN 10586 with an in-frame deletion of mupN Hothersall et al.
(2007)
P. fluorescens ∆mupO 10586 with an in-frame deletion of mupO Cooper et al.
(2005)
P. fluorescens ∆mupP 10586 with an in-frame deletion of mupP Gao et al. (2017)
P. fluorescens ∆mupR 10586 with an in-frame deletion of mupR El-Sayed et al.
(2001)
P. fluorescens ∆mupS, Q
∆macpD ∆mmpF
10586 with in-frame deletions of mupS,
mupQ, macpD, mmpF
Yadav (2017)




10586 with in-frame deletions of mupU
and mupL
Section 3.2.4.1
P. fluorescens ∆mupV 10586 with an in-frame deletion of mupV Cooper et al.
(2005)




P. fluorescens mupV V581A 10586 with a point mutation to domain 2
of mupV
Section 3.2.1
P. fluorescens mupV V581A
H631A
10586 with a point mutations to domain
2 of mupV
Section 3.2.1
P. fluorescens ∆mupW P.
fluorescens ∆mupT




P. fluorescens ∆mupX 10586 with an in-frame deletion of mupX Cooper et al.
(2005)
Continued on next page
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Table 2.1 – Continued
Strain Description and genotype Source /
reference













P. fluorescens mmpE∆OR 10586 with an in-frame deletion of the
mmpE oxidoreductase domain
Gao et al. (2014)
P. fluorescens mmpB.JC50 10586 with MmpB/TmpB hybrid 1 in
place of MmpB
Section 4.2.4.2
P. fluorescens mmpB.JC58 10586 with MmpB/TmpB hybrid 2 (full
TE) in place of MmpB
Section 4.2.4.2
P. fluorescens mmpB.JC59 10586 with MmpB/TmpB hybrid 2




10586 ∆mupU with MmpB/TmpB hybrid




10586 ∆mupU with MmpB/TmpB hybrid




10586 ∆mupU with MmpB/TmpB hybrid




10586 ∆mupV with MmpB/TmpB hybrid




10586 ∆mupV with MmpB/TmpB hybrid




10586 ∆mupV with MmpB/TmpB hybrid




10586 mmpE∆OR with MmpB/TmpB




10586 mmpE∆OR with MmpB/TmpB




10586 mmpE∆OR with MmpB/TmpB
hybrid 2 (short TE) in place of mmpB
Section 4.2.4.2
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Table 2.2: Plasmids used and generated in this study
Plasmid Size (kb) Description Source
pAKE604 7.2 Suicide mutagenesis vector, AmpR,




pJC70 6.6 Suicide mutagenesis vector, a
derivative of pAKE604 with bla
removed
Section 2.2.12








pGEM-T 3.0 T overhang, linearised cloning vector,
AmpR, lacZα, pMB1 replicon
Promega
pAKE604/V.Y167F 8.2 MupV Y167F mutagenesis vector,
derived from a 1 kb MfeI/BamHI
insert cloned to pAKE604.
Wilson, A.
(Section 3.2.1)
pAKE604/∆mupL 8.2 Mutagenesis vector for in-frame




pAKE604/∆mupU 8.2 Mutagenesis vector for In-frame




pJH2 14.5 Gene mupR in pJH10 Hothersall et al.
(2007)
pJH10/tmlOPCF 18.2 Genes tmlO, tmlP, tmlC, tmlF cloned




pJH10/tmpYOPCF 1.9 Genes tmlY, tmlO, tmlP, tmlC, tmlF
cloned EcoRI/KpnI to pJH10
Wilson, A.
(unpublished)
pUC/mmpBCT2kb 4.7 Final 2.0 kb of mmpB cloned KpnI to
XbaI into pUC18
Section 4.2.1
pUC/mmpB 8.9 Front 4.2 kb of mmpB cloned into
pUC/mmpBCT2kb, giving the full
mmpB gene in pUC18
Section 4.2.1
pJH10/mmpB 20.0 Derived from pJH10 with mmpB
cloned EcoRI/XbaI, TetR
Section 4.2.1
pJC41 6.0 Second module of tmpB cloned into
pGEM-T
Section 4.2.2.1
Continued on next page
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Table 2.2 – Continued
Plasmid Size (kb) Description Source
pJC46 6.3 Second module of tmpB cloned from
pJC41 (PciI/XbaI) to pUC.2kb.mmpB
(NcoI/XbaI)
Section 4.2.2.1
pJC50 21.6 MmpB/TmpB hybrid I in pJH10.
Derived from a 3.6 kb KpnI/XbaI
fragment from pJC46 cloned into
pJH10/MmpB
Section 4.2.2.1
pJC50.C1824A 21.6 MmpB/TmpB hybrid I in pJH10,
with C1824A point mutation to KS0
active site cysteine
Section 4.2.3.3
pJC56 6.4 MmpB/TmpB hybrid II (full length
TE) pUC18 based construction vector.
Derived from cloning PCR product
BamHI/XbaI into pJC46
Section 4.2.3.1
pJC57 6.3 MmpB/TmpB hybrid II (short length
TE) pUC18 based construction vector
Section 4.2.3.1
pJC58 21.7 MmpB/TmpB hybrid II (full length
TE) in pJH10. Derived from cloning a
3.8 kb KpnI/XbaI fragment from
pJC56 into pJC50
Section 4.2.3.1
pJC58.C1824A 21.7 MmpB/TmpB hybrid II (full length
TE) in pJH10, with C1824A point
mutation to KS0 active site cysteine
Section 4.2.3.3
pJC59 21.6 MmpB/TmpB hybrid II (short length
TE) in pJH10. Derived from cloning a
3.6 kb KpnI/XbaI fragment from
pJC57 into pJC50
Section 4.2.3.1
pJC59.C1824A 21.6 MmpB/TmpB hybrid II (short length
TE) in pJH10, with C1824A point
mutation to KS0 active site cysteine
Section 4.2.3.3
pJC74.50 10.7 MmpB/TmpB hybrid I pJC70 based
mutagenesis vector
Section 4.2.4.1
pJC74.58 10.0 MmpB/TmpB hybrid II (full length
TE) pJC70 based mutagenesis vector
Section 4.2.4.1
pJC74.59 9.9 MmpB/TmpB hybrid II (short length
TE) pJC70 based mutagenesis vector
Section 4.2.4.1
pJC99 4.0 MupV H631A mutagenesis fragment
AT cloned into pGEM-T
Section 3.2.1.2
Continued on next page
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Table 2.2 – Continued
Plasmid Size (kb) Description Source
pJC102 7.6 MupV H631A mutagenesis vector,
derived from 1.0 kb EcoRI/SalI
fragment cloned into pJC70
Section 3.2.1.2
pJC118 21.7 MmpB/TmpB hybrid generation III:
TmpB ACP replaced by MacpE,
followed by the TmpB TE domain
Section 4.2.5.1
pJC119 20.7 MmpB/TmpB hybrid generation III:
TmpB ACP replaced by MacpE,




pJC120 21.7 MmpB/TmpB hybrid generation III:
TmpB ACP replaced by MacpE,








pJC124 22.4 Genes mupO, mupP, macpE cloned
KpnI/AflII to pMMH6
Section 3.2.3.1
pJC128 7.1 Genes mupM and mupN AT cloned
into pGEM-T
Section 3.2.3.2
pJC129 8.1 Genes mupL, mupM, and mupN AT
cloned into pGEM-T
Section 3.2.3.2
pJC132 24.9 Genes mupM and mupN cloned
XbaI/BsaI to pJC124 cut XbaI/NotI.
Expression vector carrying mupO, P,
macpE, U, V, C, F, M, N
Section 3.2.3.2
pJC133 26.0 Genes mupL, mupM, and mupN
cloned XbaI/BsaI to pJC124 cut
XbaI/NotI. Expression vector
carrying mupO, P, macpE, U, V, C, F, L,
M, N
Section 3.2.3.2




All Escherichia coli strains and Bacillus subtilis were routinely incubated at 37 °C,





LB was used for the general culturing of E. coli, B. subtilis, and P. fluorescens
strains. To prepare LB, 10 g bactotryptone, 5 g yeast extract, and 10 g NaCl were
mixed. The pH was then adjusted to 7.0, and the mixture made up to 1 L dH2O. LB
was prepared by Central Services (School of Biosciences, University of Birmingham),
and was autoclaved before use. For a typical liquid culture, 5 ml of LB in a sterile
glass universal bottle was inoculated with bacteria.
Super optimal broth (SOB)
SOB was used for the recovery of bacteria following electroporation and chemical
transformation where high efficiency was required. To prepare SOB, 20 g tryptone, 5
g yeast extract, 0.5 g NaCl, and 10 ml of 250 mM KCl were mixed. The pH was then
adjusted to 7.0, and the mixture made up to 1 L dH2O, then stirred and autoclaved.
Before use 1 ml of 1 M MgCl2 was added per 100 ml SOB (Hanahan, 1983).
Super optimal broth with catabolite repression (SOC)
SOC was used for the recovery of bacteria following electroporation and chemical
transformation, where high efficiency was required. SOC is SOB with added glucose;
to generate SOC, 1 ml of 40% (w/v) glucose was added per 100 ml SOB before use
(Hanahan, 1983).
Secondary stage media (SSM)
SSM was used for mupirocin production cultures prior to HPLC analysis. To
prepare SSM, a mixture of 25 g soya flour, 2.5 g spray dried corn liquor, 5 g (NH4)2SO4,
0.5 g MgSO4.7H2O, 1 g Na2HPO4, 1.5 g K2HPO4, 1 g KCl, and 6.25 g CaCO3 was
generated. The pH of the mixture was adjusted to 7.5, and made up to 1 L dH2O
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and autoclaved. Before use 40% (w/v) glucose was added to the SSM to give a final
concentration of 4%.
Mupirocin production media (MPM)
MPM was used for xylE assays. P. fluorescens yields less mupirocin on MPM
than SSM. To prepare MPM, a mixture of 2.3 g yeast extract, 2.6 g Na2HPO4, 2.4 g
K2HPO4, 5 g (NH4)2SO4 was generated. The pH of the mixture was adjusted to 7.5,
made up to 1 L dH2O, and autoclaved. Before use 550 µl of 40% (w/v) glucose was
added per 200 ml MPM media.
Marine broth
Marine broth was used for culture of Pseudoalteromonas sp. SANK 73390. To
prepare marine broth a mixture of 33.33 g sea salt, 5 g bacteriological peptone, 0.1 g
ferrous sulphate, and 0.8 g yeast extract was generated. The mixture was made up to
1 L dH2O, and was autoclaved before use (Shiozawa et al., 1993).
M9 minimal media
M9 minimal media was used to select for P. fluorescens against a background of E.
coli S17-1 in pAKE604 mating experiments. To prepare this media, a mixture of 200
ml 3 % agar, 200 ml M9 salts, 400 µl of 1M MgSO4, 400 µl of 1M thiamine HCl, 400
µl of 100 mM CaCl2, and 2 ml of 40 % glucose was generated (El-Sayed et al., 2003).
The 3 % agar, M9 salts, CaCl2, and 40 % glucose were individually autoclaved prior
to use. The 1M MgSO4 and the 1M thiamine HCl were filter sterilised before use.
Agar
To generate solid media, 15 g of agar was added per litre of the relevant broth
recipe.
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2.1.2.2 Antibiotics and other media additives













Kanamycin dH20 50 50
Streptomycin dH20 50 50
Tetracycline 70 % (v/v)
EtOH
20 20
2.1.2.3 Other media additives
Isopropyl β-D-1-thiogalactopyranoside (IPTG)
IPTG was used for the induction of the tac and lac promoters. IPTG was filter
sterilised and stocked at 1 M in dH2O. The typical working concentration of IPTG
used in experiments was 0.5 mM.
X-Gal
X-gal was used for blue-white screening through detection of disrupted lacZα
when cloning into pUC18, pGEM-T, pAKE604, pJC70 and their derivatives. X-gal
was stocked at 20 mg ml−1 in dimethyl formamide. A working concentration of 20
µg ml−1 was used.
55
2.2 Manipulation of DNA
2.2.1 Transformation
Competent cells
To generate chemically competent cells, 250 µl of overnight culture was used to
innoculate 25 ml of LB medium. The culture was incubated at 37 °C 200 rpm until
it reached an OD600 of 0.4 to 0.6. Cultures were cooled on ice for 5 minutes, before
centrifugation at 3,000 x g, 4 °C for 7 minutes. The supernatant was discarded and
pellet resuspended in 10 ml of ice cold 100 mM CaCl2. The resuspended pellet was
incubated on ice for more than 20 minutes before centrifugation at 3,000 x g, 4 °C for
7 minutes. The supernatant was then discarded and the pellet gently resuspended in
2.5 ml of ice cold 100 mM CaCl2.
Transformation
For transformation, between 0.5 µl and 5 µl DNA was added to 100 µl competent
cells, and then the mixture was incubated on ice for 30 minutes. The mixture was
heat shocked at 42 °C for 90 seconds, before the addition of 1 ml LB or SOC, and
recovery at 37 °C for between 1 and 2 hours. Cells were then plated onto media with
suitable antibiotics to select transformants.
2.2.2 Conjugation
Conjugation was used to deliver plasmids containing oriT, such as pJH10 and
pJC70, to P. fluorescens. The plasmids were first transformed to E. coli S17-1, which
has the RP4 tra regions integrated into the chromosome (Simon et al., 1983).
For conjugation experiments expected to occur with high efficiency, such as trans-
fer of pJH10 derivatives, 10 µl overnight E. coli S17-1 culture carrying the oriT plasmid
was spotted with 10 µl recipient overnight culture onto the L-agar. The mix of cells
was grown for between 2 and 16 hours at conditions suitable for the recipient strain.
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An inoculum was then taken from the mixed spots and streaked to single colonies on
medium selective for both recipient and plasmid. For transfer of pJH10-based plas-
mids to P. fluorescens tetracycline (for the plasmid) and ampicillin (for P. fluorescens)
was used. If donor contamination was suspected then a further streak onto selective
media was performed.
Conjugations of mutagenesis plasmids, such as pJC70 derivatives, were performed
using an alternative method, mixing more cells. This is necessary as plasmids need
not only to conjugate to donor cells, but also integrate into the target sequence by
homologous recombination as well. For such conjugations, 1 ml of E. coli S17-1
culture with oriT containing plasmid was mixed with 1 ml of recipient culture. The
mixed culture was pushed through a sterile 0.45 µl milipore filter, such that the cells
were concentrated on the surface of the filter. The filter was then placed on an L-
agar plate, and incubated at conditions suitable for the recipient. After incubation
overnight, the filters were placed into universal flasks with 1 ml of 0.85 % saline,
and cells resuspended by vortexing. Serial dilutions to 10−5 in 0.85 % saline were
performed, and spread onto solid medium selective for both recipient and plasmid.
2.2.3 Plasmid miniprep
The ISOLATE II Plasmid Mini Kit purchased from Bioline Reagents Ltd. was used
for small scale plasmid extractions from overnight cultures, following the included
protocol.
2.2.4 Gel electrophoresis
Tris, acetate, EDTA buffer (TAE)
TAE buffer was used for the preparation of agarose gels and as the running buffer
for agarose gel electrophoresis. Firstly, 50 ml of 0.5 M ethylenediaminetetraacetic acid
(ETDA) was made up: 9.306 g EDTA free acid and 1 g NaOH were dissolved in 40
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ml dH2O, pH adjusted to 8.0 with NaOH, and made up to 50 ml with dH2O. A stock
of 50x TAE was prepared: 121 g tris base, 29 ml glacial acetic acid, 50 ml of 0.5 M
EDTA were mixed and made up to 500 ml dH2O.
Agarose gel preparation
Agarose gels were prepared between 0.5% and 2% (w/v) agarose depending on
DNA fragment size to be resolved. In the gels pictured in the results sections, 1%
(w/v) agarose was used unless otherwise stated. The agarose was added to a 250 ml
flask with the required amount of 1x TAE buffer for desired gel thickness (typically
100 ml). The mixture was heated in the microwave until the agarose dissolved, cooled
to hand temperature, and 2 µl of 10 mg ml−1 ethidium bromide per 100 ml gel added.
Running agarose gels
Gels were submerged in 1x TAE in tanks. DNA samples were prepared by adding
6x loading dye from either NEB Ltd. or Thermo Fisher Scientific Inc. For a typical
sample, a suitable volume of DNA was made up to 10 µl with dH2O, 2 µl 6x loading
dye added, and the solution mixed by pipetting up and down. To run a larger volume
of DNA (x µl), typically for purification, x/5 µl of 6x loading dye was added. For size
verification, 5 µl of DNA ladders were used, typically GeneRuler 1 kb from Thermo
Fisher Scientific Inc. Where small DNA fragments were visualised, the 100 bp ladder
from NEB Ltd. was used.
2.2.5 DNA purification by gel electrophoresis
For size purification of DNA fragments, DNA was run on an agarose gel and
desired band cut out with a razor under UV light. DNA was purified from the gel
using the Illustra GFX PCR DNA and Gel Band purification kit from GE Healthcare,
following the included protocol.
58
2.2.6 Ethanol precipitation
For the purification of DNA from a 20 µl solution, 5 µl of 3 M NaOAc and 110
µl of 100% EtOH were mixed, and incubated at -20 °C for 20 minutes. The DNA
pellet was collected by centrifugation at 13,000 g for 15 minutes, and washed with
70% ethanol. The pellet was dried at 48 °C for 20 minutes and resuspended in sterile
distilled water (SDW).
2.2.7 Restriction Digests
Restriction enzymes were purchased from NEB Ltd. Digests were performed us-
ing the recommended NEB protocol, typically in a 20 µl or 50 µl reaction volume with
incubation for 1 to 3 hours. For restriction digest by XbaI, plasmids were propagated
through dam negative strain E. coli ER2925 where the sequence indicated methylation
would block digestion.
2.2.8 Ligations
DNA was typically prepared for ligation by digest and size purification (Section
2.2.5). Approximately 50 ng of vector DNA was mixed with insert DNA to give an
approximate molar ratio of 1:3. Ligations were performed using T4 DNA ligase from
Invitrogen or NEB and incubated overnight at 4 °C, before transformation.
2.2.8.1 Cloning to pGEM-T-Easy
Fragments were cloned in pGEM-T-Easy for sequencing and propagation of DNA,
prior to subcloning to other vectors. An advantage pGEM-T-Easy offers over direct
cloning is that fragments gel purified from pGEM must be cut by restriction enzyme
on both sides. With direct cloning, typically 3 to 5 nucleotides were included in
primers such that when digested, around 6 to 8 nucleotides would be cleaved from ei-
ther flank of the product. Therefore digestion of the PCR product would not normally
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yield a visible size change by agarose gel electrophoresis, as products were often of
the order of kilobases. Cloning in pGEM-T-Easy also allows for identification and
quality control of the desired fragment by sequencing, after which it can be subcloned
into the suitable vector.
Gel purified (Section 2.2.5) DNA was A-tailed using Taq polymerase from Invit-
rogen (Table 2.4). A-tailed DNA was ligated to the linear pGEM-T-Easy using the
included T4 ligase following the manufacturer’s instructions.
Table 2.4: Mix for A-tailing PCR products
Component Volume (µl)
10x PCR buffer 1
DNA (typically PCR product) 6
50 mM MgCl2 1
2 mM dATP 1
Taq polymerase 1
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2.2.9 Molecular design software
Table 2.5: Software used for visualising and design of molecular approaches

























Psipred Protein secondary structure
prediction.
http://bioinf.cs.ucl.ac.uk/psipred/






Visualisation of plasmid DNA
sequences and molecular designs.
Generation of plasmid maps.
http://www.snapgene.com/




All DNA sequencing was performed by the Genomics Service at the University of
Birmingham, run on a 3730 DNA Analyser. For plasmid sequencing, 200 to 500 ng of
template DNA was mixed with 3.2 pmol primer, up to 10 µl in dH2O, and provided
to the Genomics Service. For PCR sequencing, approximately 10 ng of template DNA
was used, following the guidelines from the Genomics service. Chromatograms were
visualised using Chromas (Table 2.5).
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2.2.11 PCR
Preparation of template DNA
For PCRs from chromosomal template DNA, a boil preparation was performed.
An area of approximately 1 cm2 of culture was scraped from the surface of solid
media, and resuspended in 50 µl dH2O. The mixture was boiled at 100 °C for 10
minutes, before centrifugation for 3 minutes at 11,000 g. The supernatant was used
as template DNA for PCR. Where suitable, plasmid or PCR product template DNA
was used instead.
High fidelity
All PCRs destined for cloning were performed using high fidelity enzymes. These
proofreading enzymes have 3’ to 5’ exonuclease activity that can excise incorrectly
incorporated nucleotides. The majority of such PCRs were performed using Velocity
DNA polymerase from Bioline Reagents Ltd., while a minority were performed using
Q5 DNA polymerase from NEB Ltd. PCR reactions were performed to the respective
manufacturers protocols. Melting temperatures were estimated using Netprimer
(Table 2.5).
Low fidelity
The non-proofreading Taq polymerase from Invitrogen was used for applications
where fidelity was not required, such as screening for inserts or mutations. Mix and
cycling conditions are listed in Table 2.6. Alternatively, GoTaq DNA polymerase from
Promega was used for screening potential mutants, following the manufacturer’s
protocol using the green buffer with DNA loading dye included.
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Table 2.6: PCR with Invitrogen Taq
(a) Mix for a 50 µl reaction
Component Volume (µl)
10x PCR buffer 5
Template DNA 5
50 mM MgCl2 1
10 mM each dNTPs 1
50% glycerol 10
100 µM primer 1 0.3
100 µM primer 2 0.3
Taq polymerase 1
dH2O up to 50µl
(b) Cycling conditions
Step Time (seconds) Temp. (°C) Cycles
Initial denaturation 120 94 1
Denaturation 15 94
Annealing 30 Tm 30
Extension 60 per kb 72
Final extension 300 72 1
2.2.11.1 Overlap extension PCR
Overlap extension PCR was used broadly in this work to join DNA segments,
whilst introducing designed changes such as point mutations, deletions or insertions.
The method is explained in Figure 2.1.
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(a) Initial PCR amplification.
(b) Filling in to generate full length template DNA.
(c) Amplification of full length product.
Figure 2.1: Overlap extension PCR, used to generate primer dictated modifications
to DNA.
(a) Two PCR products are amplified using pairs of primers. The Inner primers, shown
in red and orange, are designed to overlap such that they are complementary to each
other. Design of this overlap is flexible, and can introduce new insertions, deletions
or point mutations.
(b) The PCR products are purified to remove any unincorporated primers and any
non-specific products. They now act as template for each other in a second, overlap
extension PCR. Typically, 3 PCR cycles were performed without primers, this allows
the polymerase to extend the 3’ end of DNA fragments using the other fragment as
template, shown by the dotted arrow.
(c) Now full length product with the desired modification is available in the reaction
mix. The outer primers are added, and 27 PCR cycles performed to amplify the full
length product. This is typically performed at a higher Tm than possible for the
overlap, which is why the primers are not included initially.
2.2.11.2 Colony PCR
Colony PCR was used to screen colonies for presence of insert where a large
proportion of religated empty vector was suspected, and blue white screening not
available. A PCR master mix containing all components was made up (without
template DNA), and dispensed into 20 µl aliquots. Each colony to be screened was
picked up by pipette tips, and suspended into a PCR aliquot by pipetting up and
down.
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To propagate live cells from each colony, 1 µl of each PCR aliquot was transferred
to 100 µl LB. PCR was performed and products checked by agarose gel electrophore-
sis. Where the desired size insert was present, the 100 µl LB storage cultures were
used to inoculate 5 ml LB. These were incubated overnight for plasmid preparations.
2.2.12 Suicide mutagenesis
Construction of plasmids
Primers were designed to generate two PCR fragments or arms with the desired
overlap, such that they could be stitched together by overlap extension PCR (Section
2.2.11.1). Each of these arms was typically around 500 bp long. The design of
overlapping primers defined the mutation to be made. In the scenario of a point
mutation, the overlapping primers are designed to carry the desired point mutation.
Overlapped mutagenesis products were cloned into the multiple cloning site
of pJC70. Mutagenesis vector pJC70 (Figure 2.2b) was derived in this work from
pAKE604 (Figure 2.2a), through the use of PCR to remove the majority of the ampi-
cillin resistance gene. The advantage of pJC70 is it allows selection of P. fluorescens
through its chromosomally encoded AmpR after conjugation. With pAKE604 this is
not possible, as the plasmid encoded bla gene renders the donor E. coli AmpR. Se-
lection of P. fluorescens is instead achieved using minimal media, where the bacterial
colonies can take 2-3 extra days incubation to grow to a suitable size.
Generation of mutations
Derivatives of pJC70 carrying a mutagenesis insert derived from overlap extension
PCR were transformed to E. coli S17-1. The vector includes the RK2 oriT which allows
RK2 mediated conjugation from S17-1 to P. fluorescens. Transconjugants were selected
for using kanamycin and ampicillin, which select for the plasmid and recipient P.
fluorescens respectively.




Figure 2.2: Maps of suicide mutagenesis vectors pAKE604 and pJC70.
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Figure 2.3: Example patch plates to check for kanamycin resistance.
Each streak is derived from a single sucrose resistant colony, that are putative mutat-
genesis plasmid excisants. Isolates 5 and 8 are both kanamycin and sucrose resistant,
this suggests integration of the suicide plasmid and inactivation of the sacB gene
rather than excision.
fluorescens. Therefore kanamycin selection forces integration of the plasmid into the
chromosome, mediated by homologous recombination in one of the 500 bp arms. P.
fluorescens strains with chromosomal pJC70 integrants were grown overnight in LB
without kanamycin selection. This allows a second recombination to occur, where
the plasmid excises.
The vector includes sacB, which encodes levansucrase from Bacillus subtilis, which
confers a lethal periplasmic sucrose polymerisation in gram negative bacteria (Gay
et al., 1985). Serial dilutions of these cultures were plated onto L-agar 5% sucrose to
select for strains that had lost sacB. Sucrose resistant colonies were then patched onto
L-agar with and without kanamycin, to check for plasmid loss (Figure 2.3). Typically
around 5 to 10 % of sucrose resistant strains were observed to remain kanamycin
resistant, indicative of sacB inactivation rather than plasmid excision.
If the second recombination occurs in the arm alternative to that of the first recom-
bination, then the desired mutant sequence is left in the chromosome. Alternatively,
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if the second recombination event occurs in the same arm as the first, then the WT
sequence remains. Both scenarios should occur with equal frequency, and in both
excised plasmid is non-replicative and lost through dilution. Mutant strains were
then detected by PCR, restriction digest and sequencing.
2.3 Assays
2.3.1 High performance liquid chromatography
Sample preparation
P. fluorescens 5 ml LB seed cultures, with suitable antibiotics, were inoculated in
triplicate from single colonies on solid media, and incubated for 16 hours at 30 °C.
Seed culture (200 µl) was used to inoculate 5 ml SSM media (Section 2.1.2.1) in 50
ml conical flasks. Suitable antibiotics were used to maintain any plasmids, and IPTG
added to the SSM medium where required (typical final concentration 0.5 mM). In
some later experiments, prednisone was used as an internal standard (typical final
concentration 50 µM). Prednisone was added to the flasks after incubation, such that
any discrepancies in HPLC sample preparation could be detected by comparison of
prednisone peaks on the chromatograms. SSM cultures were incubated at 22 °C 200
r.p.m. for between 40 and 64 hours.
Samples were centrifuged at 13,000 g and supernatants collected. The super-
natants were filtered through 0.2 µm millipore filters prior to injection.
HPLC analysis
HPLC was performed on a Gilson system using a reverse phase C18 column (15
cm x 4.6 mm). Mobile phase ran on a water:acetonitrile gradient, starting 95:5 (t = 0
minutes) to 30:70 (t = 30 minutes). Both the HPLC grade water and acetonitrile were




To generate figures and quantify peak area, raw data was exported from the
Gilson software and imported to OriginPro 2016. The OriginPro Peak Analyzer
tool was used to determine peak area, with asymmetric least squares smoothing to
determine baseline.
2.3.2 Plate bioassay
Plate bioassays were used to determine the antibiotic activity of a strain, through
measuring the area of inhibition of growth of susceptible B. subtilis 1604. Overnight
cultures of P. fluorescens were grown with suitable antibiotics; 10 µl of these were
spotted onto 20 ml measured L-agar plates. If IPTG induction was required it was
included in the L-agar. Plates were incubated for 16 hours at 20 °C.
B. subtilis overnight culture (8 ml) was mixed with 1 ml 5 % triphenyl tetrazolium
chloride (TTC) in 200 ml L-agar. A variety of dehydrogenase enzymes in live cells can
reduce the white TTC to red formazan (Brodie and Gots, 1952; Rodriguez et al., 1992).
B. subtilis is a mupirocin sensitive gram positive; when stained with TTC the zone of
inhibition of mupirocin and any other antimicrobials produced by P. fluorescens can
be detected. Each plate was overlaid with 15 ml of the B. subtilis containing mixture.
Plates were incubated for 16 hours at 37 °C, and diameters of zones of inhibition
measured.
2.3.3 Chromogenic xylE reporter assay
XylE reporter assays were used to determine the approximate level of mupA ex-
pression. These used the reporter strain 10586 ∆mupI mupA::xylE, which has xylE
inserted downstream of the putative mupA promoter (El-Sayed et al., 2001). To per-
form the assays, overnight LB cultures of the reporter and relevant test strains were
streaked onto MPM agar plates (Section 2.1.2.1), which were incubated for 22 hours
69
at 20 °C. Plates were then mist-sprayed with 1% catechol (w/v in H2O), and colour
change observed after 5 minutes. Colourless catechol is converted to yellow 2- hy-
droxymuconic semialdehyde, catalysed by XylE (Zukowski et al., 1983), allowing for
detection of expression from the mupA promoter.
2.3.4 Ethyl acetate extraction of PA-B
Ethyl acetate extraction was used to concentrate PA-B for use in feeding exper-
iments. This was adapted from a method for chlorothricin extraction, experienced
first hand in the Manuela Tosin lab at the University of Warwick (Parascandolo et al.,
2016). Plasmid pJH2, which carries mupR was mobilised to PA-B producing strain
10586 ∆mupU, as mupR expression increases metabolite yield (Hothersall et al., 2011).
Seed cultures were grown overnight at 30 °C in LB. SSM cultures (200 ml) in 2 L
conical flasks, were inoculated with 2 ml saturated seed culture, and incubated at 22
°C for 40 to 44 hours.
Cultures were aliquoted into 50 ml Falcon conical centrifuge tubes and centrifuged
at 3000 xg for 10 minutes at room temperature. The supernatants were collected and
pH adjusted to 4.5, before being split into aliquots in 50 ml Falcon tubes, approxi-
mately half full (25 ml). Each tube was topped up with approximately 25 ml ethyl
acetate (EtOAc), mixed thoroughly by inversion and vortexing approximately ten
times over half an hour. Where emulsions were formed, these were resolved to layers
by centrifugation (3000 x g for 5 minutes). The clear top layer was collected using
a glass pipette. Each tube was refilled with EtOAc, and the process repeated, again
collecting the top layer. The collected solvent was evaporated on a rotovap, until less
than 500 µl oily yellow liquid remained. Methanol (2 to 4 ml) was added and any
precipitated solids dissolved by pipetting. The purity and quantity of the extract was
appraised by HPLC.
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2.3.5 Determination of minimum inhibitory concentration of mupirocin
LB (100 µl) was aliquoted to all wells of 96-well microplates (12 columns by 8 rows).
A stock of mupirocin was prepared at 200 mM in DMSO from commercial powder.
This was diluted to 16 mM mupirocin in LB in a petri dish, and 100 µl was added to
the wells of column 1, diluting them to 8 mM mupirocin in LB. Serial dilutions were
performed by pipetting 100 µl from each column to the next, with pipetting up and
down to mix. This results in 100 µl of LB with mupirocin dilutions in columns 1 to
11, and 200µl of LB 4 µM mupirocin in column 12; 100 µl was removed from column
12 and discarded.
Saturated overnight cultures (grown 16 hours in LB) were diluted 1 in 50 in a petri
dish, 9.8 ml LB with 200 µl culture. These diluted cultures were used to inoculate
the microplates, adding 100 µl 1 in 50 culture dilution to each row. This resulted in
an effective 1 in 100 dilution of each culture in LB, with mupirocin concentrations
ranging from 4 mM to 2 µM across the columns.
Plates were incubated in a shaking incubator at 200 RPM with the lid on, at 37
°C for E. coli and 22 °C for P. fluorescens. After 16 hours, bacterial growth was
both appraised by eye, and OD600 absorbance readings recorded on a BMG Labtech
SPECTROstar Nano plate reader, adjusted for a non-incolulated blank row.
2.3.6 Determination of colony forming units
To determine the number of colony forming units (CFUs) within P. fluorescens
SSM cultures, serial dilutions were performed in 1.5 ml eppendorf tubes. Saline
(0.85%, 900 µl) was aliquoted to each tube, 100 µl SSM culture was added to the first,
mixed by vortex, and serial 100 µl dilutions were performed to 10−6. L-agar plates
were divided into six sections, and 20 µl of each dilution deposited in each section
as microdrops (Thomas et al., 2015). Colonies were counted after incubation at 30 °C
for 16 hours, an example plate is pictured in Figure 2.4.
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Figure 2.4: Example CFU determination plate.
Each section contains 20 µl of diluted culture, deposited as microdrops.
2.4 PCR primers
All primers used in this work were purchased from Altabioscience Ltd, and are
listed by chapter in the following tables.
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Table 2.7: Primers used in Chapter 3
Name Sequence (5’ to 3’) Purpose
M13 (-40) GTTTTCCCAGTCACGAC Sequencing of inserts in
M13 (-48) AGCGGATAACAATTTCACACAGGA lacZα cloning sites




R inner Y167F MupV TGGTTTCTTCGAAATAGTTATTGAATTCAGTGC
F inner Y167F MupV CAATAACTATTTCGAAGAAACCAAATGTGCG
R outer Y167F MupV AGAGGATCCGTTGTGGATGTAGGGGTTGTAAAAC




P17 R inner H631A MupV CAAACCAAATGCATCCATGCCAGCGATTTC
P17 F inner H631A MupV GGCATGGATGCATTTGGTTTGTATAACCACCTGG
P17 R outer H631A MupV EcoRI GCACTGGAATTCTGACGACAACTGTTGTAGTAGGC
P25 F mupOP KpnI SpeI GAACGGTACCTACTAGTGGGAGAGCAACGATGACATC
Cloning of mupO,
mupP and macpE
P25 R mupOP overlap GCCTCCTGTGGTGTGCTCCTGTTGCTGTTTG
P25 F macpE overlap ACAGGAGCACACCACAGGAGGCGTAGATGC
P25 R macpE AflII AGACTTAAGTCACTGCTCACGTTGGGC
P25 F mupLMN CCACTCTAGACAGTGAAGAGAGGGACACACAGC
Cloning of mupL,
mupM and mupN
P25 R mupLMN GGTCTCAGGCCGCGATCCAAACCTATAAGCACTG
P25 F mupMN TAGCTCTAGACTGACAGGTGTGACTGATGAGTACG
Continued on next page
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Table 2.7 – Continued
Name Sequence (5’ to 3’) Purpose
P31 F mupL H256A GATTGGGGGGCCTACACGCTTTTCTCTGATACACAAGAG Generation of mupL
H256A in pJC133P31 R mupL H256A AGCGTGTAGGCCCCCCAATCGTCCATGATG
mupL1F GGATCCGCGTTCTACAGCAGCACAC Screening for mupL
deletionmupL2R GAATTCCTTGAGCACCAGCTCTCTG
mupU1F GGATCCGACCAGATCGTCCAGTGGTTC Screening for mupU
deletionmupU2R GAATTCGTGCTCTGGTGCAGGCATTC
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Table 2.8: Primers used in Chapter 4
Name Sequence (5’ to 3’) Purpose
M13 (-40) GTTTTCCCAGTCACGAC Sequencing of inserts in





















Continued on next page
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Table 2.8 – Continued
Name Sequence (5’ to 3’) Purpose
TmpBR3 CCCTGATACATATTTTGCCATGC




R pJC46 ACPfrag TCCCGGTGCATCTTCATCTG
F mmpB full TE CAGATGAAGATGCACCGGGAGATTGGCGTTCGCTGGCG
F mmpB short TE CAGATGAAGATGCACCGGGAGGGCTCTTCTGTTTCCCCG
R mmpB TE ACATCTAGAAGATCAGAACTCGCCTGCGC
pJH10 Seq F GCCGACATCATAACGGTTCTGGC Sequencing of inserts
pJH10 Seq R CTCCTGCCAGTTGATGACCTCG in pJH10
R tmpB C1824A AACTGCAGCCTCTAGTTCATTGGTCGCTTTGC Generation of C1824A
F tmpB C1824A ATGAACTAGAGGCTGCAGTTTCAACCGGCTCACTC mutant hybrids




P16 R 2.6kb GGCGAGTGATTTGTGACGAGTCTTTTGGTTGCTC
P16 F macpE CTCGTCACAAATCACTCGCCAGACCGTCCAG
P16 R macpE stop SacI CAGAGAGCTCCTCACTGCTCACGTTGGGCG
P16 R macpE TEoverlap TTATCGCTGTTCTGCTCACGTTGGGCGAACC
P16 F TE revised GAACGTGAGCAGAACAGCGATAAAAATGAGCA
P16 R TE SacI ATTGAGCTCGTTTTCCCAGTCACGACGTTGTAA
Continued on next page
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Table 2.8 – Continued
Name Sequence (5’ to 3’) Purpose
F pJC5x XbaI CTCTCTAGACTGTTTGAGCATCCGACGC
Construction of the
pJC74 series of hybrid
10586 chromosomal
mutagenesis vectors
R pJC5x SalI TGTGGGGAAGACTGCTTGC
F hybriddownarm overlap CGTATGAGTAAAAGGTGGAGCGGCAAGGCT
R pJC50 overlap GCTCCACCTTTTACTCATACGTCACCTCATCGC
R hybrid downarm SalI CAGGTCGACAGCCGCCAATGCAGAGACTGTC








The mixture of pseudomonic acids produced by P. fluorescens NCIMB 10586 is
comprised of 90% PA-A and approximately 5% PA-B. These molecules differ by one
group at carbon 8, -H in PA-A, and -OH in PA-B. This modification is required
for antibiotic function, PA-A is active and PA-B is inactive (Figure 3.1). The X-ray
structure of PA-A complexed with IleRS (Silvian et al., 1999) revealed 4.2 Å between
carbon 8 and the closest IleRS amino acid, His67 (Figure 3.2). With the addition of the
hydroxyl, this distance could close to 2.8 Å. It is therefore possible that the C8-OH of
PA-B causes a steric hinderance that prevents target IleRS binding.
PA-B is thought to be a precursor to PA-A, with the biosynthetic removal of the
C8-OH occurring in a suprisingly convoluted fashion (Gao et al., 2017). The current
model was proposed based on reverse genetic approaches and intermediate feeding
experiments, which refuted earlier hypotheses of PA-B being generated from PA-A
or parallel biosynthetic pathways (Chain and Mellows, 1977; El-Sayed et al., 2003;
Cooper et al., 2005).
Figure 3.1: Conversion of PA-B to PA-A in mupirocin biosynthesis summary.
Processing to PA-A is required for activation of the antibiotic. Example bioassay
plates are shown, taken from the experiment in Section 3.2.3.3. Prior to the work
presented in this chapter, the seven listed enzymes had been implicated as required
for conversion (Gao et al., 2017).
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Figure 3.2: Position of PA-A C8 when bound to isoleucyl t-RNA synthetase.
The closest amino acid on the S. aureus IleRS is His67, which is 4.2 Å from carbon 8
of PA-A. Generated from PDB entry 1QU2 (Silvian et al., 1999). Mupirocin is shown
in green, with oxygens in red, IleRS is in grey with nitrogens in blue, and only His67
is shown as sticks for clarity.
3.1.1 Historical evidence and models of the biosynthesis of PA-B
and PA-A
After the discovery of mupirocin in 1971 (Fuller et al., 1971), the structure of PA-B
was first determined in 1977 (Chain and Mellows, 1977). Chain and Mellows hy-
pothesised that PA-B could be generated by enzymatic hydroxylation of PA-A. Later
experiments with radiolabelled acetate did not support this hypothesis; incorporation
of radiolabelled precursors occurred differentially between PA-B and PA-A (Mantle
et al., 2001). Mantle and colleagues expressed difficulty interpreting their results,
with limited information available on the biosynthesis pathway at this time.
This changed with the identification and sequencing of the mupirocin biosynthetic
cluster (Whatling et al., 1995; El-Sayed et al., 2003). In this work, the genes and
enzymes we now know are involved in PA-B processing were named and analysed
by homology searches, but their precise functions were not known. Repeating the

























































































Figure 3.3: Biosynthetic pathway from PA-B to PA-A proposed in Gao et al. (2017).
oxidative modification of PA-A.
A key breakthrough came with the observation that deletion of mupO, mupU,
mupV or macpE in the producing organism P. fluorescens NCIMB 10586 caused the
accumulation of PA-B (Cooper et al., 2005). A branched biosynthesis pathway was
proposed in Cooper et al. (2005), where action of these enzymes occurs before pyran
ring closure, after which the pathways to PA-B and PA-A diverge.
3.1.2 Current model: PA-B is a biosynthetic precursor to PA-A
The current model is outlined in Figure 3.3. Contradictory to the historical hy-
potheses, PA-B is now proposed to be a precursor to PA-A, first described in Hother-
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sall et al. (2007). Late stage intermediates mupirocin C1 and mupirocin F1 were
isolated from 10586 ∆mupC and 10586 ∆ mupF respectively. Slight elevation in PA-B
production was observed in 10586 ∆mupP, but not at the scale of the other PA-B
producing mutants, and therefore a role for MupP was not initially proposed in
Hothersall et al. (2007).
Intermediate mupirocin P was later detected from 10586 ∆mupP by NMR, but
proved unstable (Gao et al., 2017). Further evidence for its existence was uncovered
when the stable desepoxy mupirocin P was isolated from 10586 mmpE∆OR ∆mupP
(Gao et al., 2017). The MmpE oxidoreductase domain is thought responsible for gen-
eration of the C10,11 epoxide, and therefore 10586 mmpE∆OR produces pseudomonic
acid C, a PA-A variant lacking the epoxide. When a double mutant was generated
with ∆mupP, the stable compound desepoxy mupirocin P was observed.
When 10586 ∆mupW, a strain deficient in the earlier pathway that does not pro-
duce PA-A, was fed with exogenous PA-B, 35% conversion was observed to PA-A,
providing strong further evidence for the current model (Gao et al., 2014). This model
also fits the observation of PA-B accumulation in 10586 ∆mupU, 10586 ∆macpE, 10586
∆mupO and 10586 ∆mupV (Cooper et al., 2005).
3.1.3 Objectives
Aim 1: Determine if both domains of MupV are enzymatically active
Bioinformatic re-analysis of MupV has indicated it is a dual domain protein, with
an α/β hydrolase in addition to the first oxidoreductase domain previously reported.
In-frame deletion of mupV in 10586 yields a complete switch to PA-B production
(Cooper et al., 2005), but this could be caused by the deletion of either or both of
these domains. MupV is proposed to catalyse release of pseudomonic acid from
MacpE in PA-B to PA-A tailoring, and the discovery of a second active domain could
indicate a secondary function.
Prior to the work described in this chapter, an approach was devised where mupV
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carrying mutations to either domain would be provided on an expression plasmid to
10586 ∆mupV. However, expression of WT mupV from plasmid pJH10 proved unable
to complement PA-A production in 10586 ∆mupV (unpublished work by Stephens, E.
and Di Martino, M.).
Given this setback, an alternative approach is described in this chapter, where
point mutations to mupV were introduced to the 10586 chromosome, to help deter-
mine the functionality of both domains.
Aim 2: Develop and perform a systematic screen to identify all genes required for
conversion of PA-B to PA-A
As detailed in Section 3.1.1, the models of conversion of PA-B to PA-A have
trended towards increased complexity as our understanding has improved. The most
recent example of this is the demonstration of the function of MupP (Gao et al., 2017).
Whilst the majority of mupirocin biosynthetic enzymes have been assigned functions,
there remain a number with unknown functions such as: MupZ (hypothetical), MupA
(reduced flavin mononucleotide oxygenase), MacpA (ACP), MacpB (ACP), MupL
(hydrolase), and MmpF (ketosynthase).
In this chapter, a systematic screen is described which aimed to determine the
ability of mutants of every mupirocin tailoring gene to convert PA-B to PA-A, with
the aim of re-inforcing our current pathway model and identifying or eliminating the
role of any further cluster genes.
Aim 3: Generate an expression plasmid that provides all functions required for
conversion of PA-B to PA-A
As a counterpart to Aim 2, generation of a plasmid that carries all necessary genes
could demonstrate that all required functions had been determined. Such a plasmid
should restore conversion of exogenous fed PA-B in P. fluorescens 10586 ∆mup-cluster,
a strain with the mupirocin biosynthetic cluster deleted.
This objective has previously been undertaken in the theses of Macioszek (2009)
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and Yadav (2017); however plasmid encoded conversion was not achieved, as we
now know the generated plasmids were missing required genes. Macioszek (2009)
generated pJH10-based expression vector pMMH6, which holds mupO, macpE, mupU,
mupV, mupC and mupF, and is able to complement individual chromosomal 10586
knockouts of each gene. However, it is unable to provide all the functions for con-
version of PA-B to PA-A, which is expected as mupP was not included, and is now
thought required. Plasmid pMMH6 is also lacking the resistance gene mupM, so it is
possible any conversion to PA-A would be self inhibitory.
Aim 3 of this work was to build an expression vector that provides all functions,
starting from pMMH6, using the knowledge gained in Aim 2. These new insights
would also inform the redesign of the pathway described in Chapter 4.
Aim 4: Investigation of the putative promoter within mupL and its requirement
for conversion of PA-B to PA-A
The final aim of this chapter arose from discoveries made during Aims 2 and 3
centered around mupL. This was not an initial aim as there was no knowledge of a
requirement for mupL or a promoter within it prior to this work. Investigation of this
putative promoter led to the discovery of some intriguing potential interactions with
the resistance gene mupM, which were then investigated.
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3.2 Results
3.2.1 The role of MupV in mupirocin biosynthesis
MupV was originally bioinformatically predicted to be an oxidoreductase, and P.
fluorescens ∆mupV was observed to produce PA-B (El-Sayed et al., 2003; Cooper et al.,
2005).
3.2.1.1 The bioinformatic re-analysis of MupV reveals two predicted domains
Re-analysis of the MupV amino acid sequence revealed two predicted domains,
both the previously identified oxidoreductase and a second, α/β hydrolase domain.
All prediction methods used agreed there are two domains in MupV. NCBI con-
served domains predicted domain 1 as a short chain dehydrogenase/reductase (SDR)
(E-value 1.46E−91), and domain 2 as an α/β hydrolase (E-value 9.12E−4). A HH-
pred search of the Pfam database revealed domain 1 shows homology to the NAD
binding domain of the male sterility protein (E-value 8.6E−37), and to the 3-beta hy-
droxysteroid dehydrogenase/isomerase family (E-value 2.1E−36). By the same search,
domain 2 showed homology to an α/β hydrolase fold (E-value 1.5E−23), and also to
a thioesterase domain (E-value 3.4E−10).
The hypothesis that MupV acts as a thioesterase fits with our proposed pathway,
where it is thought to catalyse release of mupirocin P from MacpE (Figure 3.3).
However, this does not explain why two domains have evolved. One possibility is
that both are required for effective thioesterase activity, another is that MupV has a
dual enzymatic function, and a third is that one domain is functionally inactive. Point
mutations to conserved residues in both domains were designed to test whether the
function of both are required for conversion of PA-B to PA-A. It was decided not to
carry out these experiments by deletion of each domain, as this could disrupt the
structure of the other domain, preventing the attribution of any phenotypic change
















































































































































































































Figure 3.4: Active site interactions of MupV domain 1 homolog UDP-N-
acetylglucosamine 4-epimerase from Pseudomonas aeruginosa.
Residues without brackets refer to 1SB8, whereas residues with brackets are the
MupV equivalent. Tyr166, equivalent to MupV (Tyr167), forms a hydrogen bond
with NAD in the active site. Generated by Ligplot for X-ray structure 1SB8 (Ishiyama
et al., 2004).
Domain 1 (SDR) has a Rossman fold with characterised active site and NAD
binding residues, allowing for the straightforward identification of key residues for
point mutation. The residue chosen was the Tyr of the active site YxxxK motif,
with the point mutation designed to change it to Phe, Y167F (Kavanagh et al., 2008).
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Figure 3.5: Sequence logo of MupV domain 2.
PSI-BLAST was used to identify a set of 55 homologs manually curated for diversity.
The sequence logo represents the frequency of each amino acid at each position in the
alignment. Underneath the logo the MupV residue at each position is listed. His631
is highly conserved, and was therefore chosen for mutagenesis.
Phenylalanine lacks the hydroxyl that forms the hydrogen bond with NAD in the
homolog, but is otherwise the same as tyrosine, minimising the chance of structural
changes to the enzyme.
Domain 2 (α/β hydrolase) does not show homology to proteins with well-characterised
active site domains. Instead, a point mutation was designed on the basis of degree
of amino acid conservation. Alignment of 55 related sequences revealed a strongly
conserved His. The point mutation was designed to change it to Ala, H631A (Figure
3.5).
3.2.1.2 Generation of mupV point mutations
As discussed in Section 3.1.3, complementation of P. fluorescens NCIMB10586
∆mupV with mupV provided in trans on expression vector pJH10 was not achieved.
Therefore a chromosomal mutagenesis strategy was pursued, where point mutations
to both domains would be introduced into the 10586 chromosome.
Generation of the MupV domain 2 H631A mutagenesis plasmid, pJC102
Primers P17 F outer H631A MupV and P17 R inner H631A MupV were used
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(a) (b) EcoRI/SalI digests.
Figure 3.6: MupV H631A mutagenesis vector, pJC102.
(a) Map of pJC102, a pJC70 derivative carrying V581A, H631A MupV mutagenesis
insert.
(b) Screening digest of potential pJC102 isolates. Isolates 1, 3 and 4 contain a 1 kb
insert, and this was confirmed as the correct fragment by DNA sequencing. Isolates
2, 5 and 6 lack an insert and appear to be re-ligated empty pJC70.
to amplify a 546 bp fragment, and P17 F inner H631A MupV and P17 R outer -
H631A MupV to amplify a 500 bp fragment. All primer sequences used are listed in
Table 2.7. The inner primers were designed to generate a 21 bp overlap, including the
H631A mutation (DNA codon CAT to GCA). The products were overlapped by PCR
to yield 1025 bp, which was AT-cloned in pGEM-T-easy, yielding pJC99. Insert pres-
ence was confirmed by blue-white screening, followed by plasmid preparation and
diagnostic EcoRI digest. Sequencing using primers M13(-40) and M13(-48) revealed
that all isolates carried a secondary mutation, V581A. Whilst unintentional, V581A
is also a point mutation to domain 2 of MupV, and therefore deemed acceptable.
The fragment was cloned using SalI/EcoRI into mutagenesis vector pJC70, yielding
plasmid pJC102. The presence of correct insert was screened by EcoRI/SalI digest
(Figure 3.6b), and sequencing with primers M13(-40) and M13(-48).
Generation of the MupV domain 1 Y167F mutagenesis plasmid
Following a similar strategy to domain 2, primers F outer Y167F MupV and
R inner Y167F MupV were used to amplify a 555 bp upstream arm, and primers
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Figure 3.7: Map of pAKE604/V.Y167F.
F inner Y167F MupV and R outer Y167F MupV a 502 bp downstream arm. The
inner primers were designed with a 23 bp overlap, including the Y167F mutation
(DNA codon TAC to TTC). The products were overlapped by PCR to yield 1034
bp, which was cloned MfeI/BamHI to pAKE604 cut EcoRI/BamHI. The resulting
mutagenesis plasmid, pAKE604/V.Y167F (Figure 3.7), was checked by EcoRI digest
and sequencing with the M13(-40) and M13(-48) primers1.
Point mutations were generated to both domains of MupV
Plasmids pJC102 and pAKE604/V.Y167F were mobilised to the mupirocin pro-
ducer P. fluorescens 10586, and mutants generated as described in section 2.2.12. As
this suicide methodology yields strains reverted to WT and mutant at a 50:50 fre-
quency, resulting strains were screened to identify correct mutants. For Y167F, no
restriction change was included in the design of the mutation. Mutants were instead
detected by sequencing of 1 kb PCR products from primers F outer Y167F MupV
and R outer Y167F MupV.
As plasmid pJC102 included both the intended H631A and unintended V581A
mutation, screening for both was necessary. Mutagenesis with this plasmid should
yield both individual mutations and the dual mutation, depending on the random
1Design and construction of pAKE604/V.Y167F, and subsequent mutagensis of 10586, were per-
formed by undergraduate project student Amber Wilson.
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position of the crossovers during the process. After pJC102 integration and excision
into 10586 WT, 20 isolates were screened for loss of kanamycin resistance. Three
were still kanR, suggestive of inactivation of SacB rather than plasmid excision. The
remaining 17 were screened by PCR of 1 kb using primers P17 F outer H631A MupV
and P17 R outer H631A MupV, followed by NgoMIV and NsiI digests. These digests
indicated that strains carrying both V581A and H631A together, and V581A individ-
ually, had been isolated (Figure 3.8). Two of each of these strains were confirmed
by sequencing of the PCR products with the outer primers, and carried forward for
assays.
3.2.1.3 Both domains of MupV are required for conversion of PA-B to PA-A
The three MupV mutant strains were assayed for active mupirocin production
against Bacillus subtilis as described in Section 2.3.2. The Y167F and H631A (with
V581A) mutations decreased the zones of inhibition compared with WT, whereas the
unintended V581A mutation displayed no effect (Figure 3.9). This demonstrated that
enzymatic activity of both domains of MupV is required for full production of active
mupirocin.
P. fluorescens 10586 ∆mupV, carrying an in-frame deletion of mupV, has been pre-
viously demonstrated to produce PA-B as its primary metabolite (Cooper et al., 2005).
HPLC analysis of the point mutations demonstrated that both domains are required
for conversion of PA-B to PA-A (Figure 3.10). This observation of accumulation of
PA-B was confirmed by our collaborators at University of Bristol by LC-MS and 1H-
NMR (C. Willis and L. Wang 2017, personal communication, 7 June). As these are
point mutations to key residues rather than deletions, the deficiency is likely due to
a lack of enzymatic function. This suggests that either both domains are involved
in the putative role in intermediate release from MacpE, or that MupV has a further
function in PA-B to PA-A conversion.
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(a) Map of mupV domain 2 PCR product.
(b) Simulated restriction digest
gel.
(c) Restriction digests, 2% agarose gel
Figure 3.8: Screening for mupV domain 2 mutations.
Map (a) and simulated digest (b) show the extra NgoMIV and NsiI sites introduced
by the V581A and H631A mutations respectively.
(c) Of the 9 PCR products from potential mutant strains shown, all contain the V581A
mutation, with the 350 bp band in place of 410 bp in the NgoMIV digest. Strains 1
and 4 have the WT NsiI restriction profile, suggesting they are not mutant at H631.
All other strains carry the H631A restriction profile.
These digests suggest strains 1 and 4 are V581A single mutants, and all others are

































Figure 3.9: Point mutation to either domain of MupV decreases mupirocin activity.
(a) Mutants Y167F and V581A+H631A show deficient zones of clearing compared
with WT. No defect is present for unintended mutant V581A.
(b) Areas of inhibition, expressed as % of WT. Bioassays were performed indepen-
dently in duplicate, error bars are standard deviation.






























Figure 3.10: HPLC of MupV point mutants.
In-frame deletion of mupV, 10586 ∆mupV, switches production from PA-A to PA-B.
Point mutation of domain 1 (Y167F) and domain 2 (H631A) reproduces this switch to
PA-B. This suggests that enzymatic function of both domains of MupV is required for
conversion of PA-A to PA-B. Analyses were performed independently in triplicate,
and representative chromatograms shown.
92
3.2.2 Screening tailoring gene mutants for the ability to convert PA-
B to PA-A
Deletion of mupU, macpE, mupV, or mupO causes accumulation of PA-B, directly
implicating these genes as required for conversion to PA-A (Cooper et al., 2005). Dele-
tion of mupC and mupF cause accumulation of later stage intermediates mupirocin C
and F respectively (Hothersall et al., 2007). Recently, requirement for further genes
or functions has been demonstrated: mupP (Gao et al., 2017), and both domains of
mupV (in this work). Given the historical identification of further genes required
for conversion to PA-A, together with the several mupirocin cluster genes without
assigned functions, an approach was devised to systematically screen all mupirocin
tailoring genes for ability to convert PA-B to PA-A.
This approach aimed to identify all required genes by feeding PA-B to individ-
ual chromosomal mutations of each tailoring gene. Firstly, the logical preliminary
objective was to observe conversion of fed PA-B to PA-A in a positive control strain.
This was initially attempted by co-inoculation of SSM media with saturated LB
culture of 10586 ∆mmpA and 10586 ∆mupU. The ∆mupU mutant is known to produce
PA-B, whereas MmpA is a PKS in part responsible for monic acid biosynthesis, and
therefore 10586 ∆mmpA does not produce any pseudomonic acid but is expected
to be able to convert PA-B to PA-A. Theoretically, in co-culture the ∆mupU mutant
could generate PA-B that the ∆mmpA strain could convert to PA-A. However, no
pseudomonic acid production was detected by HPLC from these co-cultures.
3.2.2.1 A Pks− strain, deficient in pseudomonic acid production, is able to convert
fed PA-B to PA-A
With the failure of the co-culturing approach, an alternative was pursued where
PA-B would be extracted and fed to test cultures. To decrease the amount of PA-B
required, it was necessary to downscale the 25 ml SSM production cultures used
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in previous experiments with 10586. Good mupirocin yields were observed from 5
ml SSM cultures in 50 ml conical flasks, whereas no yield was observed from 5 ml
cultures in vented 50 ml Falcon tubes or 30 ml universal containers.
Plasmid pJH2, carrying the gene for transcriptional activator MupR, was mo-
bilised to 10586 ∆mupU. Expression of mupR in trans has been observed to increase
mupirocin metabolite production (Hothersall et al., 2011). To generate PA-B, 200 ml
SSM cultures in 2 L flasks were inoculated with 10586 ∆mupU [pJH2]. One possibility
for purifying PA-B was to fraction collect by HPLC, however this would not have
efficiently generated the scale of PA-B necessary for these experiments.
Instead, ethyl acetate extractions were performed: the ethyl acetate top layer was
collected and evaporated to less than 500 µl yellow oily liquid per 200 ml starting
culture, using the method described in Section 2.3.4. To aid resuspension of any solid
matter, 2 to 4 ml of methanol was added to each. The approximate concentration of
PA-B present in each extract was analysed by comparison to mupirocin standards by
HPLC. For the first two batches of PA-B generated, a working concentration of 1%
(v/v) was used in subsequent experiments (very approximately 200 µM). The third
batch contained a higher concentration of PA-B, and a working concentration of 0.5%
(v/v) was used, also approximately 200 µM.
As a preliminary experiment, SSM cultures of Pks− strain 10586 ∆mmpA were fed
with PA-B in triplicate. Gratifyingly, 42.2% ±4.8 (s.d.) of the fed PA-B was converted
to PA-A, measured by integrated peak area (Figure 3.11). No PA-A was detected in
negative control 10586 ∆mup-cluster, a strain with all mupirocin biosynthesis genes
deleted with the exception of transcriptional regulators mupR, mupX and mupI. As
expected, deletion of genes known to be required for conversion such as mupU as
part of the cluster deletion, prevents conversion from occuring. This demonstrated
that this method can screen for mutants that are deficient in conversion.
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Figure 3.11: HPLC: conversion of fed PA-B to PA-A by 10586 ∆mmpA.
Strains 10586 ∆mmpA and ∆mup-cluster both produce no pseudomonic acids in the
methanol (1% v/v) control. When fed with PA-B extract (1% v/v) (shown in red),
conversion is observed in ∆mmpA but not ∆mup-cluster.
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3.2.2.2 Identification of tailoring genes required for conversion of PA-B to PA-A
Continuing from the successful preliminary experiment, the same method was
used to screen individual mutations to 35 mupirocin tailoring genes. SSM cultures
were grown with 0.5% methanol or 0.5% PA-B, initially in duplicate, and supernatants
analysed by HPLC. The amount of PA-A and PA-B present in each sample was
determined by integration of HPLC peak areas.
To determine the percentage of conversion of fed PA-B to PA-A, samples were
first adjusted for their methanol controls, to account for any inherent production of
either compound by the strains. The calculations are listed below, where A = area of
PA-A, B = area of PA-B, xPA−B = from sample fed with PA-B, xMeOH = from control
sample fed with methanol:
A = APA−B − AMeOH




This screening method proved successful, with a distinct phenotype between
converters and non-converters for the majority of genes (Figure 3.12). Mutants of
genes macpE, mupF, mupU, mupO, mupP and both domains of mupV were deficient in
conversion, all of which were already thought required in the current model (Section
3.1). Mutants of genes with characterised functions earlier in the pathway, such as
mmpA or mupW and mupT, were capable of conversion as expected.
Interestingly, deletions of multiple further genes were deficient in conversion:
∆mupM, ∆mupN and ∆mupR. These are logical requirements, mupM encodes the
mupirocin resistance gene, and this requirement is explored further in Section 3.2.4.
Gene mupN encodes a phosphopantetheinyl transferase, and this is the first evidence
that it is presumably obligately required for generation of the MacpE holoenzyme.
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(b) Example HPLC chromatograms
Figure 3.12: Screening of 10586 mutants for ability to convert PA-B to PA-A.
Mutations to macpE, mupF, mupM, mupN, mupO, mupP, mupR, mupU and mupV were
unable to convert fed PA-B to PA-A. The ∆mupL mutant was observed to variably
convert or not convert. The mupC mutant is able to produce some PA-A as well as
mupirocin C.
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Table 3.1: Genes implicated by screening experiment as required for conversion
Gene Putative encoded function









mupU Acyl CoA synthase
mupV Oxidoreductase and thioesterase
in vitro, whereas soluble MacpE was not achieved in the experiment (Shields et al.,
2010). Thirdly, mupR encodes the transcriptional activator known to be required for
mupirocin gene expression (Hothersall et al., 2011).
The ability of the non-mupirocin producing, ∆mupI mutant to convert was supris-
ing, and this is explored in the following Section 3.2.2.3.
Two further mutants demonstrated an intermediate phenotype, ∆mupC and ∆mupL.
The mupC mutant has been previously observed to produce a lower amount of PA-A
than WT, as well as intermediate metabolites mupirocin C1 and C2 (Gao et al., 2014).
The mupL mutant was observed to be variably able to convert PA-B to PA-A (n=16).
This variability was also observed and explored further in experiments described in
Section 3.2.4.
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3.2.2.3 The extracted PA-B includes the signalling lactone, facilitating the conver-
sion of PA-B to PA-A by P. fluorescens ∆mupI
The 10586 ∆mupI knockout mutant has previously been observed to be deficient
in pseudomonic acid production (El-Sayed et al., 2001). MupI is an N-acylhomoserine
lactone synthase, responsible for production of the quorum sensing signalling molecule
(Hothersall et al., 2007). This lactone is required for activation of transcription of the
mupA promoter, and likely other promoters in the mupirocin biosynthesis cluster (El-
Sayed et al., 2001). The observation in Section 3.2.2.2 that the ∆mupI mutant is able to
convert fed PA-B to PA-A is therefore unexpected. In this mutant, there should not
be expression of other genes required for conversion, such as macpE or mupO.
One hypothesis that explains this observation is that the extract is complementing
the lack of MupI. As the PA-B extract was generated from the supernatant of a
∆mupU strain without any selective purification, it could have contained the MupI
product, the signalling lactone. This hypothesis was tested using a xylE reporter strain
generated in El-Sayed et al. (2001), 10586 ∆mupI mupA::xylE. This strain lacks MupI,
and therefore does not produce homoserine lactone, and has chromogenic reporter
gene xylE fused to mupA downstream of its promoter. This allows for detection of
induction of mupA expression using catechol, and the method is described in Section
2.3.3.
This reporter strain can detect the presence of the signalling lactone. When grown
close to 10586 WT on solid media, the WT produces the lactone, which diffuses to the
reporter and activates xylE expression. This is demonstrated by the positive control,
the reporter next to 10586 WT turns yellow in presence of catechol (Figure 3.13a). As
expected, no colour change is observed in the reporter next to the negative control
test 10586 ∆mupI, as this strain does not generate the lactone (Figure 3.13b).
To test the PA-B extract for lactone presence, 20 µl PA-B extract, or methanol as a
negative control, were spotted onto paper discs and dried overnight. The discs were




Figure 3.13: Transcriptional xylE assay demonstrating presence of signalling lac-
tone in PA-B extract.
The reporter strain, 10586 ∆mupI mupA::xylE, expresses xylE in the presence of the
signalling homoserine lactone, that it does not produce itself (El-Sayed et al., 2001).
Lactone presence activates xylE expression, the product XylE catalyses the conversion
of catechol to the yellow compound 2- hydroxymuconic semialdehyde (Zukowski
et al., 1983).
(a) 10586 WT produces the signalling lactone that induces expression of xylE in the
reporter strain, n=2.
(b) 10586 ∆mupI does not produce the lactone, therefore no xylE expression or colour
change is observed, n=2.
(c) The PA-B extract is able to induce xylE expression in the reporter (n=9) as it con-
tains the lactone, whereas no colour change is observed in the methanol negative
control.
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sprayed with catechol, the reported clearly turned yellow in the proximity of the
PA-B extract and not in proximity of the negative control (Figure 3.13). This result
neatly explains how the 10586 ∆mupI mutant is able to convert fed PA-B, because the
extract also contains the signalling lactone.
3.2.3 Demonstration of the minimum set of genes required for con-
version of PA-B to PA-A
The counterpart to screening for all genes required, is to clone them all to build
a multi-gene expression plasmid, then test if it can provide all functions necessary
for conversion. This idea was first explored in the PhD thesis of Macioszek (2009),
who generated pJH10 based expression plasmid pMMH6, carrying: mupO, macpE,
mupU, mupV, mupC and mupF. This plasmid was demonstrated to complement the
mupirocin production deficiency of individual in-frame deletions of each included
gene in 10586, detected by bioassay. However, pMMH6 did not include all genes
required, and as such was unable to catalyse conversion of PA-B to PA-A.
Later mutagenesis and feeding experiments using PA-C demonstrated mupP is
also required for C8-OH removal (Gao et al., 2017). Insertion of mupP into pMMH6
was attempted in the PhD work of Yadav (2017), but due to difficulties with cloning,
this was not achieved. The systematic approach undertaken in Section 3.2.2.2 has also
implicated mupM and mupN, as well as a variable phenotype for mupL. Therefore
an aim of this study became to clone mupP, L, M, N into pMMH6 already carrying
mupO,U,V,C,F, and macpE.
3.2.3.1 Construction of expression vector carrying mupOPUVCF and macpE
Plasmid pMMH6 proved a very useful starting point, as it already carried six of
the desired ten genes, and they had been confirmed functional by bioassay. However,
the restriction cloning opportunities were fairly limited, and the stop codon of mupO
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was missed in the design of pMMH6, resulting in an additional 27 random amino
acids on MupO before a stop codon was reached. As such, the planned approach
was to clone mupO, mupP, macpE on a KpnI/AflII fragment, and then insert mupL,
mupM, mupN XbaI/NotI, at the back of the cloned operon.
A schematic and maps of the constructions are shown in Figure 3.14. Primers
P25 F mupOP KpnI SpeI and P25 R mupOP overlap were used to amplify a 2371 bp
fragment carrying mupO and mupP, which neighbour each other on the chromosome.
These were designed to include the ribosome binding sites (RBS) of both genes.
Primers P25 F macpE overlap and P25 R macpE AflII were used to amplify a 278 bp
fragment carrying macpE, again with the native RBS. These were designed to overlap,
and SOEing PCR performed to generate a 2627 bp fragment carrying mupO, mupP
and macpE. This fragment was cloned KpnI/AflII into pMMH6, resulting in pJC124,
after effectively replacing mupO/macpE with mupO/mupP/macpE. A unique SpeI site
was included next to KpnI to maintain future cloning flexibility.
Plasmid DNA from transformants that could potentially contain the planned
pJC124 were checked by diagnostic KpnI/AflII digests (Figure 3.15), and sequenced
using primer P25 R macpE AflII (partial coverage). The XbaI site of pMMH6 and
consequently pJC124 is blocked by Dam methylation, and therefore pJC124 was
transformed and prepped from Dam− E. coli ER2925. Further diagnostic digests
were performed, both repeating the KpnI/AflII digests, and using XbaI/NotI to check
agreement with the restriction map prior to the next step (not shown).
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Figure 3.14: Map and construction of pJC124.
A 2.6 kb PCR product carrying mupO, mupP and macpE was cloned KpnI/AflII to
pMMH6, yielding pJC124.
Figure 3.15: Diagnostic KpnI/AflII digest of pJC124.
Isolates 1, 2, 3 and 7 have the 2.6 kb fragment indicative of size increase due to mupP.
Isolates 3, 4, 8, and 9 appear to be recircularised pMMH6, whereas isolates 6, 10, 11
and 12 appear to be recircularised vector that has lost the KpnI/AflII fragment.
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Figure 3.16: Complementation analysis to check that genes present in pJC124 are
functional.
Areas are average zones of clearance of B. subtilis expressed as a percentage of 10586
WT, n=4 for pJC124, n=2 for pJH10 and pMMH6; error bars show standard deviation.
Complementation of 10586 ∆mupO, 10586 ∆mupP, and 10586 ∆macpE by pJC124
In generating pJC124, mupO, mupP and macpE were derived from overlap PCR
products, which could therefore contain sequence errors. Sanger sequencing with
primer P25 R macpE AflII yielded relatively short reads of approximately 500 bp,
leaving the majority of the cloned 2.6 kb unsequenced. Instead of performing further
sequencing, pJC124 was tested for its ability to complement individual chromosomal
mutations of each of the three genes.
Empty expression vector pJH10 and tailoring gene plasmids pMMH6 and pJC124
were mobilised into 10586 ∆mupO, 10586 ∆mupP, and 10586 ∆macpE. Bioassays were
performed against the susceptible test strain, B. subtilis (Figure 3.16). With the empty
vector, all three mutations are inhibitory to active mupirocin production, as predicted.
Plasmid pMMH6 is able to complement 10586 ∆mupO and ∆macpE as reported by
Macioszek (2009). Suprisingly, intermediate complementation of ∆mupP was also
observed, despite pMMH6 not carrying mupP. This could perhaps indicate that over-
expression of the related pathway genes, mupO,U,V,C,F, macpE on pMMH6 is able to
overcome some of the ∆mupP deficit.
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Table 3.2: Ribosome binding site of mupO






Plasmid pJC124 was observed to complement all three mutations to WT levels,
both with and without IPTG induction. Plasmid pMMH6 only complemented 10586
∆mupO and 10586 ∆macpE fully with IPTG induction. This could be caused by the
missed stop codon on mupO in pMMH6 having translational effects on downstream
genes; in pMMH6 macpE begins 61 bp before the artificial stop codon of mupO.
There is also a difference in the design of mupO cloning between the plasmids, with
the RBS in pMMH6 beginning with C compared with G in pJC124 and the 10586
chromosome (Table 3.2). However, neither of these match the E. coli consensus at this
position (Chen et al., 1994). Another possibility is that insertion of mupP in pJC124
has downstream translational effects.
The full complementation of knockout mutants of each of the three genes, indi-
cated that pJC124 carried functional copies of each, an important conclusion for later
experiments.
3.2.3.2 Addition of mupLMN to expression vector
The last step towards building an expression vector carrying all necessary genes
identified in the systematic screening experiment, was cloning mupL, mupM and
mupN into pJC124. As a variable mupL phenotype was observed in Section 3.2.2.2,
versions with and without mupL were designed. As these genes lie together on the
10586 chromosome, mupL, M, N were amplified as a 5102 bp PCR product, using
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primers P25 F mupLMN and P25 R mupLMN. A 4074 bp PCR product carrying
mupM and mupN was amplified using primers P25 F mupMN and P25 R mupLMN.
These were designed to include the native RBS for each gene.
There is a NotI site internal to mupN, and cloning XbaI/NotI was one of the very
few available possibilities in pJC124. This site could have been removed through over-
lap PCR by introducing silent point mutation, but instead a quicker BsaI approach
was used, detailed in Figure 3.18. The mupMN and mupLMN PCR products were
AT ligated into cloning vector pGEM-T, yielding plasmids pJC128 and pJC129 respec-
tively. Correct isolates were identified using SacI and BsaI/XbaI diagnostic digests,
and by sequencing using primers M13(-40) and M13(-48).
The mupMN and mupLMN inserts were released from pJC128 and pJC129 respec-
tively by XbaI/BsaI digest. These were ligated to XbaI/NotI digested pJC124 isolated
from dam− E. coli ER2925, as the XbaI site overlapped a Dam methylation site. This
yielded plasmid pJC133, carrying mupO, P, macpE, mupU, V, C, F, L, M, N, and pJC132
carrying the same genes without mupL (Figure 3.17). Isolates were checked by SacI
diagnostic digest (Figure 3.19).
3.2.3.3 Expression plasmid pJC133 can complement individual chromosomal dele-
tions of each of the ten genes carried
In sequencing of pGEM-T cloning vectors used to construct pJC132 and pJC133,
only coverage of mupL and mupN was achieved. The larger mupM was not covered by
the sequencing reads. Instead, the ability of pJC133 and pJC132 to complement 10586
∆mupM would be tested. The ∆mupM has a dual phenotype: defective mupirocin
production and decreased mupirocin resistance (Hothersall et al., 2007). Complemen-
tation of the resistance phenotype is later explored in Section 3.2.4.3.
For completeness, both plasmids were mobilised to individual 10586 chromosomal
in-frame deletions of each of the ten (nine for pJC132) mupirocin genes carried, along
with the empty expression vector, pJH10. Bioassays were performed on each inde-
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Figure 3.17: Maps and construction of pJC132 and pJC133.
PCR products carrying mupM, N and mupL, M, N were amplified, cloned in pGEM-T,
then digested XbaI/BsaI. These were ligated to pJC124 XbaI/NotI, to yield expression












    5'-GGCCGC...-3'
        3'-CG...-5'






BsaI digested PCR product
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Figure 3.18: Generation of a NotI overhang using BsaI.
As the mupLMN PCR product would contain an internal NotI site, a BsaI site was
used instead. BsaI cuts away from its recognition site, such that a 5’ overhang of any
four nucleotides can be generated. NotI is a more typical 8-cutter, that cuts in the
middle of its recognition palindrome.
Figure 3.19: SacI diagnostic digests of pJC132 and pJC133.
As digest by XbaI would require passage through a dam− strain, a SacI diagnostic
digest was performed instead. As seen in the simulated gel on the left, the size of the
middle fragment is expected to increase when mup(L)MN is cloned in pJC124. All
of the potential pJC132 isolates (1 to 9) have the correct 6.3 kb fragment for mupMN
insertion. Isolates 11 and 12 have the correct restriction profile for pJC133, whereas











































Figure 3.20: Complementation of chromosomal knockouts by pJC132 and pJC133.
Bioassay areas against B. subtilis, expressed as percentage WT area. All combinations
were performed in triplicate with 500 µM and no IPTG induction. Error bars represent
standard deviation. The graph shows the best performing induction condition in each
case, which was 0 IPTG for all, except ∆mupM [pJC132] and ∆mupN [pJC132], which
were 500 µM IPTG (marked #).
pendently in triplicate, both with 500 µM IPTG induction and without IPTG (Figure
3.20). Complementation was observed of each knockout to approximately 65 to 90%
of WT area. There were some exceptions to this, as ∆mupL was not complemented
by pJC132, as expected since the plasmid lacks mupL. Complementation of the mupL
mutation by pJC133 was observed at the lower level of 44% of WT. Plasmid pJC132
complemented the mupM and mupN mutants to a lower level than pJC133; this is
putatively due to a promoter present within mupL in pJC133, and this is explored in
Section 3.2.4.3.
Complementation of mupL, mupM and mupN was also confirmed by HPLC (Figure
3.21). Mirroring the bioassay results, pJC133 was observed to complement individual
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Figure 3.21: HPLC: plasmid pJC133 carries functional copies of mupL, mupM and
mupN.
Representative HPLC chromatograms, analyses performed independently in qua-
druplicate without IPTG induction. Prednisone is included as an internal HPLC
standard. Deletion of mupL, mupM or mupN is inhibitory to mupirocin production,
no pseudomonic acid was observed with the negative control pJC124 [-], which is the
expression plasmid prior to mupLMN cloning. Plasmid pJC133 [LMN] was observed
to complement all three mutant strains, providing evidence that functional copies of
each gene are carried on pJC133. Plasmid pJC132 [MN] was observed to complement
10586 ∆mupN but not ∆mupL or ∆mupM.
10586 chromosomal deletions of each of these genes. By contrast pJC132, which lacks
mupL, did not complement the ∆mupL or ∆mupM strains, without IPTG induction.
The demonstration of complementation of the three new cloned genes mupL,
mupM and mupN by HPLC, together with the improvement in zone of inhibition for
all mutants carrying pJC133, provides evidence that functional copies of all genes are
carried on the plasmid. These plasmids could now be tested for ability to provide all
functions necessary for conversion of PA-B to PA-A.
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3.2.3.4 Conversion of PA-B to PA-A by functions provided in trans on plasmid
pJC133 achieved
To test if plasmid encoded conversion could be achieved, pJC132 and pJC133,
along with empty vector pJH10, were mobilised to 10586 ∆mup-cluster. This 10586
strain has all mupirocin biosynthesis genes deleted, with the exception of the tran-
scriptional regulatory genes mupR, mupX and mupI, and cannot therefore convert
PA-B to PA-A (Figure 3.11). SSM cultures of 10586 ∆mup-cluster carrying plasmids
pJH10, pJC132 and pJC133, fed with 1% (v/v) PA-B, both with and without IPTG
induction, were performed in quadruplicate. SSM with 1% (v/v) methanol negative
control cultures were performed in duplicate.
In HPLC analysis of supernatants of negative methanol controls (without fed PA-
B), no peaks were observed at either the PA-B or PA-A positions. When PA-B was
fed to 10586 ∆mup-cluster carrying the empty vector pJH10, no conversion to PA-A
was observed (Figure 3.22). These results mirror the observations of Section 3.2.2.1
(Figure 3.11).
Gratifyingly, HPLC revealed conversion of 42% ±1.7 (s.d.) PA-B to PA-A in ∆mup-
cluster [pJC133] without IPTG induction (Figure 3.22). No conversion was observed
with the empty pJH10, or pJC132, which lacks mupL; this is explored in the following
Section 3.2.4. No conversion was observed in any combination of strain and plasmid
with 500 µM IPTG induction (not shown). This indicates that all mupirocin cluster
functions required for conversion are included on plasmid pJC133, with the exception
of the transcriptional regulators still present in 10586 ∆mup-cluster.
3.2.3.5 Further assorted short experiments with expression plasmid pJC133
With the significant milestone of in trans encoded conversion achieved, plasmid
pJC133 facilitated several short further experiments.
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Figure 3.22: HPLC: conversion of PA-B to PA-A via plasmid encoded functions.
Representative chromatograms shown, 0 IPTG, analysis performed independently in
quadruplicate. Each sample was fed with 1% PA-B extract at the point of inoculation.
No PA-A was observed in 10586 ∆mup-cluster carrying the empty vector, as it is
unable to produce PA-A or convert fed PA-B to PA-A. With plasmid pJC132 in trans
[MN], no conversion is observed. With plasmid pJC133 [LMN], conversion of fed PA-
B to PA-A is restored, indicating all necessary biosynthetic genes from the mupirocin
cluster have been cloned in pJC133.
Conversion does not require the genes mupR, mupX or mupI
As the regulatory genes mupR, mupX and mupI are still present in 10586 ∆mup-
cluster, it was still possible that these could be required for pJC133 based conversion.
However, this seemed unlikely, as cloned gene transcription in pJC133 is driven by the
lac/trp fusion tac promoter, which is completely unrelated to mupirocin regulation.
To eliminate this possibility, pJC133 and empty vector pJH10 were mobilised to 10586
∆mupR, 10586 ∆mupX and 10586 ∆mupI. HPLC of SSM culture supernatants fed
with and without PA-B, without IPTG induction, were performed in triplicate (Figure
3.23).
As expected, plasmid pJC133 was observed to provide conversion functions in
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Figure 3.23: HPLC: conversion of PA-B to PA-A in mupI, mupR and mupX knock-
outs with pJC133.
Analysis was performed without IPTG induction, independently in triplicate. Pred-
nisone was used as an internal standard in biological samples. Each sample was
fed with 0.5% (v/v) PA-B at the point of inoculation. Plasmid pJC133 can provide
all functions necessary for conversion without mupR, mupX or mupI individually.
With the exception of unlikely redundancy, this demonstrates all mupirocin cluster
conversion functions are present on pJC133.
∆mupR and 10586 ∆mupX. This demonstrates that mupR and mupX are not required
for pJC133 based conversion. As detailed in Section 3.2.2.3, the ∆mupI mutation is
complemented by the lactone present in the PA-B extract, and is therefore already
able to convert to PA-A, as well as likely produce PA-A from its mupirocin pathway.
In this case, pJC133 was observed to increase the proportion of PA-A from 53% ±4
(s.d.) in ∆mupI [pJH10] 0.5% PA-B, to 70% ±3 (s.d.) in ∆mupI [pJC133] 0.5% PA-B.
This increase is significant, by unpaired two-tailed t test (p=0.0036<0.05).
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Table 3.3: Mupirocin MICs (µg ml−1)
Strain [pJH10] [pJC133]
P. fluorescens 10586 >3000 >3000
P. fluorescens SBW25 1500 >3000
E. coli DH5α 94 188
Plasmid based conversion not achieved in alternative strains
The ability of pJC133 to provide conversion functions was also assayed in alter-
native strains, E. coli DH5α and P. fluorescens SBW25, both of which do not contain
mupirocin clusters. LB cultures with 0.5% PA-B were inoculated with DH5α [pJC133]
in triplicate, but no conversion was observed (not shown). In DH5α supernatants,
a compound was observed in the negative controls at the PA-A position, which
absorbed at 233 nm on the UV HPLC detection. This meant that low levels of con-
version would not have been detected, but certainly there was no conversion to PA-A
of the same order as in 10586 (approximately 40%). Conversion was also tested in
P. fluorescens SBW25 [pJC133] using SSM media cultures, but no conversion was
observed.
The mupirocin resistance of both P. fluorescens SBW25 and E. coli DH5α with
pJH10 (empty vector) and pJC133, was determined in duplicate as detailed in Section
2.3.5. An increase in resistance was observed in both strains in the presence of
pJC133, indicative of in trans MupM expression. However the DH5α mupirocin MIC
remained low at 188 µg ml−1 with pJC133, which is of a similar order of magnitude to
the concentration of PA-B included in feeding experiments. Therefore, if DH5α were
able to convert to PA-A, it seems likely that the antibiotic would be self-inhibitory.
The poor performance of mupM expression in E. coli may suggest that the other nine
genes are unlikely to all function efficiently as well.
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Expression plasmid pJC133 is not immediately suitable for in vitro protein exper-
iments
To test if pJC133 might prove suitable for in vitro protein experiments, E. coli
DH5α [pJC133] and E. coli BL21 [pJC133] cultures were grown at various tempera-
tures and induction conditions. Cells were lysed by sonication, and run on SDS-PAGE
gels with coomassie staining. DH5α [pJC133] was compared with DH5α [pJH10] for
each condition, and no difference in banding was observed in any case (not shown).
As no difference was observed to the empty vector, there was no indication of high
scale protein expression. To explore in vitro protein experiments in the future, a sen-
sible approach would be to clone the individual genes into a generic E. coli protein
expression vector such as pET28a.
3.2.4 Investigation of the roles of mupL and mupM in conversion of
PA-B to PA-A
In screening 10586 mutants for conversion of PA-B to PA-A, the mupL mutant
demonstrated a reproducibly variable phenotype (Figure 3.24). Three independently
generated 10586 ∆mupL strains were included in the conversion tests, performed by
PA-B feeding and monitoring by HPLC (as described in Section 3.2.2.2). For each of
these independent strains, it was observed that some cultures would convert PA-B to
PA-A, but others would not. This demonstrates that the phenotype is unlikely to be
caused by a random secondary mutation to another mupirocin gene. Therefore, the
mupL gene is needed to allow consistent conversion of PA-B to PA-A.
Similarly, plasmid pJC133, carrying ten genes including mupL, was able to pro-
vide all functions required for conversion (Section 3.2.3.4), whereas pJC132, a sister
expression plasmid carrying nine genes without mupL, failed to restore conversion in
10586 ∆mup-cluster, n=6. This indicated that the mupL gene is strictly required for in
trans conversion in this configuration. However, this did not agree logically with the
screening experiments, wherein approximately 50% of the cultures conversion would
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Figure 3.24: Variable levels of conversion observed in the ∆mupL mutant.
Conversion to PA-A measured by integrated HPLC peak area, as detailed in Section
3.2.2.2. Each data point represents an independent culture and analysis; X-axis varia-
tion is simply to prevent overlap of data points. The ∆mupP mutant is known to be
deficient in conversion (Gao et al., 2017), whereas the ∆mmpB mutant is included as
a positive converter.
occur in the absence of mupL.
This led to investigation of whether MupL enzymatic activity is required for
conversion, and whether there were effects on expression of downstream gene mupM.
3.2.4.1 MupL first acts before MupU in mupirocin biosynthesis
The relative order of mupirocin biosynthesis enzyme action has previously been
explored by dual mutations. Starting with two individual mutants with different
mupirocin production phenotypes, if a dual mutant mirrors one of these phenotypes,
it indicates that the mutated enzyme acts first in the pathway. This approach was
used to demonstrate MupU acts before MupC (Hothersall et al., 2007).
A similar experiment was conceived to determine whether MupL or MupU acts
first in mupirocin biosynthesis. MupU (Acyl CoA synthase) putatively loads MacpE




Figure 3.25: Screen for double mupL and mupU knockout 10586 mutants.
Strains A1-5 are 10586 ∆mupL mutants that have undergone suicide mutagenesis
with p604/∆mupU. Stains B1-8 are the inverse, starting ∆mupU, screening for mupL
mutation. Hence all of B1-8 have the 1.1 kb deleted mupU size PCR product, compared
with 2.6 kb WT mupU. This PCR screening revealed strains A1, A2, A4, B1, B2, B7
and B8 are all the desired double mutants.
lite. The role of MupL (putative hydrolase) in mupirocin biosynthesis is unknown.
To generate a double knockout mutant, individual mutants 10586 ∆mupL (Hother-
sall et al., 2007) and 10586 ∆mupU (Cooper et al., 2005) were used as starting points.
The second knockout was generated in each strain using the mutagenesis plasmids
pAKE604/∆mupU and pAKE604/∆mupL respectively. Suicide mutagenesis was per-
formed as described in Section 2.2.12. After mutagenesis plasmid excision, mutants
were identified by PCR screening with primers mupL1F, mupL1R, and mupU1F,
mupU1R (Figure 3.25).
To test the phenotype of the double mutant, 10586 ∆mupL ∆mupU, SSM cultures
and HPLC analysis were performed in quadruplicate (isolates A1, A4, B1, B8). For
117




1 0 0 0
1 2 5 0
W T
 m u p L
 m u p U
 m u p L   m u p U








P A - B P A - A
Figure 3.26: HPLC: 10586 ∆mupU ∆mupL does not produce pseudomonic acid B.
Representative chromatograms shown, experiment performed independently in trip-
licate, except ∆mupL∆mupU that was performed in quadruplicate. Single mutant
10586 ∆mupL does not produce pseudomonic acid, whereas 10586 ∆mupU primarily
produces PA-B. The double mutant 10586 ∆mupL ∆mupU does not produce pseu-
domonic acid, mirroring the ∆mupL phenotype.
comparison, 10586 WT, 10586 ∆mupL and 10586 ∆mupU were performed in triplicate.
HPLC analysis revealed that the double mutant phenotype mirrored the ∆mupL phe-
notype, with no pseudomonic acid production observed (Figure 3.26). This suggested
that MupL acts first before MupU in the pathway. Therefore, MupL would have to
act multiple times in mupirocin biosynthesis if it were to also act after MupU in the
conversion of PA-B to PA-A.
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(a) MupL homolog amino acid sequence logo
(b) MupL Pfam output
Figure 3.27: Analysis of MupL homologs.
(a) The sequence logo shows the amino acids near the His256 chosen for mutation to alanine. The numbering is relative to
MupL.
(b) The Pfam output shows the level of conservation of the full MupL protein sequence. The lines are labelled as follows:
#HMM is the hidden Markov model consensus, #MATCH represents the matches between the HMM and MupL sequences,
#PP is a confidence degree (higher is better), and #SEQ is the MupL sequence.
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3.2.4.2 Enzymatic activity of MupL is not required for conversion
To test whether MupL enzymatic activity is required for conversion, versions of
pJC133 carrying point mutations to mupL were generated. MupL is a predicted α/β
hydrolase that does not show strong homology to any well characterised enzyme.
Consequently, sequence conservation was used to choose mutation targets, rather
than relying on experimental evidence from homologs, as was the case with MupV
domain 1.
An alignment of 42 proteins homologous to MupL was generated, manually
curated for diversity. This revealed a histidine is completely conserved within the
alignment at position 256 in MupL, which was chosen as a mutation target to alanine
(Figure 3.27).
Construction of the mupL point mutant expression plasmid
The mutation was generated in a similar fashion to that used to insert mupL,
mupM, and mupN into pJC124 to generate pJC133 (Section 3.2.3.2). Primers P25 F -
mupLMN and P31 R mupL H256A were used to amplify an 809 bp fragment. Primers
P31 F mupL H256A and P25 R mupLMN were used to amplify a 4313 bp fragment.
These were designed to overlap, carrying the H256A mutation (DNA codon CAC
mutated to GCC). The two fragments were stitched by SOEing PCR using the outer
primers P25 F mupLMN and P25 R mupLMN, to generate a 5102 bp fragment.
This fragment carried mupL (with H256A mutation), mupM and mupN, with XbaI
and BsaI (NotI overhang) restriction sites. The overlapped fragment was AT cloned in
pGEM-T, yielding intermediate plasmid pJC145. Correct insert size was confirmed by
XbaI/BsaI digest, and sequencing performed using primers M13(-40) and M13(-48).
The insert was released by XbaI/BsaI digest, and cloned into pJC124 XbaI/NotI,
isolated from dam− E. coli ER2925. This resulted in expression plasmid pJC133.H256A,
carrying mupO, P, macpE, mupU, V, C, F, L, M, N, with point mutation H256A to
mupL. The presence of insert of the correct size was detemined by SacI digest (Figure
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3.28). The construction technique used exactly mirrored the cloning technique used
previously to generate pJC133 (Figure 3.17).
The point mutation H256A is disruptive to MupL enzymatic function
Plasmid pJC133.H256A, together with pJC133 and empty pJH10 as controls,
were mobilised to 10586 ∆mupL to check for disruption of MupL enzymatic func-
tion. As mupM and mupN had been derived from PCR product in construction of
pJC133.H256A, the plasmids were also mobilised to 10586 ∆mupM and ∆mupN, to
check for ability to complement, therefore detecting any significant PCR errors.
Antibiotic activity produced by all combinations of strain and plasmid were tested
by plate bioassay against B. subtilis (Figure 3.29). As expected, 10586 ∆mupN, 10586
∆mupM, and 10586 ∆mupL were deficient in active mupirocin production, as indi-
cated by the decreased zones observed with empty vector pJH10. Both pJC133 and
pJC133.H256A were observed to complement the ∆mupM and ∆mupN mutations,
which demonstrated that pJC133.H256A carries functional copies of both of these
genes.
Plasmid pJC133 complemented the ∆mupL mutation to 70% of WT area, whereas
no complementation was observed for pJC133.H256A. This provided evidence that
mutant version of MupL is not enzymatically functional, either because the conserved
His256 is required for function or because the mutant version no longer folds correctly.
Plasmid pJC133.H256A can still provide all functions required for conversion
Plasmid pJC133.H256A, along with controls pJH10 and pJC133, were mobilised
to P. fluorescens ∆mup-cluster. SSM cultures were grown with 0.5% PA-B, and the
supernatants analysed by HPLC (Figure 3.30). Conversion to PA-A was still observed
with inactivated MupL, at the same level as with functional MupL present. This
clearly indicated that MupL enzymatic function is not required for conversion of
PA-B to PA-A.
The observed conversion phenotypes for the different mupL experiments are sum-
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(a) Plasmid map (b) SacI digest gel
Figure 3.28: Map and digest of plasmid pJC133.H256A, carrying point mutation to
mupL.
Isolate 2 has the correct SacI restriction profile for pJC133.H256A. Isolates 1, 3, and 5
appear to have lost a SacI site, most likely recircularised XbaI/NotI digested pJC124.
























Figure 3.29: The H256A mutation results in loss of MupL function.
Bioassay zones of inhibition against B. subtilis, expressed as percentage area of WT
[pJH10]. WT, ∆mupN and ∆mupM experiments were performed independently in
triplicate, for ∆mupL n=9. Error bars represent the standard error of the mean.
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Figure 3.30: HPLC: pJC133.H256A can still provide all functions required for PA-B
to PA-A conversion.
Representative HPLC chromatograms shown, analysis performed independently in
quadruplicate. Each sample was fed with 0.5% (v/v) PA-B at time of inoculation. No
conversion to PA-A was observed in 10586 ∆mup-cluster with empty vector, pJH10.
Plasmid pJC133.H256A, carrying an enzymatically inactive version of MupL, was
still able to restore conversion to the same level as seen in pJC133.
marised in Figure 3.31.
3.2.4.3 Deletion of mupL decreases mupM expression
The experimental evidence presented so far has indicated plasmid pJC133 requires
the presence of mupL for conversion to occur, but does not require MupL enzymatic
function. MupL first acts before MupU in the biosynthetic pathway, and when mupL
is deleted in the 10586 chromosome, a variable conversion phenotype is observed. A
potential explanation is that mupL contains a promoter that is required to increase
downstream mupM and mupN expression (Figure 3.32). There is a putative promoter
sequence within mupL, 5’-TACACA-18nt-TATGCT-3’, positioned 200 bp before the
mupM start.
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Figure 3.31: Summary of plasmid based mupL PA-B conversion phenotypes.
Plasmid pJC132, which lacks mupL, is unable to convert fed PA-B to PA-A, whereas
pJC133, with WT mupL, is able to provide conversion functions. When MupL is
inactivated by point mutation on pJC133.H256A, conversion still occurs. These results
suggest that for conversion to occur in this configuration, mupL must be present, but
MupL enzyme function is not necessary.
In the P. fluorescens 10586 cluster, there is an 82 bp gap between mupL and mupM,
whereas in the P. psychrotolerans NS383 cluster, mupL and mupM overlap (Figure 3.33).
There is an 87 bp open reading frame in the gap in 10586, out of frame with mupL, that
shows some homology at the C-ter of NS383 mupL. The C-ter is not conserved in the
thiomarinol homolog tmlL either, or in distant homologs. The conserved functional
structure may not continue to the end of the NS383 mupL, which would facilitate the
genetic divergence observed.
The potential promoter within mupL could be detected by comparison of MupM
levels in plasmids with mupL (pJC133) and without mupL (pJC132). If mupL contains
a promoter that is functional in the culturing conditions used, then pJC133 should
provide more MupM than pJC132. This could be detected by complementation of
either of the ∆mupM phenotypes, decreased mupirocin resistance and production.
Plasmid pJC133 can complement PA-A production in 10586 ∆mupM without IPTG
induction, observed by HPLC (Figure 3.34a) and previously by bioassay (Figure 3.20).
However, IPTG induction is required for complementation by pJC132 (Figure 3.34b).
This is consistent with the previous bioassay results in Figure 3.20. These results
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Figure 3.32: Map of the chromosomal 10586 mupirocin gene cluster region of the
conversion genes.
The nine genes required for conversion of PA-B to PA-A are shaded in black, mupL
is shown in grey. The putative promoter within mupL would start transcription into
mupM then mupN. The mupL, M, N operon is also in place in pJC133.



















Map of mupL and mupM
100%
Figure 3.33: Relative genetic position of mupL, mupM, and their homologs.
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Figure 3.34: HPLC: IPTG induction is required for pJC132 to complement 10586
∆mupM.
Parts (a) and (b) were performed separately on different HPLC columns, with differ-
ent injection volumes: (a) 50 µl, (b) 25 µl. Part (a) is a subset of the data from Figure
3.21, included for comparison purposes, prednisone was used as an internal stan-
dard. Representative chromatograms shown, (a) analysis performed independently
in quadruplicate, (b) independently in duplicate.
Plasmid pJC132 [MN], can complement 10586 ∆mupM with IPTG induction, but can-
not without (Figure 3.21). However, pJC133 [LMN], which does complement ∆mupM
without IPTG, complements less well with induction.
126
support the hypothesis that mupL is required for conversion because of an internal
promoter that drives mupM expression. When mupL is not present, IPTG induction
is needed to increase mupM expression to the required level.
To test for complementation of the ∆mupM increased mupirocin sensitivity pheno-
type, minimum inhibitory concentrations (MIC) were recorded of mupirocin against
10586 ∆mupM strains, carrying plasmids pJC132, pJC133 and negative control pJC124
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Figure 3.35: Presence of mupL is required for complementation of the decreased
mupirocin MIC of 10586 ∆mupM.
Absorbance readings of 10586 LB cultures grown in a 96-well plate for 16 hours,
with serial dilutions of mupirocin. The ∆mupM experiments were performed in
quadruplicate, and the WT in duplicate. Error bars represent standard deviation.
Plasmid pJC133 was observed to complement mupirocin resistance of 10586 ∆mupM
to WT levels, with or without IPTG induction. Plasmid pJC132, which lacks mupL, is
unable to complement ∆mupM.
The WT strain with negative control plasmid pJC124, was fully resistant to the
highest concentration of mupirocin tested, 2 mM, which was limited by solubility in
LB media. The ∆mupM strain with control pJC124, demonstrated decreased resistance,
with an MIC of 500 µM. Plasmid pJC133 complemented this deficiency to the WT
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level of >2 mM, both with and without IPTG induction; whereas pJC132 suprisingly
decreased the MIC to 250 µM without IPTG induction, and remained the same at 500
µM with induction.
Considering the mupirocin production deficiency phenotype, IPTG induction can
increase MupM production in the absence of mupL to the required levels. However,
complementation of the MIC phenotype obligately required the presence of mupL.
This could be because of how the different experiments are performed: with the MIC
determination mupirocin is introduced immediately to the cultures, whereas when
testing for production, the culture media initially contains no mupirocin. In this case,
mupirocin is only present when production switches on at stationary phase, allowing
time for expression of sufficient mupM from pJC132 with IPTG.
10586 ∆mupL is deficient in growth at high mupirocin concentrations
As a counterpart to the plasmid based experiments, the effect of a chromosomal
deletion of mupL on MupM production was assayed through analysis of mupirocin
resistance. The MIC of 10586 ∆mupL was observed to remain at the WT level of >2
mM, with testing of higher concentrations limited by solubility (Figure 3.36). How-
ever, at 2 mM mupirocin the OD600 of 10586 ∆mupL was 1.4 ± 0.2 (s.d.), compared
with 2.4 ± 0.1 in WT.
This could be explained by the deletion of the promoter within mupL decreasing
constitutive mupM expression. However, we would still expect mupM expression at
stationary phase once the mupirocin cluster is switched on, driven by the upstream
mupirocin regulated promoters of the mmpE operon. A futher test would be to repeat
this experiment whilst monitoring over a time course, as the model predicts that
∆mupL will exhibit a lack of initial growth in the presence of mupirocin that could
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Figure 3.36: Chromosomal deletion of mupL decreases level of growth in presence
of mupirocin.
Absorbance readings of 10586 LB cultures grown in a 96-well plate for 18 hours, with
serial dilutions of mupirocin. Experiments were performed in quadruplicate. Error
bars represent standard deviation.
3.2.4.4 Non-converting ∆mupL cultures display loss of culturability at 44 hours
When 10586 ∆mupL is grown with exogenous PA-B, it was consistently observed
to variably convert this to PA-A (Figure 3.24). However, the chromosomal ∆mupL
∆mupU dual mutant (Section 3.2.4.1) and in trans mupL point mutant experiments
(Section 3.2.4.2) demonstrated that MupL enzymatic function is not required for
conversion of PA-B to PA-A. In the previous Section 3.2.4.3, evidence was presented
for the presence of a promoter within mupL that drives expression of mupM. This
could be the cause of the variable conversion phenotype observed in 10586 ∆mupL.
To test this hypothesis, growth of 10586 ∆mupL with exogenous PA-B was analysed.
Monitoring the absorbance of cultures was considered unsuitable, as P. fluorescens
10586 produces mupirocin at stationary phase, and the production media (SSM) is
opaque with solid precipitates. Instead, viable cells were analysed by colony forming
unit (CFU) count, using the method described in Section 2.3.6. SSM cultures were
inoculated with 10586 ∆mupL, either with 0.5% PA-B or 0.5% methanol as a negative
control (n=6). CFUs were counted at 16 and 44 hours (Table 3.4). At 16 hours, all
cultures yielded CFUs of between the order of 108 and 109 cells ml−1, indicative of
growth to near saturation. At 44 hours, half of the PA-B cultures had collapsed to
between 103 and 105 CFU ml−1, whereas all other cultures were saturated at 1010.
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Table 3.4: CFU estimates of 10586 ∆mupL cultures with exogenous PA-B
(a) CFU count (cells ml−1) + MeOH (0.5% v/v)
#1 #2 #3 #4 #5 #6
16 hours 5.3 × 109 2.2 × 109 1.8 × 109 5.6 × 109 4.4 × 109 2.5 × 109
44 hours 3.1 × 1010 3.4 × 1010 4.0 × 1010 3.8 × 1010 3.0 × 1010 4.8 × 1010
(b) CFU count (cells ml−1) + PA-B (0.5% v/v)
#1 #2 #3 #4 #5 #6
16 hours 1.3 × 109 7.5 × 108 1.4 × 109 8.5 × 108 3.5 × 108 3.0 × 108
44 hours 2.9 × 1010 2.2 × 1010 2.7 × 1010 2.5 × 103 4.0 × 105 2.0 × 103
MeOH and PA-B samples are not paired
At 44 hours, cultures were imaged by phase contrast microscopy to analyse cell
morphology and numbers (Figure 3.37). Despite a more than five orders of magnitude
decrease in CFUs, no difference in cell counts were observed between the low and
high CFU groups. This suggests the low CFU group of cultures are not colony
forming rather than low in absolute cell count.
The percentage conversion of fed PA-B to PA-A in supernatants of the six cultures
was measured by HPLC (Figure 3.38). Half the cultures were observed to convert,
averaging 37% ±5 (s.d.), and these were observed to contain high CFUs at 44 hours
(Table 3.4). The low CFU cultures failed to convert (1.3% ±1.5).
Given the evidence for the ∆mupL mutation decreasing self-resistance gene mupM
expression, it seems likely that the decreased level of MupM is the cause of the
collapse in cell culturability. However, why this would vary between cultures and
why this would occur on a culture-wide level is yet unclear. This is discussed, together
with the extensive potential future experimentation, in Section 3.3.3.3.
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Figure 3.37: Microscopy of 10586 ∆mupL cultures with exogenous PA-B.
Images are 40x phase contrast. No difference was apparent between the 10586 ∆mupL
cultures yielding low and high CFUs. 100 and 10−1 represent undiluted and a ten-fold
dilution of cultures respectively.
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Figure 3.38: HPLC: conversion of PA-B to PA-A by 10586 ∆mupL correlates with
CFU count.
Samples labelled #1 to #6 are 10586 ∆mupL with 0.5% PA-B; these are the same
samples from the CFU count experiment (Table 3.4).
Investigation of the growth phenotype of 10586 ∆mupM
When 10586 ∆mupM was first tested in Hothersall et al. (2007), our research group
noted the decreased PA-A production, and hypothesised that either there is a polar
effect or MupM forms part of a multi-enzyme complex required for biosynthesis.
Self-killing was not considered a possibility as the cultures were observed to be
viable; they reached saturation in LB liquid media, and cell growth in SSM was not
monitored. If the ∆mupL decrease in cell culturability after stationary phenotype
is caused by a lack of MupM, then 10586 ∆mupM should also exhibit a growth or
viability deficit.
To investigate this possibility, SSM 10586 ∆mupM cultures were grown in qua-
druplicate, with 10586 WT in duplicate as a control. Note that these cultures did
not contain PA-B as in the previous CFU experiments. At 44 hours, the CFU count
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was recorded and cultures examined by microscopy. Each of the ∆mupM cultures
had CFUs >2 to 4 orders of magnitude lower than WT (Table 3.4). A significantly
decreased number of cells was observed by microscopy, with visible clumping (Figure
3.39). It therefore seems likely that self-inhibition is the cause of the low levels of
mupirocin production observed in 10586 ∆mupM cultures.
Table 3.5: 10586 ∆mupM demonstrates decreased CFUs in SSM compared with WT
CFUs at 44 hours (cells ml−1)
10586 WT > 5 × 109 > 5 × 109 - -
10586 ∆mupM 5 × 105 5 × 106 2 × 107 1 × 106
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Figure 3.39: Microscopy of 10586 ∆mupM cultures.
The SSM cultures were imaged after 44 hours incubation. 100 and 10−1 represent
undiluted and a ten-fold dilution of cultures respectively.
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3.3 Discussion
In this chapter, nine mupirocin cluster enzymes were identified and demonstrated
sufficient for conversion of PA-B to PA-A. This increased and re-inforced our un-
derstanding of the mupirocin tailoring pathway, and an updated putative model of
conversion is presented. As the variable mupL mutant phenotypes were of particular
interest, a model is presented to explain this observation, linking it to the role of
MupM in biosynthesis.
3.3.1 Nine mupirocin cluster genes are required and sufficient for
conversion of PA-B to PA-A in P. fluorescens 10586
The systematic screening of mutants for ability to process PA-B implicated ten
genes as required. This informed the design of a series of expression plasmids, which
ultimately revealed nine enzymes are required for conversion of PA-B to PA-A.
3.3.1.1 Systematically screening 10586 mutants for conversion of exogenous PA-B
proved successful, yielding ten candidate genes
The systematic screening for ability of 10586 mutants to convert PA-B to PA-A,
reported in Section 3.2.2.2, proved successful. Ten candidate mutants deficient in
conversion were identified, mupO, mupP, mupU, mupV, mupC, mupF, mupL, mupM,
mupN and macpE. Importantly, this ruled out the involvement of mupirocin genes
of unknown function, such as mupZ, mupA, mupB, mupD, macpA, and macpB. This
information guided the choice of thiomarinol homologs used in the experiments of
Chapter 4. All of the genes we have reported previously as required for conversion
were re-discovered (Cooper et al., 2005; Hothersall et al., 2007; Gao et al., 2017). Three
further genes were implicated for the first time: mupL (enzyme not required), mupM
and mupN. Without this knowledge, the plasmid based conversion experiments
would not have succeeded.
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The initial design for this experiment called for wide scale successive deletions
of the mupirocin cluster. The generation of 10586 ∆mup-cluster demonstrated that
large deletions were readily achieveable with our mutagenesis methodology. Starting
from a deletion strain that is able to convert PA-B to PA-A, such as 10586 ∆mmpA,
successive large deletions could be made to arrive at a minimal set of genes required
for conversion of PA-B to PA-A. However, we decided instead to systematically screen
existing mutants of each individual gene. This approach proved successful and very
efficent, taking advantage of the considerable 10586 mutant library available.
A disadvantage of the systematic approach is that it would not detect redundancy
of function, if two genes were able to substitute for each other then deletion of ei-
ther would still give conversion. Given the dissimilarity of the predicted function of
the various genes tested, with the exception of the five ACPs MacpA-E, functional
redundancy seems unlikely. Redudancy between these ACPs is not likely, as each
individual macpA-E knockout strain is defective in PA-A production, and comple-
mentation experiments have demonstrated that these do not substitute for each other
(Shields et al., 2010).
This method could potentially be adapted to investigate other points of the path-
way, although the majority of the earlier biosynthesis pathway is thought to occur
on PKS enzymes, which would likely limit the point of pathway entry for exogenous
substrates. No other pseudomonic acid intermediate is produced on the scale of PA-B,
so any alternative substrates would likely need to be chemically synthesised.
3.3.1.2 Plasmid encoded conversion of PA-B to PA-A demonstrated that nine func-
tional mupirocin enzymes are required and sufficient
The systematic screening experiments informed the design of a series of multiple
mupirocin tailoring gene plasmids summarised in Figure 3.40. The ability of pJC133
to provide all necessary functions for conversion of exogenous PA-B to PA-A in 10586
∆mup-cluster is the first demonstration that all necessary mupirocin cluster genes
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Figure 3.40: Summary of multiple tailoring gene plasmids generated.
Starting from pMMH6 (Macioszek, 2009), additional tailoring genes were inserted
into the expression plasmids as guided by the screening experiments. This culminated
with pJC133.H256A, which demonstrated that nine mupirocin cluster enzymes can
provide all necessary functions for conversion: MupO, MupP, MacpE, MupU, MupV,
MupC, MupF, MupM and MupN.
have been identified.
Together with the screening experiments, this represents the first evidence that
conversion of MacpE to the holoenzyme obligately requires MupN (phosphopan-
tetheinyl transferase), and therefore also that the native P. fluorescens PPTase cannot
activate MacpE. MupN has been observed to convert MacpA, MacpC and MacpD
to their holoenzyme in vitro, however MacpE was not tested due to solubility issues
(Shields et al., 2010).
Plasmids pJC132 and pJC133 were observed to complement individual 10586
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knockouts of mupU, mupV, macpE, mupO, mupP, mupC and mupF to between 65 and
90% of WT antibiotic activity (Figure 3.20). Earlier plasmids pMMH6 and pJC124
complemented to full 100% WT antibiotic activity (Figure 3.16) (Macioszek, 2009).
As summarised in Figure 3.40, the difference between pJC133 and pJC124 is the
addition of mupL, mupM and mupN. That pJC132 also confers the lower activity and
lacks mupL logically suggests the addition of either mupM or mupN to the plasmids
decreases mupirocin production. Which of these causes this effect could readily be
tested by plasmid based expression of mupM and mupN individually in 10586 WT,
and observing biological activity with and without IPTG induction.
Intriguingly, no conversion of exogenous PA-B to PA-A was observed in P. flu-
orescens SBW25 carrying pJC133. One possible explanation is that the biosynthesis
genes carried on pJC133 are not expressed in SBW25, as it lacks the mupirocin regu-
latory genes. However, this seems unlikely as the cloned genes are under the control
of the tac promoter, which is unrelated to mupirocin biosynthesis. The putative pro-
moter within mupL from the 10586 chromosome does not appear to be under MupR
regulation, as pJC133 provides conversion functions in 10586 ∆mupR. Indeed, the
observed increase in mupirocin MIC from 1500 µg ml−1 in SBW25 [pJH10] to >3000
in SBW25 [pJC133] is evidence that mupM is expressed from pJC133 in SBW25, and
that the mupL promoter is still functional.
An alternative explanation is that there are further genes required outside of the
mupirocin biosynthetic cluster in the 10586 genome, that are missing in SBW25. Else-
where in the mupirocin biosynthesis pathway, functional analysis of MupW (Rieske
dioxygenase) and MupT (Ferredoxin) revealed they belong to a Rieske oxygenase
system (Connolly, 2014 - unpublished), which characteristically require a third re-
ductase component (Ferraro et al., 2005). The putative reductase of this electron
transport system has not been identified, and is proposed to be present elsewhere on
the genome. As pJC133 was observed to provide the conversion functions in 10586
∆mupR (Figure 3.23), we can predict that if any genes are required elsewhere on the
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10586 chromosome, they will not be under MupR regulation.
Future work: bioinformatic screening for any genes required outside of the mupirocin
cluster
Bioinformatic analyses could be performed to identify any putative further genes
required for mupirocin biosynthesis outside of the identified gene cluster. Five
genomes could be compared: the first identified mupirocin producer P. fluorescens
10586 (Haines, unpublished), P. fluorescens BRG100, P. synxantha A342, P. pyschrotoler-
ans NS383, and P. fluorescens SBW25. BRG100 and A342 contain >99% (A.A.) similar
mupirocin clusters to 10586, and it is therefore possible the genomes would be too
similar to yield any useful comparisons. NS383 is a sequenced P. fluorescens group
strain carrying a mupirocin cluster with approximately 65-70% similarity to 10586. It
was sequenced as part of a meta-genomics study largely at the species level, which
did not focus or identify individual clusters, and as such it has not been confirmed
to produce mupirocin (Midha et al., 2016).
Any genes required for mupirocin biosynthesis that are located outside of the
cluster that are responsible for the lack of PA-B conversion in SBW25 [pJC133], should
logically be present in the chromosomes of 10586, BRG100, A342 and NS383, but not
in SBW25. The first step would be developing a software search for such genes, which
could then be appraised for likelihood of involvement in biosynthesis, and reverse
genetic experiments later on. It is conceivable that this would generate too large a
list to be useful for identifying potential missing conversion genes. However, this
could still be useful in identifying components where the encoded enzyme type could
be predicted, such as the predicted third component of the MupW, MupT electron
transport chain.
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3.3.1.3 The relative level of mupV expression may be essential to complementa-
tion in trans
As discussed in Section 3.1.3, two attempts to complement 10586 ∆mupV with
independently constructed pJH10/mupV expression plasmids failed (Di Martino, M.,
Stephens, E., unpublished). Given this negative result, an alternative chromosomal
point mutatagenesis strategy was pursued in this study (Section 3.2.1). However,
the failure of these mupV expression plasmids to complement is intriguing, as this
complementation has been observed in alternative scenarios. Complementation of
10586 ∆mupV was observed by multi-gene expression plasmids pJC124, pJC132 and
pJC133 in this work (Section 3.2.3.3), as well as by their parent, pMMH6 (Macioszek,
2009). Complementation was also observed by an alternative design of pJH10/mupV
constructed during the thesis of Cooper (2003).
In these different designs, the 5’ side of mupV has been cloned differently, sum-
marised in Table 3.6. Multiple gene expression plasmids pJC124, pJC133 and pMMH6
all use the 10586 chromosomal DNA sequence between the end of the preceding
mupU and mupV. However, the different pJH10/mupV versions were constructed to
make use of a RBS already present in expression vector pJH10, upstream of the multi-
ple cloning site. The pJH10/mupV designed by Maura Di Martino was cloned using
MfeI into the EcoRI, with 9 bp between translation start and the RBS, compared with 7
bp in the consensus. This plasmid was observed inhibitory to mupirocin production
in 10586 WT. Expression of mmpB was achieved using this exact same 5’ setup, re-
ported in Section 4.2.1 of this work. The pJH10/mupV designed by Sian Cooper was
cloned using KpnI, which follows EcoRI in the multiple cloning site, which resulted
in 15 bp between translation start and the RBS.
It is possible that the Di Martino plasmid is inhibitory to mupirocin production
because the relative expression of mupV is too high. The 10586 chromosomal mupV is
single copy and under MupR regulation, whereas the plasmid is 12 copy (Frey et al.,
1992) and the cloned mupV expressed by the IPTG regulated, strong taq promoter.
140
Table 3.6: Ribosome binding site of mupV in different experiments











pJH10/mupV Cooper AGGAAACAGAATTCGGTACCATG +
In this explanation, the Cooper plasmid is able to complement 10586 ∆mupV as the
expression is decreased by the increased spacing between the RBS and start of 15 bp.
An equivalent increase in RBS spacing in E. coli was observed to reduce reporter gene
expression more than 6-fold (Chen et al., 1994). In the pMMH6 derived plasmids, a
near consensus optimally spaced RBS is present, but the plasmid also includes the
genes encoding enzymes that could logically interact with MupV: MupU, MupO and
MacpE. The expression of mupV may need to at a similar level to one or more of these
related genes, and that the Di Martino pJH10/mupV is inhibitory because the relative
expression of mupV is too high. This hypothesis could be tested by replacement of
mupV with reporter gene lacZ in each scenario to assay expression, and by addition of
mupU, mupO or macpE to the Di Martino pJH10/mupV to check for relief of inhibition.
3.3.2 Models of PA-B to PA-A conversion
3.3.2.1 Both domains of MupV are required for conversion
Re-analysis of mupV revealed two predicted domains: short chain reductase and
hydrolase. Chromosomal point mutation of either of these domains in 10586 fully
switched production to PA-B (Section 3.2.1). This suggested that both domains are
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required for conversion of PA-B to PA-A, Aim 1 of this chapter. When these mutant
strains were fed with exogenous PA-B no conversion to PA-A was observed (Section
3.2.2.2), supporting this conclusion. It is possible MupV has a dual function, or that
both domains are required for its proposed function of polyketide offloading from
MacpE.
3.3.2.2 Putative schematic pathway of conversion
The results discussed in this chapter support the current model of conversion
of PA-B to PA-A, most recently proposed in Gao et al. (2017). This is presented in
Figure 3.41, with slight modification to the timing of release from MacpE, based on
the hypothesis described in the next Section 5.2.1.1. This conversion schematic is
logically based on historical reverse genetics experiments.
The functions of MupP, MupC and MupF have been characterised by accumula-
tion of late stage intermediates mupirocin P, C1, and F in their respective chromsomal
knockout mutants (Hothersall et al., 2007; Gao et al., 2017). Deletion of either macpE
(ACP), mupO (cytochrome P450), mupU (acyl CoA synthase) or mupV (oxidoreductase
and TE) causes a near complete switch to PA-B production (Cooper et al., 2005). It is
logical that MacpE (acyl carrier protein) is the site of at least some of the conversion
pathway, and the evidence in Sections 3.2.2 and 3.2.3 suggests that MupN (phos-
phopantetheinyl transferase) catalyses formation of the MacpE holoenzyme. MupU
(acyl CoA synthase) is the most likely candidate for loading PA-B onto MacpE in an
ATP dependent reaction. The second domain of MupV (thioesterase) could catalyse
release of pseudomonic acids from MacpE. This leaves the first domain of MupV
(oxidoreductase) and MupO (cytochrome P450). These could both function together




























































































Figure 3.41: Putative PA-B to PA-A conversion schematic.
Enzymatic order and steps proposed by Gao et al. (2017), MacpE release timing
modified as discussed in Section 5.2.1.1.
3.3.3 Gene mupL contains a putative promoter that could be key for
cell viability
In Section 3.2.4, various evidence was presented that supports presence of a
putative promoter within mupL, which later led to intriguing discoveries regarding
interactions with downstream mupM.
3.3.3.1 Evidence for a promoter within mupL
As summarised in Figure 3.40, multi-gene expression plasmid pJC132 without
mupL failed to provide PA-B to PA-A conversion functions, whereas pJC133 with
mupL does. Inactivation of the MupL enzyme by point mutation demonstrated that
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its activity is not required for conversion. Analysis of the complementation of both
the mupirocin production and decreased resistance phenotypes of 10586 ∆mupM by
pJC132 and pJC133 suggested improved mupM expression in pJC133. This supports
the hypothesis that mupL contains a promoter that drives transcription of downstream
genes mupM and mupN.
As the putative mupL promoter and mupM are required for plasmid based con-
version, and conversion can occur in 10586 ∆mupR [pJC133], it is likely the putative
mupL promoter is not MupR regulated.
Future work
The experimental evidence presented in this work all supports presence of a
promoter within mupL, however it would be sensible to demonstrate this using tran-
scriptional assays. There are various options to accomplish this: quantitative reverse-
transcriptase PCR (RT-PCR) of a product in mupM with and without mupL presence,
β-galactosidase assays of the putative promoter fused to lacZ, or RNA sequencing of
the 10586 transcriptome with and without mupL.
3.3.3.2 The promoter within mupL may have evolved to increase mupM expres-
sion before or after mupirocin biosynthesis
Upon discovery of the putative promoter, we hypothesised that its role was to
express mupM prior to the pathway being switched on, such that sufficient MupM is
already present in the cytoplasm before mupirocin production begins, preventing self-
action. However, there is an alternative hypothesis; the promoter may have evolved
to prevent self action after mupirocin production finishes. There are two isoleucyl
tRNA synthetases (IleRS) in the 10586 chromosome, the eukaryotic like IleRS-R2
(MupM) that confers high mupirocin resistance, and the more susceptible IleRS-R1
(Yanagisawa and Kawakami, 2003), which explains why 10586 ∆mupM is viable.
A prediction for how mupM expression levels could vary between in 10586 WT
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compared with 10586 ∆mupL is presented in Figure 3.42. It is conceivable that the
constitutive promoter within mupL is required to provide sufficient MupM after
cluster switch off, if PA-A levels in the cell were to remain high. This possibility is
supported by the observation that mupirocin concentrates in sensitive B. subtilis at
nine times the extracellular concentration (Capobianco et al., 1989). Therefore it is
likely that 10586 intra-cellular PA-A concentration remains higher than extracellular,














Figure 3.42: Prediction of how deletion of the promoter within mupL could change
mupM expression.
Alternatively, the promoter may have evolved to provide cells where the cluster
is switched off with constitutive mupirocin resistance, to guard against mupirocin
produced by neighbouring P. fluorescens cells in the native soil rhizosphere. How-
ever, this is contradicted by the quorum sensing regulation of mupirocin production
(Hothersall et al., 2011). We might expect P. fluorescens cells close in space to either
both be on or off together with respect to mupirocin biosynthesis regulation.
3.3.3.3 10586 ∆mupL is variably unable to convert PA-B to PA-A, correlating with
a decrease in cell culturability
Providing an explanation of the reproducibly variable conversion of exogenous
PA-B to PA-A in 10586 ∆mupV and corresponding decrease in cell culturability is
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difficult, as an explanation must account for the culture wide effect observed. Several
conclusions, and clues as to what could be responsible can be deduced from the
experimental evidence.
The observation that 10586 ∆mupM grows poorly in SSM, with low CFUs and
clumps visible by light microscopy (Section 3.2.4.4), logically suggests that produced
PA-A is self-inhibitory in this strain. Furthermore, the decreased mupirocin produc-
tion observed in 10586 ∆mupM could then be explained by a lack of cell density.
The key observation is that 10586 ∆mupL SSM cultures fed with PA-B will grow to
saturation, before a proportion of the culture’s CFUs collapse, and correspondingly in
these cultures, no PA-A conversion is observed. These different observed phenotypes
are summarised in Figure 3.43.
In the previous Section 3.3.3.1, evidence was discussed for the presence of a
promoter within mupL that drives mupM expression. Given that PA-A production
seems inhibitory in a mupM knockout, and the ∆mupL mutant may lack a promoter
that drives mupM expression (Section 3.3.3.1), the observed collapse in CFUs in PA-B
SSM 10586 ∆mupL cultures could be caused by self inhibition due to lack of MupM.
Whilst this provides a potential mechanism for CFU collapse, it is more difficult to
explain how this could occur variably, on a culture-wide basis, after the cultures reach
stationary phase.
Mupirocin is regulated by quorum sensing, with a signalling homoserine lactone
produced by MupI (Hothersall et al., 2011). This provides a possible mechanism for
a culture wide phenomenom to occur, further complicated by the presence of the
lactone within the fed PA-B extract (Section 3.2.2.3).
If MupR regulation were to switch off through MupI signalling in some saturated
10586 ∆mupL SSM PA-B cultures, then any PA-A already produced could prove self



















~40% conversion to PA-A
High cell density
Low CFUs
No conversion to PA-A
t = 0 hrs
t = 0 hrs
t = 44 hrs
t = 44 hrs
Figure 3.43: Summary of growth and PA-A conversion or production phenotypes
of mupL and mupM mutant SSM cultures.
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Future work
The culture wide collapse in CFUs in some 10586 ∆mupL SSM cultures was an
unexpected result, which due to time contraints has not yet been fully explored. The
immediate experiments should aim to reproduce this effect. From there, various
exploratory approaches could be undertaken, such as recording the culture CFUs
at more frequent time points over a wider range. It would be very interesting to
test where the decision is made if a culture is split at a given timepoint, will all the
aliquots present with the same phenotype?
It would be worthwhile assaying the level of lactone in low and high CFU ∆mupL
SSM cultures; this could be performed by xylE assay as in Section 2.3.3 (El-Sayed et al.,
2001). Whilst it is not clear why the lactone level would fall in some cultures, it is a
culture-wide signal that could potentially drive such a culture-wide phenotype. More
advanced microscopy could be performed; of particular interest would be live-dead
staining (such as propidium iodide) of the high cell density, low CFU cultures.
Further reverse genetic investigation is already underway, with the design and
generation of a 10586 mupL nonsense mutation, with MupL curtailed by an early stop
codon, leaving the putative promoter intact. An in-frame deletion of the majority
of mupL that leaves the putative promoter intact has also been designed. We would
expect these new mupL mutants to be deficient in mupirocin production, because of
the lack of MupL, and its unknown requirement in the mupirocin pathway. However,
they should be able to reliably convert fed PA-B to PA-A, if the hypothesis is correct
that the failure to convert and low CFU effect is due to MupM levels.
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Chapter 4




As outlined in Section 1.5.1, a long term goal of the Thomas research group is to
generate in vivo mupirocin-NRP derivatives through fusion of additional modules
to MmpB. However, the inactive PA-B is proposed to be released from MmpB, and
converted to active PA-A on the discrete enzyme MacpE (Section 3.1). This established
the key goal pursued in this work: the re-engineering of mupirocin biosynthesis to
generate PA-A ”in cis” on MmpB.
A previous attempt to achieve this is described in the PhD thesis of Omer-Bali
(2013). Omer-Bali reported that an mupU-macpE fusion on an expression plasmid
could complement 10586 ∆macpE ∆mupU. This fusion was then inserted into the
chromosomal mmpB gene of 10586 ∆macpE ∆mupU, however this proved completely
disruptive to pseudomonic acid production. The mupU-macpE fusion was also in-
serted into mmpA (PKS) of 10586 ∆macpE ∆mupU, and the resulting strain was ob-
served to produce PA-B. This suggests that this insertion did not disrupt MmpA
function, but that MupU-MacpE do not function in this position as PA-A was not
produced.
In the work presented in this Chapter, an alternative strategy is pursued using
enzymatic domains from the biosynthesis of the similar antibiotic, thiomarinol.
4.1.1 Two strategies for C8-OH removal found in nature
In mupirocin biosynthesis PA-B (C8-OH) is proposed to undergo TE-catalysed
release from MmpB (Section 3.1). MupU (acyl CoA synthase) is proposed to then
load PA-B onto MacpE (ACP), before successive action by MupO (cytochrome P450)
and MupP (dehydratase) to remove the C8-OH. Tailoring of the pyran ring is then
completed by MupC (NADH oxidase) and MupF (ketoreductase). Release from
MacpE is proposed to be catalysed by the second domain of MupV (TE), and there is










































Figure 4.1: Overview of the mupirocin and thiomarinol late-stage biosynthesis pathways.
(a) In mupirocin biosynthesis, PKS MmpB is proposed to synthesise 9-hydroxynonanoic acid (9-HN) to generate PA-B with
C8-hydroxy. The inactive PA-B is released from the PKS and then undergoes a multi-step pathway to remove the C8-OH and
form active PA-A, proposed to occur on MacpE.
(b) In thiomarinol biosynthesis, TmpB is proposed to synthesise 8-hydroxyoctanoic acid, generating marinolic acid B (C8-OH).
This intermediate may then undergo KS0-mediated transfer to the module 2 ACP (the fifth ACP of TmpB). The equivalent steps
that may occur on MacpE are proposed to occur on this module 2 ACP, removing the C8-OH. The C8-H marinolic acid A could
be released from TmpB, where it then undergoes amidation with pyrrothine to generate thiomarinol A.
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Intriguingly, the equivalent step in thiomarinol biosynthesis may be accomplished
in an alternative fashion. A putative pathway is proposed in Figure 4.1b, based on
bioinformatic analysis and logical comparisons with mupirocin (Fukuda et al., 2011).
Homologs to mupO, mupP, mupC and mupF are present in the thiomarinol gene
cluster, with 43%, 30%, 55% and 33% amino acid similarity respectively, named tmlO
and so forth. However, there are no thiomarinol homologs to mupV or macpE. The
mupU homolog tmlU is one of the few genes that have been studied by knockout
in thiomarinol biosynthesis, and it has been demonstrated to have an alternative
function to MupU: the TmlU and HolE-catalysed amidation of pyrrothine to mari-
nolic acid (Section 1.5.1.1) (Dunn et al., 2015). Therefore thiomarinol biosynthesis is
missing the mupirocin genes that encode MacpE, and the enzymes proposed to load
and offload it.
(a) MmpB (2077 amino acids)
(b) TmpB (2751 amino acids)
KS0
Figure 4.2: Comparison of the domains of MmpB and TmpB
(a) MmpB is the type I iterative PKS responsible for 9-hydroxynonanoic acid biosyn-
thesis in the mupirocin pathway. The KS, DH, KR, 3 ACPs work together with the
trans-AT on MmpC to perform three successive Claisen condensations, then the C8-
OH intermediate is released, catalysed by the TE.
(b) The thiomarinol homolog, TmpB, has an additional module, consisting of a non-
elongating KS0, KS-AT linker (AT’), and ACP. Removal of the C8-OH is hypothesised
to occur on this extra module. The reason for the additional ACP in module one is
not known.
TmpB has an extra module not present in MmpB, consisting of a non-elongating
ketosynthase (KS0), a KS-AT linker domain (AT’) and acyl carrier protein (ACP)
(Figure 4.2). The KS0 domain lacks the conserved histidine of the HGTGT motif that
is required for elongation, and it instead has QGTGT (Robbins et al., 2016). However,
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this domain still has the conserved cysteine (Cys1824) required for chain transfer,
and therefore may be able to transfer intermediates, but not catalyse condensations.
This extra module could be the site of C8-OH removal in thiomarinol biosynthesis,
performing an equivalent role to MacpE in mupirocin. In the proposed hypothesis,
the first KS and associated domains catalyse two iterative Claisen condensations to
generate the C8-OH intermediate. The KS0 then acts equivalently to MupU, loading
the C8-OH intermediate onto the following ACP on TmpB. Whilst on this ACP, TmlO,
TmlP and possibly TmlC and TmlF could catalyse the equivalent tailoring steps to
their mup counterparts. Finally the thioesterase would release the C8-H polyketide,
equivalent to MupV action.
This model of C8-OH removal in thiomarinol is supported by the observation
that no C8-OH thiomarinol is detected by LC-MS analysis of cultures of its producer
SANK73390 (Fukuda et al., 2011; Murphy et al., 2014). In mupirocin biosynthesis,
approximately 5% of the pseudomonic acids produced are PA-B with C8-OH. It is rea-
sonable that there would be some leak of PA-B in the transfer from MmpB to MacpE
in mupirocin biosynthesis, but none of the equivalent thiomarinol intermediate, as it
does not leave the PKS.
Recent bioinformatic searches of MmpB have revealed what appears to be a rem-
nant KS-AT linker located between ACP7 and the TE domain, which has been named
AT’ in the diagrams in this work. This domain shows around 30% amino acid sim-
ilarity to a variety of putative Bacillus subtilis PKS and NRPS enzymes, and 14%
similarity to AT domains with solved X-ray structures, with HHPRED identifying the
M. tuberculosis Pks13 AT domain (PDB: 3TZY) as the closest hit.
This putative KS-AT linker in MmpB is not positioned in the canonical cis-AT
domain position, where it would follow the KS domain (Staunton and Weissman,
2001). It is not known if this domain has a function within MmpB, but with a length
of 150 amino acids it is likely to have an effect on the 3D positioning of the following
TE domain. The existence of this putative domain was not known when the work
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presented in this chapter was performed.
Similar KS-AT linkers are present following the KS domains on MmpA, MmpB
and MmpD. These are positioned in the correct in cis position and have been hy-
pothesised to be a potential position for the docking of the trans-acting AT domains
of MmpC. Although the position of trans-acting AT domain interactions with the
KS is not known (Gay et al., 2014), and could not be the same for all systems. In
some previous work on the mupirocin biosynthesis, these KS-AT linkers have been
referred to as docking domains (Gurney and Thomas, 2011; Gurney, 2012). However,
in the wider field of polyketide research, in particular of the model erythromycin, the
term docking domains has been used to describe docking between PKS polypeptides
(Broadhurst et al., 2003; Weissman, 2006; Zeng et al., 2016). Given the lack of direct
evidence for the hypothesised trans-AT docking role, and the potential for confusion
with the inter-peptide function, in this study these domains have been termed AT’.
4.1.2 Objectives
The key objective of the work described in this chapter was to re-engineer C8-OH
removal in mupirocin biosynthesis so that it occurs on MmpB, in a similar manner
to that proposed in thiomarinol biosynthesis.
Aim 1: Complement 10586 ∆mmpB with mmpB provided in trans
The first aim was to generate an mmpB expression plasmid, then mobilise to
10586 ∆mmpB and test for complementation. This would establish the basis for in
trans expression of mmpB so that later work on mmpB-tmpB derivatives could also be
performed in trans.
Aim 2: Insert the second module of TmpB into MmpB and test for function
The next aim was to generate a functional MmpB/TmpB hybrid through insertion







Figure 4.3: Aim 2: Construction of an MmpB/TmpB hybrid protein
Blue represents MmpB (mupirocin) domains and red TmpB (thiomarinol) domains.
A hybrid of MmpB and TmpB was designed, with the front end of MmpB, up to and
including the third of its ACP triplet, ACP7. After this, the second module of TmpB
would be fused on, ending with the TmpB TE domain.
design iterations for a functional hybrid to be achieved. Furthermore, an aim was to
inactive the transferase activity of the KS0 domain of the hybrid by point mutation
and test function. Inactivation of the KS0 domain should decrease throughput if it is
actively processing intermediates.
Aim 3: Provide the candidate thiomarinol tailoring enzymes and attempt to con-
vert PA-B to PA-A on the MmpB/TmpB hybrids
With a functional MmpB/TmpB hybrid generated, the next aim was to provide
the thiomarinol tailoring enzymes putatively involved in C8-OH removal, and test
for C8-OH removal on the hybrid (Figure 4.4). Logistically, this required insertion of
the various hybrid iterations into the chromosome of 10586 strains deficient in the
mupirocin C8-OH removal pathway. Then, informed by the work described in Chap-
ter 3, a selection of thiomarinol tailoring enzymes could be provided on a plasmid



























Hybrid to be tested in a 
strain deficient in mup 
enzyme tailoring to PA-A
PA-A
Figure 4.4: Aim 3: Conversion of PA-B to PA-A on an MmpB/TmpB hybrid catal-
ysed by tml enzymes.
A later iteration of the MmpB/TmpB hybrid enzymes is shown, which has the MmpB
TE domain (in blue).
Aim 4: Use the TmpB KS0 to load MacpE fused to MmpB and convert PA-B to
PA-A on the MmpB/TmpB hybrids
At the outset of this work, Aim 3 was the envisaged path to ”in cis” PA-B to
PA-A conversion on MmpB/TmpB hybrid enzymes. However, with the successful
splicing of the KS0 domain in MmpB, an alternative possibility was considered. The
KS0 domain could be used to re-engineer the native mupirocin tailoring pathway to
occur on MmpB. This would require splicing of the normally free-standing, MacpE
into the MmpB/TmpB hybrids, and testing for conversion to PA-A on the hybrid
(Figure 4.5).
Together success in Aims 3 and 4 could unlock the potential for coupling of NRPS
modules on MmpB/TmpB, to generate PA-A-NRP in vivo derivatives in the future.
KS0
Figure 4.5: Aim 4: Construction of a hybrid protein where the TmpB KS0 domain
is positioned to load MacpE.
The TmpB module 2 ACP would be replaced by the normally free-standing MacpE,
which could then be loaded by the transferase activity of the KS0 domain. Conversion
to PA-A could then occur on the hybrid through the native mup tailoring pathway on
this fused MacpE domain.
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4.2 Results
4.2.1 Complementation of P. fluorescens ∆mmpB
Two approaches were considered for modifying mmpB to introduce new modules
into MmpB: replacement of the 10586 chromosomal copy with modified versions, or
provision of modified mmpB on an expression plasmid to P. fluorescens NCIMB10586
with mmpB deleted. Although a mixture of both approaches were eventually pursued,
initially the latter in trans approach was used. To establish the feasibility of this, an
important preliminary aim was to test if 10586 ∆mmpB could be complemented by
WT mmpB provided on an expression vector.
4.2.1.1 Construction of pJH10/mmpB
Amplification of mmpB was achieved in three parts, both to alleviate difficulties
amplifying the full length gene and to remove several internal EcoRI sites, to facilitate
its use for cloning. The first 270 bp of the gene were amplified using primers MmpBF1
and MmpBF2, followed by a 4 kb fragment amplified with MmpBF2 and MmpBR3.
All of the primers used in this chapter are listed in Table 2.8. The PCR strategy and
generation of intermediate construction plasmids is summarised in Figure 4.6.
These two fragments were designed to overlap, with a silent mutation (Glu92 GAA
to GAG) to remove an internal EcoRI site. Overlap extension PCR was performed
(Section 2.2.11.1) with primers MmpBF1 and MmpBR3, generating a 4.3 kb fragment.
This fragment reached from the gene start to its native unique KpnI site.
The final 2 kb segment of mmpB, from its native KpnI site to the stop codon,
was amplified from the 10586 chromosome using primers MmpBF2 and MmpBR3.
This end segment was cloned in high copy vector pUC18 KpnI/XbaI, yielding pUC/-
mmpBCT2kb.
The 4.3 kb fragment containing the front of the gene was cloned in pUC/mmpB-
CT2kb EcoRI/KpnI, yielding the full length mmpB in pUC18. This was named
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Figure 4.6: Cloning of mmpB.
The mmpB gene in pUC18 was confirmed by sequencing. The correct full gene was
then subcloned EcoRI/XbaI to broad host range expression vector pJH10, to yield
pJH10/mmpB.
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(a) Plasmid map (b) EcoRI/SacI digest
Figure 4.7: Construction of pJH10/mmpB.
(a) Map of pJH10/mmpB, mmpB is cloned EcoRI/XbaI downstream of the tac promoter.
(b) EcoRI/SacI diagnostic digests. Digest of pJH10/mmpB plasmid isolates yielded
two bands corresponding to the 14 kb plasmid backbone and the 6.2 kb mmpB insert.
pUC/mmpB, and contained the full mmpB flanked by unqiue EcoRI and XbaI sites1.
The XbaI site of pUC/mmpB is blocked by Dam methylation, therefore plasmid
isolates were passaged through dam− E. coli ER2925. Potential pUC/mmpB isolates
were checked by EcoRI/XbaI digest, and sequenced with M13(-40), M13(-48) and
internal primers mmpBF5, mmpBF6, mmpBF7, and mmpBR4. Plasmids containing
the correct mmpB sequence were identified, and the gene subcloned in expression
vector pJH10 EcoRI/XbaI, yielding pJH10/mmpB (Figure 4.7a). Diagnostic digests
with EcoRI and SacI confirmed the presence of mmpB (Figure 4.7b) (SacI was used in
place of XbaI to avoid the need for passaging through a dam− strain).
The IncQ plasmid pJH10 has several key features that make it a suitable expression
vector. It is derived from RSF1010, with its broad host range oriV for replication,
and conjugation components repA, repB and oriT (Scholz et al., 1989), which allow
1Primer design and mmpB PCRs were performed by undergraduate project student Alicia Nash.
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its conjugative transfer to P. fluorescens from donor strain E. coli S17-1. E. coli
S17-1 provides the RP4 conjugative machinery from its chromosome (Simon et al.,
1983). Transcription of cloned genes is driven by the lac-trp hybrid promoter, tac,
and a ribosome binding site (RBS) included upstream of the EcoRI site. The vector
also holds lacI, which is not present on the 10586 chromosome. LacI represses the
tac promoter through binding of the lac operator, also allowing for IPTG induction
(Amann et al., 1983).
4.2.1.2 P. fluorescens NCIMB 10586 ∆mmpB is complemented by pJH10/mmpB
Plasmids pJH10/mmpB and an empty pJH10 control were mobilised to P. fluo-
rescens NCIMB 10586 WT and 10586 ∆mmpB. The ∆mmpB mutant has an in-frame
chromosomal deletion of the majority of mmpB, removing 1991 amino acids (AA),
leaving 30 AA at the N-terminus and 54 AA at the C-terminus. Complementation
of 10586 ∆mmpB by pJH10/mmpB was observed by plate bioassay (Figure 4.8) and
HPLC (Figure 4.9). On the bioassays, the deletion of mmpB was observed to prevent
production of active mupirocin, and provision of mmpB in trans restored production
to WT levels. HPLC analysis confirmed the bioassay observations; no detectable
PA-A is produced by the ∆mmpB strain, and full complementation was observed.
Complementation of MmpB domain mutants 10586 mmpB∆ACP567 (Figure 4.10b)
and 10586 mmpB∆TE (not shown) was also observed. These mutations remove all
acyl carrier proteins and the thioesterase domain, respectively, both resulting in no
production of mupirocin.
Each of these experiments was initially performed with 500 µM IPTG induction
and without induction. Complementation to WT level activity was observed without
induction, whereas no complementation was observed with 0.5 mM IPTG induction.
These observations held across all the mmpB mutants tested.
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Figure 4.8: Bioassay demonstrating complementation of 10586 ∆mmpB.
Assay performed independently in triplicate, a representative plate is shown. No
zone of inhibition is observed in the P. fluorescens 10586 ∆mmpB mutant, as MmpB
is required for mupirocin production. When pJH10/mmpB is provided in trans, a
similar zone of inhibition to WT was observed.





1 0 0 0
1 2 5 0
M u p  2 0 0  µ M
W T  [ p J H 1 0 ]
∆m m p B  [ p J H 1 0 ]
∆m m p B  [ p J H 1 0 / m m p B ]








P A - AP A - B
Figure 4.9: HPLC: complementation of 10586 ∆mmpB by pJH10/mmpB
Pseudomonic acid A elutes at approximately 20 minutes, as indicated by the standard,
n=4. Complementation was observed to WT level, confirming the bioassay result.
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4.2.1.3 Induction of mmpB expression is inhibitory to mupirocin biosynthesis
In pJH10/mmpB, mmpB is positioned downstream of the tac promoter and lac
operator. With IPTG induction, LacI repression is relieved, and the near consensus
tac promoter will direct transcription of high levels of mmpB. A high level of IPTG
induction (500 µM) was inhibitory to pJH10/mmpB complementation, whereas full
complementation was observed without IPTG. However, there remains a wide space
of induction concentrations to test between these, and it was conceivable that a lower
level of induction could improve mupirocin production levels.
To investigate this, bioassays were performed at a range of IPTG concentrations
on P. fluorescens WT and mmpB∆ACP567 (Figure 4.10). In the WT without plasmid, or
with empty pJH10, IPTG concentration was observed to have no significant effect at
any concentration (Figure 4.10a). However, at 500 µM IPTG induction, pJH10/mmpB
was inhibitory to antibiotic production of the WT, whereas 50 µM had an intermediate
effect. In 10586 mmpB∆ACP567 without a plasmid, or with empty pJH10, small
zones corresponding to no mupirocin production were observed across the range
of IPTG concentrations. Induction of pJH10/mmpB to complement this mutation
appeared to work best at approximately 2 to 10 µM IPTG. Again the inhibitory
effect was observed with high induction levels, with zones corresponding to the
non-complemented mutant size observed at 500 µM IPTG.
To summarise, full complementation of P. fluorescens NCIMB 10586 ∆mmpB was
observed without IPTG induction. Overexpression of mmpB on the plasmid was in-
hibitory towards mupirocin production in the WT producing strain, and correspond-
ingly overexpression prevented complementation of mmpB mutant strains. These re-
sults opened the possibility of expressing modified versions of mmpB in trans. Strong
IPTG induction proved inhibitory in all of the plasmid expression experiments per-
formed with mmpB and its derivatives. Therefore, for all of the remaining plasmid
mmpB, and mmpB derivatives, expression results presented in this chapter were per-
formed without IPTG induction.
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(a) 10586 WT
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Figure 4.10: Bioassay of pJH10/mmpB across an IPTG induction gradient.
Assays were peformed independently in triplicate; error bars represent standard
deviations. (a) In 10586 WT, pJH10/mmpB was inhibitory to antibiotic activity with
high IPTG induction of 500 µM. (b) Complementation of 10586 mmpB∆ACP567 by
pJH10/mmpB was observed to work best at 2-10 µM IPTG.
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4.2.2 MmpB/TmpB hybrid generation I: Insertion of tmpB module
2 into mmpB
As discussed in Section 4.1.2, a key objective pursued in this work was to attempt
to re-engineer the mup pathway to convert PA-B to PA-A in cis as may occur in the tml
pathway (Figure 4.1). The second module of TmpB is comprised of the non-elongating
KS0 and an ACP, on which we proposed that PA-B is converted to PA-A.
Generation I consisted of a single MmpB/TmpB hybrid, formed by splicing the
second module of TmpB (KS0-ACP-TE) after ACP7 of MmpB, as summarised in
Figure 4.11. The amino acid sequence of the junction between MmpB and TmpB
sequence is shown in Figure 4.12. This was designed to show whether MmpB can
still function with the extra module, and whether the TE domain of TmpB would
function in the mupirocin system. The longer term goal was to re-engineer the
pathway to convert PA-B to PA-A on the hybrid polypeptide, facilitated by these
extra TmpB domains.
4.2.2.1 Molecular construction of MmpB/TmpB hybrid I
The second module of tmpB was amplified as three fragments using pTML1 as
template DNA: primers TmpBF1 and TmpBR2 amplified 1354 bp, TmpBF2 and
TmpBR3 amplified 499 bp, and TmpBF3 and TmpBR1 amplified 1217 bp 2. These
and all other primers that were used in the work described in this chapter are listed
in Table 2.8. TmpBF2 and TmpBR2 were designed to overlap, whilst making silent
mutations to remove a PciI and an XbaI site. TmpBF3 and TmpBR3 were also designed
to overlap, making a further silent mutation to remove a PciI site.
The three fragments were spliced by overlap extension PCR, using outer primers
TmpBF1 and TmpBR1, which contained a PciI and an XbaI site respectively. This
yielded a 3031 bp fragment flanked by unique PciI and XbaI sites at either end. The
2Primer design and initial tmpB PCRs were performed by undergraduate project student Wenqian
Wang
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(a) MmpB (2077 amino acids)
(b) TmpB (2751 amino acids)
KS0
(c) MmpB/TmpB hybrid generation I: JC50 (2620 amino acids)
KS0
Figure 4.11: Domain map of MmpB, TmpB, and MmpB/TmpB hybrid I
Blue represents MmpB (mupirocin) domains and red TmpB (thiomarinol) domains.
(a) MmpB does not have a second module, PA-B is thought to be released from MmpB,
and processing to PA-A, C8-OH removal, occurs on MacpE.
(b) TmpB has a second module, consisting of KS0 and ACP, where the equivalent
C8-OH removal putatively occurs.
(c) MmpB/TmpB hybrid generation I (JC50) was designed to have the front end of
MmpB, up to and including the third of its ACP triplet, ACP7. After this, the second
module of TmpB was fused on, ending with the TmpB TE domain.
fragment was AT cloned into cloning vector pGEM-T, yielding pJC41, and with the
insert size checked by EcoRI, XbaI, and SpeI/AatII digests (not shown). Two correct
plasmids were confirmed by sequencing with primers M13 (-40), M13 (-48), TmpBF2
and TmpBR3.
The sub-cloning strategy used to generate the MmpB/TmpB hybrid expression
plasmid is summarised in Figure 4.14. The 3 kb tmpB fragment was cut from pJC41
PciI/XbaI, and cloned NcoI/XbaI to pUC/mmpBCT2kb, yielding pJC46. This made
use of the compatible sticky ends of PciI and NcoI, and as a result destroyed both
sites in the product. The partial mmpB tmpB module 2 hybrid was then released from
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Figure 4.12: Amino acid sequence of the junction point between MmpB and TmpB domains in JC50.
The top line shows an approximate annotation of where each domain is positioned, the second line shows the amino acid
number at both the start and end of the sequence displayed, respective to each protein. The third line shows the amino acid
sequence, and the fourth line is the predicted secondary structure from Jpred (H is α-helix and E is β-strand). The valine and
glycine between the junction points in JC50 were introduced as a by-product of the molecular construction strategy used, and
do not originate from either MmpB or TmpB.
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Potential pJC50 plasmids were checked by EcoRI/SacI restriction digest (Figure
4.13) and sequencing with primers pJH10seqF, pJH10seqR, TmpBF2 and TmpBR3.
This resulted in MmpB/TmpB hybrid generation I, consisting of a single expression
plasmid, pJC50. Given the variation in motility of the smallest band from EcoRI/SacI
digestion, and some of the negative complementation phenotypes discussed in the fol-
lowing section, construction of pJC50 was repeated from independent PCR products.
All the phenotypes reported were reproducible with both independently constructed
replicates of pJC50.
Figure 4.13: Diagnostic EcoRI/SacI digest of pJC50.
All of the 8 potential pJC50 isolates contain a band at around 1.4 kb band indicative
of presence of insert, due to the extra EcoRI site in tmpB module 2. Isolate 1 was
confirmed correct by sequencing. The reason for the slight variations in the motility
of the smallest band between potential pJC50 isolates is not known, and was not
explored further.
4.2.2.2 The TmpB TE domain in the pJC50-encoded MmpB/TmpB hybrid does
not off-load PA-B
To test if the first generation hybrid was functional, pJC50 was mobilised to 10586
∆mmpB. No complementation of PA-A production was observed by HPLC or bioassay
(not shown). A summary of the phenotypes of all MmpB/TmpB hybrids tested in



































































Figure 4.14: Maps of pJC50 and plasmids used in its construction.
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This could have been due to the failure of one or more individual domains to
complement, or insertion of the extra module could have disrupted the structure of
MmpB, or the hybrid protein may not be expressed from pJC50. Plasmid pJC50 was
mobilised to the two available mmpB domain deletion strains: 10586 mmpB∆ACP567,
and 10586 mmpB∆TE. Mupirocin production was determined by HPLC of SSM
culture supernatants.
P. fluorescens 10586 mmpB∆ACP567 carries an in-frame deletion of the ACP triplet
in MmpB. As expected, without any ACPs MmpB is non-functional and this strain
does not produce PA-B or PA-A. Suprisingly, pJC50 was observed to complement the
PA-A production of 10586 mmpB∆ACP567 (Figure 4.15a). This logically suggests that
pJC50 the failure to complement 10586 ∆mmpB is not due to a lack of expression of
the hybrid, or a wide scale disruption of its protein structure.
However, no complementation of 10586 mmpB∆TE was observed (Figure 4.15b).
This could suggest that the TmpB TE domain carried on hybrid I on pJC50 is not
functional in mupirocin biosynthesis.
As was the case for pJH10/mmpB (Section 4.2.1.3), induction of expression of the
hybrid from pJC50 by 0.5 mM IPTG proved inhibitory to mupirocin biosynthesis in
10586 WT, and complementation of 10586 mmpB∆ACP567 (not shown).
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(a) Production of MmpB/TmpB hybrid I encoded by pJC50 in 10586 mmpB∆ACP567

























(b) Production of MmpB/TmpB hybrid I encoded by pJC50 in 10586 mmpB∆TE
Figure 4.15: HPLC: the TmpB TE domain in hybrid I may not be functional.
Representative chromatograms shown, n=6. The ellipses on the right are a reminder
of MmpB variants, blue represents MmpB domains, and red TmpB domains.
(a) Complementation of PA-A production in 10586 mmpB∆ACP567 was observed to
WT levels by pJC50 and pJH10/mmpB.
(b) Complementation of PA-A production in 10586 mmpB∆TE was observed by
pJH10/mmpB, whereas no complementation was observed for pJC50.
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4.2.3 MmpB/TmpB hybrid generation II: insertion of the MmpB
thioesterase domain into hybrid I
The failure of MmpB/TmpB hybrid I (pJC50) to complement 10586 mmpB∆TE
suggested the TmpB TE domain may not be functional in mupirocin biosynthesis.
Therefore hybrid generation II was designed, where the TmpB TE was replaced with
the native MmpB TE (Figure 4.16).
(a) MmpB (2077 amino acids)
(b) TmpB (2751 amino acids)
KS0
(c) MmpB/TmpB hybrid generation I: JC50 (2620 amino acids)
KS0
(d) MmpB/TmpB hybrid generation II: JC58, JC59 (2658, 2619 amino acids)
KS0
Figure 4.16: Domain map of MmpB, TmpB and MmpB/TmpB hybrid generations
I and II.
Blue represents MmpB (mupirocin) domains and red TmpB (thiomarinol) domains.
(d) MmpB/TmpB hybrid generation II has the MmpB TE domain spliced after module
2 from TmpB. Generation II hybrid JC58 has the full length MmpB TE domain,




















































Figure 4.17: Amino acid sequence of the junction point between the TmpB ACP and MmpB TE in MmpB/TmpB hybrid
generation II.
The top line shows an approximate annotation of where each domain is positioned, the second line shows the amino acid
number at both the start and end of the sequence displayed, respective to each protein. The third line shows the amino acid
sequence, and the fourth line is the predicted secondary structure from Jpred (H is α-helix and E is β-strand).
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The junction between the module 2 ACP and MmpB TE domain was decided
based on an alignment of MmpB and TmpB TE domains. The amino acid sequence of
the junction is shown in Figure 4.17. The domains have 33% amino acid identity, yet
align reasonably well without gaps, supported by the secondary structure prediction
(Figure 4.18). Interestingly, the MmpB TE domain is 35 AA longer at the N-terminal
side than TmpB. This seemed a real difference rather than an annotation inaccuracy,
as if the TmpB TE domain were annotated to the same length, it would cross the
preceding ACP domain. To investigate the significance of this region, two versions
were designed in MmpB/TmpB hybrid generation II: one with full length MmpB TE
and one truncated to the TmpB length.
Figure 4.18: Alignment of MmpB and TmpB TE domains.
The first two lines are the amino acid sequence of MmpB and TmpB respectively.
Jpred secondary structure predictions are included underneath, E is extended (β-
strand), H is α-helix.
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4.2.3.1 Molecular construction of MmpB/TmpB hybrid generation II
Construction of MmpB/TmpB hybrid generation II plasmids was performed in
two stages. Firstly, overlap PCR was used to generate the desired hybrid sequences
from the KpnI site within ACP5 to the XbaI site following the hybrid, which was
cloned in pUC18 (Figure 4.19). Secondly, these KpnI/XbaI fragments were subcloned
in pJC50 (hybrid I in expression vector pJH10), to give hybrid generation II expression
vectors (Figure 4.20).
Stage 1: Construction of KpnI/XbaI hybrid generation II fragments
A 186 bp fragment was amplified from pJC46 using primers F pJC46 ACPfrag
and R pJC46 ACPfrag (Figure 4.19). This provided a bridge from the native BamHI
site within the second module ACP to the desired junction point, the start of the
TE domain. This fragment was designed to overlap with two mmpB fragments, one
full length and one truncated to tmpB TE length. The full length mmpB TE fragment
was amplified from pJH10/mmpB using primers F mmpB full TE and R mmpB TE,
whereas the short length used F mmpB short TE and R mmpB TE.
The ACP bridging fragment and the two different length TE fragments were joined
by overlap extension PCR with primers F pJC46 ACPfrag and R mmpB TE. The
resulting fragments were digested BamHI/XbaI (XbaI was included in R mmpB TE)
and cloned into pJC46. This yielded pJC56 and pJC57, pUC18 based vectors carrying
the full length, and short length TE fragments respectively (Figure 4.19).
Stage 2: Construction of hybrid generation II expression vectors
The hybrid fragments were released from both pJC56 and pJC57 by KpnI/XbaI
digest, and cloned in pJC50, yielding pJC58 and pJC59 respectively (Figures 4.20 and
4.21). The resulting plasmids are pJH10 derivatives with MmpB/TmpB hybrid II
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Figure 4.19: Stage 1: Construction of MmpB/TmpB hybrid II intermediate vectors
pJC56 and pJC57.
To build MmpB/TmpB hybrid 2, PCR product of the mmpB TE domain was over-
lapped with a short linker in the ACP domain amplified from pJC46. This was
cloned into pJC46 BamHI/XbaI, yielding pJC56. The same steps were also performed
with a shorter version of the mmpB TE, truncated to tmpB TE length, yielding pJC57
(not shown). The resulting pJC56 and pJC57 are pUC18 derivatives carrying the TE
alteration ready for cloning KpnI/XbaI.
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positioned under control of the taq promoter. These were confirmed by restriction
digest (Figure 4.22), and sequencing with primer pJH10 seq R, which gave good reads






Figure 4.20: Stage 2: Construction of MmpB/TmpB hybrid II expression vectors
pJC58 and pJC59.
The full length and truncated swapped TE domain fragments were excised using
KpnI/XbaI from pJC56 and pJC57 respectively. These were cloned into pJC50, which
is a pJH10 derivative carrying MmpB/TmpB hybrid I.
The resulting plasmid, pJC58, is a pJH10 derivative carrying MmpB/TmpB hybrid II




















Figure 4.21: Map of pJC59, MmpB/TmpB hybrid generation II expression plasmid
with truncated TE.
Figure 4.22: Diagnostic digests of pJC58 and pJC59.
AflII/XbaI digest released the same 19.7 kb fragment from all plasmids. A smaller
fragment corresponding to 1.84 kb was released from pJC50 (MmpB/TmpB hybrid I)
and pJC59 (MmpB/TmpB hybrid II, with truncated TE). A larger 1.96 kb fragment
was released from pJC58, due to the longer TE domain. Plasmids pJC58 and pJC59
were confirmed to have the correct mmpB TE domain DNA by sequencing.
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4.2.3.2 MmpB/TmpB hybrid II is functional in P. fluorescens NCIMB10586
MmpB/TmpB hybrid generation II expression vectors pJC58 and pJC59 were
mobilised to P. fluorescens mutants: ∆mmpB, mmpB∆TE, and mmpB∆ACP567. Com-
plementation was tested by plate bioassay against B. subtilis and HPLC of SSM culture
supernatants.
As expected, deletion of the ACP triplet, the TE domain or the entire mmpB
disrupted mupirocin production with a decrease in bioassay inhibition zone to 10%
of WT, when carrying empty vector pJH10 (Figure 4.23). Both of the Mmp/TmpB
hybrid II expression plasmids were observed to complement these mutations to
approximately 70 to 75% of WT zone area. The complementation of PA-A production
was confirmed by HPLC analysis (Figure 4.24). These data suggest that both variants
MmpB/TmpB hybrid generation II can perform normal MmpB function, thought to






























Figure 4.23: Complementation of 10586 mmpB mutants by MmpB/TmpB hybrid
generation II plasmids pJC58 and pJC59.
Plate bioassays against B. subtilis, performed independently in duplicate, error bars
are standard deviation.
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(a) MmpB/TmpB hybrid generation II in 10586 mmpB∆TE
(b) MmpB/TmpB hybrid generation II in 10586 ∆mmpB
Figure 4.24: HPLC: MmpB/TmpB hybrid II is functional.
In this experiment, PA-A eluted at approximately 20 minutes, as demonstrated by the
standard. Experiments were performed independently in triplicate, representative
chromatograms are shown.
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Hybrid I (TmpB TE) failed to complement 10586 mmpB∆TE and 10586 ∆mmpB,
whereas hybrid generation II (MmpB TE) complemented these mutants. This suggests
that the reason for the non-function of Hybrid I (pJC50) is that the TmpB TE domain
is not offloading PA-B in this scenario.
Through integration of HPLC peak areas, full length TE domain plasmid pJC58
restored an average of 189 mV2 PA-A peak, compared with 149 mV2 in the truncated
TE version, pJC59. However, a two-tailed unpaired t test indicated that this difference
is not significant at the 95% confidence level, p=0.24>0.05, n=3. Indeed, no differ-
ence between the versions was observed when used as controls in later experiments.
Therefore, the additional 35 amino acids at the N-terminus of the MmpB TE that are
not present in the TmpB TE do not seem to be essential for function.
The key conclusion from this experiment is that MmpB can remain structured and
functional after insertion of the second module of TmpB. This result is a key step
towards the development of a hybrid on which PA-B can be converted to PA-A, in an
in cis manner as it may occur on TmpB. However, these data do not yet demonstrate
that the second module KS0 is actively functional in the hybrids.
4.2.3.3 Inactivation of the second module KS0 in MmpB/TmpB hybrid genera-
tions I and II by point mutation
To test whether the TmpB KS0 inserted into the hybrids is functional, a point
mutation was designed to the active site cysteine. If the KS0 function is required, this
should disrupt the complementation phenotype of hybrid generation II. The mutation
was also performed in hybrid I for completeness. The active site cysteine was readily
identified by NCBI conserved domains as Cys1824, and confirmed by an alignment
with BLASTp hits. A mutation was designed to change this to alanine, C1824A. The
equivalent mutation to DEBS KS1, C211A, completely disrupted catalytic activity
(Robbins et al., 2016).
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Molecular construction of C1824A mutants
The construction strategy used is overviewed in Figure 4.25. A 1.3 kb 5’ fragment
was amplified using pJC58 as template, using primers MmpBF3 and R tmpB C1824A.
This spanned from the KpnI site within ACP5 to the C1824A mutation within the KS0,
and this fragment was the same for all hybrids.
A second fragment was generated spanning from C1824A to the end of the protein;
this fragment was different for each hybrid. For MmpB/TmpB hybrid I, a 2.5 kb
fragment was amplified from pJC50 using primers F tmpB C1824A and pJH10 Seq R.
For MmpB/TmpB hybrid generation II a 2.6 or 2.5 kb fragment was amplified with
the same primers from pJC58 (full length TE) and pJC59 (truncated TE) respectively.
Each of these 2.5 or 2.6 kb fragments were spliced to the shared 5’ 1.3 kb fragment
by overlap extension PCR, with the overlap designed to introduce the C1824A muta-
tion. Each were AT-cloned in pGEM-T, checked by AatII/PstI digest, and sequenced
using primers TmpBF1, M13(-40) and M13(-48). The three fragments were released
by KpnI/XbaI digest, and cloned in pJC58. This yielded plasmids pJC50.C1824A,
pJC58.C1824A and pJC59.C1824A, each the KS0 mutant variant of their parent name-
sake. The C1824A mutation introduced an additional PstI site, which facilitated
detection by digestion (Figure 4.26).
4.2.3.4 Inactivation of the second module KS0 is inhibitory to MmpB/TmpB hy-
brid II activity
The KS0 C1824A mutant hybrid expression plasmids pJC50 (generation I), pJC58
and pJC59 (generation II) were mobilised to 10586 ∆mmpB to determine their effect
on mupirocin production. Mupirocin production was determined by plate bioassay
(Figure 4.27) and HPLC of SSM culture supernatants (Figure 4.28). As in Section
4.2.2.2, no complementation of 10586 ∆mmpB by hybrid I expressed from pJC50 or its
KS0 mutant version pJC50.C1824A was observed by bioassay or HPLC (not shown).




KpnI/XbaI vector KpnI/XbaI insert
PCR of 1.3 kb fragment 
from pJC58
PCR of 2.5 kb fragment 
from pJC50
pJC58
Figure 4.25: Construction of C1824A MmpB/TmpB hybrid expression vectors.
A 1.3 kb PCR product was overlapped with a 2.5 kb product to yield a 3.8 kb
KpnI/XbaI fragment carrying the KS0 mutation, C1824A. This overlapped fragment
was cloned KpnI/XbaI to pJC58, the MmpB/TmpB hybrid II expression vector. The
diagram shows construction of pJC50.C1824A, mutants of the other hybrids were





Figure 4.26: Diagnostic digests of C1824A mutant hybrids in expression vectors.
(a) XbaI/KpnI digest releases a fragment from ACP5 to the end of the gene: 3.6 kb in
tmpB TE length hybrids (pJC50 and pJC59) and 3.8 kb in the mmpB TE length variant
(pJC58).
(b) The C1824A mutation introduced a PstI site. In pJC50, without the mutation,
there is a 12.3 kb band, which is cleaved into 10.0 kb and 2.3 kb in C1824A mutants.
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(b) Example bioassay plate
Figure 4.27: Bioassay: MmpB/TmpB hybrids with point mutation to KS0.
Plate bioassay against B. subtilis, n=3, error bars are standard deviations.
∆mmpB to approximately 70% of the area of 10586 WT, which agrees with the data
presented in the previous section. The KS0 mutant variant of pJC59 complemented
to a similar level, suggesting that the hybrid from pJC59 can generate PA-B without
KS0 activity. With the other hybrid from generation II, pJC58 (full length TE), a drop
from 79% (% area of WT) to 57% was observed with the mutation. This difference
was significant at 95% confidence level by unpaired two-tailed t test, p=0.008<0.05,
n=3.
HPLC analysis revealed a more definitive phenotypic difference in the comple-
mentation of hybrids with the C1824A mutation (Figure 4.28). Complementation of
10586 ∆mmpB was again observed by both hybrid II expression plasmids. For pJC59
(truncated TE), point mutation of the KS0 decreased PA-A peak area to 29% of the
non-mutant, whereas for pJC58 (full length TE), C1824A decreased the peak area to
10%. This difference for hybrid II, pJC58, was significant by unpaired two-tailed t test
of integrated peak areas, p=0.0005<<0.05, n=5. Excitingly, this suggests that the KS0
enzymatic activity contributes to the function of hybrid II, and that intermediates
may be actively passed through the extra module.
However, the mutation did not completely abolish mupirocin production, with
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(b) Repeat HPLC analysis of pJC58 and pJC58.C1824A
Figure 4.28: HPLC: inactivation of the KS0 domain of MmpB/TmpB hybrid gener-
ation II by point mutation decreases function.
(a) Representative chromatogram for comparison of pJC58 and pJC59, n=3.
(b) Repeat analysis of 10586 ∆mmpB [pJC58] and [pJC58.C1824A], n=2. (b) was per-
formed independently from (a), from the point of conjugation of plasmid DNA. This
repeat analysis is included to demonstrate that the split peaks in (a) are due to the
condition of the HPLC column and not a characteristic of the produced metabolites.
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small PA-A peaks detected by HPLC and large zones of inhibition present on bioas-
says. This discrepency between bioassay zones and production detected by HPLC has
been observed previously in other experiments performed on mupirocin biosynthesis,
such as in the PA-C producer mmpE∆OR (Gao et al., 2014) or in later generation III
tests of pJC119 (Section 4.2.5.3). This could be due to the difference in conditions of
each experiment, as HPLC was performed on supernatants of liquid SSM cultures
incubated at 22 °C with shaking, whereas bioassays were performed on solid LB
medium incubated at 20 °C then 37 °C on the second day. These assays measure
different aspects of production: the HPLC method measures the final concentration
of PA-A in the extra-celullar liquid culture, whereas bioassay measures inhibition of
the growth of B. subtilis, which is likely influenced by production level, timing of
production, diffusion rate, and compound antibiotic activity.
To summarise, these data provide evidence that the second module of TmpB
in MmpB/TmpB hybrid generation II is enzymatically active. This represents an
important step towards the goal of re-engineering the C8-hydroxy removal tailoring
step to occur on the hybrid.
4.2.4 Conversion of PA-B to PA-A on MmpB/TmpB hybrids using
thiomarinol enzymes
Now that a hybrid with a seemingly functional second domain had been con-
structed, the next goal was to express the thiomarinol tailoring enzymes with the
hybrid, and determine whether PA-A can be generated on the second module of the
hybrid. The primary candidate tailoring enzymes identified were TmlO, TmlP, TmlC
and TmlF. All are homologs of their mupirocin namesakes, with 43%, 30%, 55%,
33% AA identity respectively. TmlY (hypothetical membrane protein), which lacks a
mupirocin homolog, was also considered as a secondary, more speculative target 3.
3 Design and construction of thiomarinol tailoring enzyme expression plasmids were performed by
Yusra Alsammarraie (pJH10/tmlOPCF) and Amber Wilson (pJH10/tmlOPCF and pJH10/tmlYOPCF).
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One option considered was cloning these tml genes into the expression vectors
carrying mmpB/tmpB hybrids, such as pJC58, and expressing all genes at once in trans.
However, cloning into an increasingly large pJH10 based plasmid (starting at 21.7
kb) may have proved a difficult molecular construction. Also, the simplest way of
building such a vector would be to place all genes behind the taq promoter. However,
this would prevent use of IPTG induction, due to the inhibitory effect of mmpB over
expression.
An alternative option was to provide tmlOPCF on a second expression vector. The
vector would need to be of a different compatibility group to pJH10, and be broad
host range, ruling out the E. coli replicon plasmids. Co-expression from IncP vectors
with the IncQ pJH10 has previously been attempted, but proved inconsistent (Shields,
2008).
Therefore, the most immediate way to express these proteins together was to
insert the mmpB/tmpB hybrids into the P. fluorescens chromosome. This would allow
for the expression of tmlOPCF from the reliable pJH10 vector.
4.2.4.1 Construction of suicide vectors for insertion of mmpB/tmpB hybrids into
the P. fluorescens NCIMB10586 chromosome
The suicide mutagenesis strategy used requires homology arms for recombina-
tion flanking the desired mutational sequence. Fortunately, MmpB/TmpB hybrid
II already has such a setup, with module 2 of tmpB flanked on both sides by mmpB
sequence. A 3.6 kb PCR product was amplified with pJC58 as template, using primers
F pJC5x XbaI and R pJC5x SalI. This was cloned XbaI/SalI into mutagenesis vector
pJC70, yielding pJC74.58 (Figure 4.29). The equivalent steps were performed for
MmpB/TmpB hybrid II with truncated TE domain, using pJC59 as template and
yielding pJC74.59.
The construction of the mutagenesis vector for MmpB/TmpB hybrid I required
one further step, as there is no downstream homology arm already in place. A 3.6
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Figure 4.29: Maps of pJC74 suicide mutagenesis vectors.
Plasmid pJC74.50 was constructed for insertion of hybrid I into the 10586 chromo-
some, named for the equivalent hybrid expression plasmid pJC50.
Plasmids pJC74.58 and pJC74.59 were constructed for insertion of hybrid generation
II into the chromosome, both full TE length (JC58) and truncated TE (JC59).
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kb product was amplified with pJC50 as template using primers F pJC5x p604 XbaI
and R pJC50 overlap. This product has a 600 bp region of mmpB, followed by the
second module and TE of tmpB, to the stop codon. To generate the downstream
homology arm, the 600 bp region following mmpB on the 10586 chromosome was
amplified using primers F hybriddownarm overlap and R hybriddownarm SalI. The
two products were spliced by overlap extension PCR, and the resulting 4.2 kb product
cloned XbaI/SalI to pJC70, yielding pJC74.50 (Figure 4.29).
The resulting suicide vectors (pJC74.50, pJC74.58, pJC74.59) were screened by
XbaI/SalI digest to check for presence of insert. Correct DNA sequence was con-
firmed by sequencing with primers M13(-40), M13(-48), and F tmpB C1824A. Plas-
mid pJC74.50 was further sequenced with primers TmpBF3 and R tmpB S2298A to
achieve full coverage.
4.2.4.2 Replacement of the P. fluorescens NCIMB10586 chromosomal mmpB with
mmpB/tmpB hybrids
Mutagenesis plasmids pJC74.50, pJC74.58 and pJC74.59 were used to replace the
10586 chromosomal copy of mmpB with their respective hybrids, using the method
described in Section 2.2.12. Mutant strains were PCR screened using primers F pJC5x-
p604 and R hybriddownarm SalI (Figure 4.30).
Each of the three hybrid mutations were introduced to four P. fluorescens NCIMB-
10586 strains: 10586 WT, 10586 ∆mupU, 10586 ∆mupV, and 10586 mmpE∆OR. The
mupU and mupV mutant strains were included as these are deficient in the native
mupirocin PA-B to PA-A tailoring pathway. In the absence of MupU or MupV, restora-
tion of PA-A production in these strains through a combination of MmpB/TmpB
hybrids and thiomarinol enzymes would indicate C8-OH removal by the thiomarinol
enzymes.
The oxidoreductase domain of MmpE is required for formation of the C-10,11
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Figure 4.30: Example of PCR screening for MmpB/TmpB hybrid chromosomal mu-
tations
The lower bands correspond to 2.6 kb, the size of the WT mmpB fragment ampli-
fied. The larger bands correspond to 4.2 kb, the size with tmpB module 2 hybrid.
Sample number 2 has bands for both WT and mutant; this pattern is likely due to
incorporation of the mutation elsewhere in the chromosome.
et al., 2014). Thiomarinol also lacks the epoxide, therefore it was conceivable the tml
TE domain in hybrid I was showing specificity towards desepoxy intermediates. The
hybrids were therefore introduced to 10586 mmpE∆OR to test this hypothesis.
Mupirocin production of the 12 generated mmpB/tmpB mutant strains was tested
by bioassay (Figure 4.31). In 10586 WT, similarly to the plasmid-based results pre-
sented so far in this chapter, PA-A was still produced after replacement of MmpB
with either TE variant of MmpB/TmpB hybrid generation II. MmpB/TmpB hybrid I
again proved non-functional.
No restoration of PA-A production was observed in the PA-B producing strains
10586 ∆mupU and 10586 ∆mupV. The PA-C producer, 10586 mmpE∆OR was in-
cluded to test whether the TmpB TE was demonstrating specificity towards des-epoxy
polyketide intermediates. However, no clearing zone was observed for mmpE∆OR
with MmpB/TmpB hybrid I (pJC50).


































Figure 4.31: Bioassay zones of inhibition for MmpB/TmpB hybrid chromosomal
replacements
Average inhibition zone area against B. subtilis, performed independently in duplicate,
error bars represent standard deviation.
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Figure 4.32: Complementation of MmpB/TmpB hybrid I chromosomal mutants by
pJH10/mmpB.
Representative chromatogram shown, analyses performed independently in dupli-
cate. Chromosomal mutant 10586 mmpB.JC50 (hybrid I) is fully deficient in PA-A
production, and was complemented by pJH10/mmpB. Similarly, PA-C production
was complemented in 10586 mmpE∆OR mmpB.JC50 by pJH10/mmpB.
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strains to check for complementation. HPLC analysis confirmed that all MmpB/TmpB
hybrid I strains have a complementable phenotype (Figure 4.32), which suggests that
the phenotype is caused by lack of hybrid I function rather than any polar effect.
4.2.4.3 Small scale conversion of PA-B to PA-A was achieved on MmpB/TmpB
hybrids with plasmid encoded tmlO, tmlP, tmlC and tmlF
Now that a suite of 10586 MmpB/TmpB hybrid mutants had been generated, the
candidate thiomarinol genes could be provided on expression plasmids. Two expres-
sion plasmids were constructed, pJH10/tmlOPCF (Figure 4.33) and pJH10/tmlYOPCF
(Alsammarraie, Y. and Wilson, A., unpublished)4.
Figure 4.33: Map of pJH10/tmlOPCF.
Plasmid pJH10/tmlYOPCF has the same gene order, although with tmlY inserted
upstream of tmlO 4.
The tmlOPCF and tmlYOPCF plasmids, together with empty vector pJH10, were
mobilised to WT and mutants of 10586 carrying ∆mupU, and ∆mupV plus their deriva-
tives with mmpB.JC50, JC58 and JC59. Mupirocin production of each combination of
4 Design and construction of thiomarinol tailoring enzyme expression plasmids were performed by
Yusra Alsammarraie (pJH10/tmlOPCF) and Amber Wilson (pJH10/tmlOPCF and pJH10/tmlYOPCF).
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strain and plasmid was tested by plate bioassay, both with 0.5 mM and without IPTG
induction (Figure 4.34).
As first reported in Cooper et al. (2005), deletion of either mupU or mupV causes a
switch to production of the inactive PA-B, and a corresponding deficiency in clearing
zone was observed. None of the mmpB.JC50 strains (carrying MmpB/TmpB hybrid I)
displayed any antibiotic activity, as was the case in every test reported in this chapter
where hybrid I was the sole mmpB version available to the bacteria.
Gratifyingly, restoration of 35% ±6.6 (n=4) of the WT zone was observed in 10586
∆mupU mmpB.JC58 (MmpB/TmpB hybrid II) when pJH10/tmlOPCF was present.
Without mupU the native mupirocin pathway is only able to produce the inactive
metabolite PA-B. This partial complementation of antibiotic activity suggests restora-
tion of PA-A production mediated by some or all of the thiomarinol enzymes. Plasmid
pJH10/tmlYOPCF complemented to a similar level. As complementation worked as
well without tmlY, it seems unlikely that tmlY is involved or required for this part of
the pathway. IPTG Induction of tml gene expression from the plasmids was observed
completely inhibitory to antibiotic production (Figure 4.34b).
To further investigate these promising results, HPLC analysis of SSM culture
supernatants was performed with 10586 ∆mupU, 10586 ∆mupU mmpB.JC58, carry-
ing plasmids pJH10 or pJH10/tmlOPCF (Figure 4.35). As was originally reported
in Cooper et al. (2005), deletion of mupU switches production to the inactive PA-
B. When the mupU deletion is combined with mmpB.JC58, MmpB/TmpB hybrid
II can substitute for normal MmpB function, and only PA-B is produced. When
pJH10/tmlOPCF is provided to 10586 ∆mupU mmpB.JC58, some PA-A production is
restored. By integration of peak areas, this was measured as 12% ±3.0 (n-4) PA-A
as a proportion of total pseudomonic acids. A lower level of PA-A production was
observed in 10586 ∆mupU [pJH10/tmlOPCF], at 5.9% ±1.2 PA-A as a proportion of
total pseudomonic acid.














































































Figure 4.34: Bioassay: pJH10/tmlOPCF can partially complement mupirocin pro-
duction in 10586 ∆mupU with MmpB/TmpB hybrid II, JC58.
Areas of inhibition of B. subtilis, analyses performed independently in quadruplicate;
error bars are standard deviation.
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Figure 4.35: HPLC: partial restoration of PA-A production in 10586 ∆mupU with
MmpB/TmpB hybrid I and pJH10/tmlOPCF.
Representative chromatogram shown, no IPTG induction was used, analyses were
performed independently in quadruplicate, with the exception of WT [pJH10] that
was performed in duplicate.
hybrid II, in the absence of MupU, agrees with the bioassay data (Figure 4.34a). This
could suggest successful re-engineering of the pathway to make use of the thiomari-
nol enzymes, and convert PA-B to PA-A on the hybrid version of MmpB. However,
the HPLC data indicated the hybrid is not obligately required for TmlOPCF mediated
restoration of PA-A production in the absence of MupU, as some PA-A was observed
in 10586 ∆mupU [pJH10/tmlOPCF]. TmlOPCF were obligately required; no PA-A
was observed in the ∆mupU mutant strains without pJH10/tmlOPCF.
Regardless of whether C8-OH removal is occurring on MmpB/TmpB hybrid II
or not, the PA-A yields achieved using the thiomarinol enzymes were much lower
than usual. An alternative strategy was conceived where the native MmpB enzymes
would be re-engineered to work on the MmpB/TmpB hybrids (Section 4.2.5).
196
4.2.5 MmpB/TmpB hybrid generation III: splicing of MacpE be-
hind the thiomarinol KS0
MmpB/TmpB hybrid generation III consisted of three constructions, each of which
have MacpE fused behind the TmpB KS0 in place of the TmpB ACP of generations I
and II. The structures of each of the hybrids is outlined in Figure 4.36.
The first construction of hybrid generation III, JC118, was designed with the TmpB
TE domain following MacpE, in a similar fashion to hybrid I. As discussed in Section
4.2.2.2, the TmpB TE domain was not functional in hybrid I. However, this may be due
to the TmpB TE domain demonstrating specificity towards polyketide intermediates
that had lost the C8-OH, which would be logical given that this step is proposed to
occur on TmpB in thiomarinol biosynthesis. If mupirocin enzyme-catalysed C8-OH
removal were to occur on the fused MacpE of JC118, then it is possible that the TmpB
could act as a gatekeeper for PA-A release.
The second construction of generation III, JC119, was designed without a TE
domain. As covered in Chapter 3, the release of late biosynthesis stage pseudomonic
acids is proposed to be catalysed by MupV. If C8-OH removal were to occur on the
fused MacpE of JC119, then MupV could potentially catalyse release of PA-A.
Thirdly, JC120 was designed with the MmpB TE domain following MacpE, in a
similar fashion to hybrid generation II. This was designed as hybrid generation II
had proven functional.
An important decision in the design of hybrid generation III was the positioning
of the junction of MacpE and MmpB/TmpB. To aid this, an amino acid alignment
was generated of the TmpB module 2 ACP to be replaced, MacpE from P. fluorescens
NCIMB10586, and MacpE from P. pyschrotolerans NS383 (Figure 4.38). These aligned
without gaps, supported by the Jpred predicted secondary structure. The junction
was designed with MacpE beginning from its third amino acid (Ile) at position 2264
in the hybrids, such that the MacpE PP-carrying serine was positioned in the same
place as the TmpB ACP serine previously (position 2298).
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(a) MmpB (2077 amino acids)
(b) TmpB (2751 amino acids)
KS0
(c) MmpB/TmpB hybrid generation I: JC50 (2620 amino acids)
KS0
(d) MmpB/TmpB hybrid generation II: JC58, JC59 (2658, 2619 amino acids)
KS0
(e) MmpB/TmpB hybrid generation III: JC118 (2620 amino acids)
KS0
(f) MmpB/TmpB hybrid generation III: JC119 (2341 amino acids)
KS0
(g) MmpB/TmpB hybrid generation III: JC120 (2659 amino acids)
KS0
Figure 4.36: Domain maps of MmpB, TmpB and MmpB/TmpB hybrid generations
I, II and III.
Blue represents MmpB (mupirocin) domains, and red TmpB (thiomarinol) domains.
































Figure 4.37: Amino acid sequence of the junction points between the TmpB derived sequence in the hybrid and MacpE in
JC120.
The top line shows an approximate annotation of where each domain is positioned, the second line shows the amino acid
number at both the start and end of the sequence displayed, respective to each protein. The third line shows the amino acid
sequence, and the fourth line is the predicted secondary structure from Jpred (H is α-helix and E is β-strand).
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Figure 4.38: Amino acid alignment of MacpE with the TmpB module 2 ACP.
The first line is the ACP from TmpB module 2, which is the fifth ACP of TmpB and
the fourth ACP in the MmpB/TmpB hybrids. Lines two and three are MacpE from
P. fluorescens NCIMB10586 and P. pyschrotolerans NS383. Jpred secondary structure
predictions are included underneath, E is extended (β-strand), H is α-helix.
4.2.5.1 Molecular construction of MmpB/TmpB hybrid generation III expression
plasmids: pJC118, pJC119 and pJC120
To construct the generation III hybrids, DNA fragments were generated by overlap
PCR spanning from the KpnI site within ACP5 to a SacI site following the stop
codon5. Each of these fragments were then cloned KpnI/SacI to pJC58 (although any
hybrid expression plasmid or pJH10/mmpB would have been suitable), to give full
MmpB/TmpB hybrid generation III expression plasmids. This molecular construction
approach is summarised in Figure 4.39 for the version without a TE domain, and
Figure 4.40 for the versions with TE domains.
A 2599 bp fragment was PCR amplified from pJC58 using primers P16 F 2.6kb
and P16 R 2.6kb, which spanned from the KpnI site within ACP5 to the macpE junc-
tion point, and was used in the construction of all three generation III variants. To
construct the variant without a TE domain, a 260 bp macpE fragment was amplified
from the 10586 chromosome using primers P16 F macpE and P16 R macpE stop SacI.
This included the native macpE stop codon, which would become the stop codon of
this hybrid version. A 2837 bp fragments was generated by overlap PCR of the 2599
and 260 bp fragments, using primers P16 F 2.6kb and P16 R macpE stop SacI. This
was cloned KpnI/SacI to pJC58, yielding pJC119 (Figure 4.39).
To create the generation III variant with the mmpB TE domain (JC120), a 255 bp
macpE containing fragment was amplified from the 10586 chromosome using primers
5Molecular construction and assay of the hybrid generation III plasmids was performed by both
this author and Amber Wilson.
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Figure 4.39: MmpB/TmpB hybrid generation III: construction overview of pJC118,
without a TE domain.
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End  (2599)KpnI  (29)Start(0)  
mmpB tmpB
ACP5
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Figure 4.40: MmpB/TmpB hybrid generation III: construction overview of pJC120,
with the MmpB TE domain.
The TmpB TE domain version, pJC119, was generated in a similar fashion, but with
the TE domain amplified from pJC50 (hybrid I) instead of pJC58 (hybrid II).
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P16 F macpE and P16 R macpE TEoverlap. This omitted the macpE stop codon so
that translation could continue into the TE domain of the hybrid. A 1058 bp frag-
ment was amplified from pJC58 using primers P16 F TE revised and P16 R TE SacI,
designed to carry the mmpB TE domain through to the hybrid stop codon. A 3870
bp fragment was generated by overlap PCR of the 2599, 255, and 1058 bp fragments,
using primers P16 F 2.6kb and P16 R TE SacI. This was cloned KpnI/SacI to pJC58,
yielding pJC120 (Figure 4.40).
To generate the tmpB TE variant, a 931 bp TE-containing fragment was amplified
from pJC50 (hybrid I), using primers P16 F TE revised and P16 R TE SacI. In a
similar fashion to the mmpB TE variant, a 3742 bp fragment was generated through
overlap PCR of the 2599, 255 and 931 bp fragments. This was cloned KpnI/SacI to
pJC58, yielding pJC118.
Replacement of the tmpB module 2 ACP with macpE was confirmed by BamHI
digest of the plasmids, since there is a BamHI site in the tmpB ACP not present in
macpE. The correct sequence from ACP5 to the end of the hybrid was confirmed in
pJC118, pJC119 and pJC120 by sequencing with primers pJH10 seq R, P16 F macpE
and R pJC5x p604 SalI.
4.2.5.2 Generation III hybrid expression plasmids pJC119 and pJC120 are able to
produce PA-B
Generation III MmpB/TmpB hybrid expression plasmids pJC118, pJC119 and
pJC120, and control plasmids pJH10 and pJC58, were mobilised to 10586 ∆mmpB and
10586 ∆mmpB ∆macpE ∆mupU to test function. Pleasingly, plate bioassay of 10586
∆mmpB with pJC120 indicated complementation to 124% ±13.9 (n=3) of the WT
zone of inhibition (Figure 4.41). This indicated that pJC120 is able to restore MmpB
function, that is production of 9-HN and therefore PA-B, which can then be processed
by the native enzymes to PA-A. However, no significant complementation of zones of
inhibition was observed for plasmids pJC118 and pJC119. This is reminiscent of the
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Figure 4.41: Bioassay: MmpB/TmpB generation III hybrid pJC120 can complement
10586 ∆mmpB.
Analyses performed independently in triplicate. Bars represent average areas. Error
bars are standard deviation.
HPLC of SSM culture supernatants confirmed that 10586 ∆mmpB with pJC120
produces significant PA-A, 272% ±7 (n=3) of the integrated peak area of WT [pJH10]
(Figures 4.44 and 4.42). As with the bioassay, no complementation was observed by
the TmpB TE version, pJC118. Unlike the bioassay, pJC119 without a TE domain was
observed to complement PA-A production of 10586 ∆mmpB, to 65% ±8 (n=3) WT
[pJH10] peak area.
The generation III hybrids were also tested in triple mutant 10586 ∆mmpB ∆macpE
∆mupU, the rationale being to ensure that the native pathway of MupU-catalysed
loading onto free-standing MacpE cannot proceed. No bioassay zones of inhibition
were observed in this triple mutant carrying any of the plasmids tested: pJH10
(negative control), pJC58 (hybrid II), pJC118, pJC119 or pJC120 (not shown). HPLC
analysis revealed that pJC120 could restore PA-B production in the triple mutant, and
pJC119 to a lesser extent (Figure 4.43). This is logical as the hybrids can complement
the mmpB knockout, which leaves a deficiency in macpE and mupU. 10586 ∆macpE






Figure 4.42: HPLC: MmpB/TmpB generation III hybrids pJC119 and pJC120 com-
plement PA-A production in 10586 ∆mmpB.
Representative chromatograms are shown, analyses were performed independently
in triplicate. In the hybrid domain overview reminders on the right, blue represents
MmpB domains, red TmpB and yellow MacpE.
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Figure 4.43: HPLC: MmpB/TmpB hybrid generation III cannot restore PA-A pro-
duction in the absence of MupU and MacpE.







































Figure 4.44: HPLC: Integrated PA-A peak areas of 10586 ∆mmpB complementation
by generation III hybrid expression plasmids.
Example chromatograms shown in Figure 4.42, analyses performed independently
in triplicate, error bars are standard deviation.
this suggested that conversion to PA-A does not occur on MmpB/TmpB generation
III hybrids in the absence of MupU.
4.2.5.3 Conversion to PA-A achieved on hybrids JC119 and JC120 in the presence
of MupU
MupU is thought to be responsible for loading of PA-B onto MacpE, therefore the
equivalent function in the hybrids should be performed by the KS0 domain. However,
if a complex of tailoring enzymes (such as MupU, MupV, MupO and MupP) were
to form on MacpE, it is conceivable that the absence of MupU could disrupt the
formation of this complex. This would prevent conversion of PA-B to PA-A on the
generation III hybrids. It was therefore desirable to test the hybrids on 10586 ∆mmpB
∆macpE, but this strain had not yet been generated.
To produce this double mutant, mutagenesis plasmid pAKE604/∆mmpB (Hother-
sall, J., unpublished) was used to make an in-frame deletion of mmpB in 10586
∆macpE (Cooper et al., 2005). Mutagenesis was performed as described in Section
2.2.12, and mmpB deletion strains were identified by PCR with primers MmpB 1F Jo
and R hybriddownarm SalI (Figure 4.45). This amplified 1280 bp in mmpB dele-
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tions, whereas no band was amplified in WT mmpB strains as the PCR was not
optimised for the expected 7.2 kb. Correct in-frame deletion of mmpB and generation
of 10586 ∆mmpB ∆macpE was confirmed by sequencing of the PCR product with
primer MmpB 1F Jo.
Figure 4.45: PCR screening for the mmpB deletion in the generation of 10586
∆mmpB ∆macpE.
PCR of mmpB using primers MmpB 1F Jo and R hybriddownarm SalI, expected to
amplify 1280 bp in the in-frame deletion of mmpB and 7.2 kb in WT. Each lane differs
by template DNA used, the first is a no template negative control, the second has
10586 WT, and the third has 10586 ∆mmpB (known mutant). The remainder are the
potential double mutants being tested: isolates 1, 2, 3, and 6 have the 1.3 kb band
indicative of mmpB deletion.
Generation III hybrid plasmids pJC118, pJC119 and pJC120, alongside pJH10
and pJC58 controls, were mobilised to the newly generated 10586 ∆mmpB ∆macpE.
Mupirocin production was tested by bioassay (Figure 4.46), and HPLC of SSM cul-
ture supernatants (Figure 4.48). As logically expected, 10586 ∆mmpB ∆macpE with
empty vector pJH10 did not generate a clearing zone on plate bioassays, or any pseu-
domonic acids as detected by HPLC. When generation II MmpB/TmpB hybrid pJC58
was introduced to 10586 ∆mmpB ∆macpE, complementation of PA-B production was
observed by HPLC, with no restoration of clearing zone on bioassay. This can be
rationalised by complementation of the mmpB deletion, restoring production of the


















































Figure 4.46: Bioassay: MmpB/TmpB generation III hybrid pJC120 can complement
10586 ∆mmpB ∆macpE.
Analyses performed independently in duplicate, bars represent average areas, error
bars are standard deviation.
Gratifyingly, generation III hybrid pJC120 was observed to complement active
antibiotic production of 10586 ∆mmpB ∆macpE to 156% ±12 (n=2) of the WT [pJH10]
clearing zone. A corresponding restoration of PA-A production was observed by
HPLC, with 10586 ∆mmpB ∆macpE [pJC120] producing 124% ±10 (n=3) PA-A peak
area compared with WT [pJH10] (Figure 4.47). PA-B production of a similar order to
PA-A was observed in 10586 ∆mmpB ∆macpE [pJC120]. Encouragingly, these results
suggest that at least some of the tailoring to PA-A is occurring on hybrid pJC120, as
the only copy of MacpE, which is mandatory for C8-OH removal, is located within
the hybrid.
As has been the case in every hybrid with the tml TE domain reported on in
this chapter, no pseudomonic acid production was observe with hybrid pJC118. The
generation III hybrid without TE domain, pJC119, was not observed to complement
the clearing zone of 10586 ∆mmpB ∆macpE by plate bioassay (Figure 4.46). However,
this is expected, as it previously also failed to complement the clearing zone of 10586
∆mmpB (Figure 4.41). Suprisingly, 10586 ∆mmpB ∆macpE with pJC119 was observed
by HPLC to produce 40% ±1.8 (n=3) PA-A peak area of WT [pJH10]. Unlike pJC120,
no PA-B production was detected with pJC119.
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To summarise, these results represent the accomplishment of a key milestone
towards the MmpB directed in vivo re-engineering of mupirocin biosynthesis. The
C8-OH removal tailoring steps that would natively occur on free-standing MacpE























































Figure 4.47: Integrated HPLC peak areas: C8-OH removal occurs on hybrid gener-
ation III constructs pJC119 and pJC120.
Example chromatograms are shown in Figure 4.48, analyses performed indepen-
dently in triplicate, error bars are standard deviation. Bars represent average peak
area eluting at the same time as PA-B and PA-A standards, 19.7 and 20.6 min respec-








Figure 4.48: HPLC: C8-OH removal occurs on hybrid generation III constructs pJC119 and pJC120.
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Figure 4.49: Summary of MmpB/TmpB hybrid tests reported in this chapter.
Legend: +++ represents higher production (>50% of WT), + lower production (<50% of WT), ** is not tested, red dash
represents no PA-A or PA-B.
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4.3 Discussion
In the work presented in this chapter, the timing of C8-OH removal in mupirocin
biosynthesis has been re-engineered, drawing on the knowledge gained in Chapter
3. A series of MmpB/TmpB hybrids were generated that demonstrate the capability
of the KS0 to load following ACPs, including the non-cognate MacpE. In the course
of these experiments, further insights have been gained into the function of MmpB,
TmpB and the PA-B to PA-A tailoring pathways.
4.3.1 The TmpB KS0 domain may transfer PA-B onto the following
ACP
The successful complementation of 10586 ∆mmpB by MmpB/TmpB hybrid gen-
eration II demonstrated that the PKS could tolerate the presence of the foreign extra
module, whilst still performing the normal MmpB function of 9-hydroxynonanoic
acid (9-HN) biosynthesis. The TmpB KS0 is lacking the conserved histidine of the
HGTGT motif, which is required for chain elongation, but instead it has QGTGT (start-
ing from Gln2090 in TmpB). The KS0 domain does have the conserved active site
cysteine, Cys1824, the equivalent of which has been demonstrated to be absolutely
required for turnover in DEBS (Robbins et al., 2016). As predicted if the inserted
module is functional, inactivation of the KS0 domain by point mutation (C1824A)
decreased the throughput of pseudomonic acid on the generation II hybrids.
However, there was still some throughput with the mutation, indicated by comple-
mentation of PA-A production in 10586 ∆mmpB by pJC58.C1824A and pJC59.C1824A
at 10% and 29% of the non-mutant versions respectively. This suggests that either
offloading is occurring directly from the MmpB ACP triplet, as would occur in WT
MmpB, or that PA-B is somehow transferred to the module 2 ACP at a lower rate.
This could perhaps occur through the simultaneous docking of two ACPs to the KS,














































Figure 4.50: The thioesterase skipping hypothesis: the MmpB TE may catalyse
release of PA-B from its native ACP triplet in the MmpB/TmpB hybrids.
The proportion of PA-B released directly from the ACP triplet is inferred from the
level of PA-B production in the KS0 mutants. It is possible that the functional KS0
could decrease the proportion of PA-B released by the proposed skipping mechanism
compared with the KS0 mutants, due to competing rates of reaction.
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the latter seems unlikely. Instead the former hypothesis seems more likely: the
thioesterase can effectively skip the second module, albeit with lower efficiency, and
directly offload PA-B from ACP5, ACP6 or ACP7 (Figure 4.50).
This is supported by the observation that the proposed skipping occurs more
efficiently in hybrid JC59 (29%) than JC58 (10%). In JC59, the N-terminus of the
thioesterase domain is truncated by 35 AA, which decreases the number of amino
acids between the ACP triplet and TE domain. This could potentially aid contact
between the TE and ACP triplet.
To test this proposed model, a point mutation to alanine could be made to the
phosphopantetheine (PP) carrying serine of the module 2 ACP, Ser2298. The TE
skipping module would predict that this would yield the same phenotype as the KS0
mutation. However, if the 10% or 29% PA-B still produced by the KS0 mutant hybrids
was somehow due to transfer to the module 2 ACP, then S2298A should abolish this
entirely.
These experiments have demonstrated the ability of this thiomarinol KS0 to pro-
cess PA-B, and its usefulness as a tool for re-engineering mupirocin biosynthesis.
It is also possible that it could prove useful for the in vivo re-engineering of other
PKS pathways, especially as the hybrid generation III results indicated it can load a
foreign ACP. However, we do not know what, if any, substrate specificity the KS0 has,
beyond that it accepts PA-B and the equivalent thiomarinol intermediate (marinolic
acid B). It is possible that the KS0 could display gatekeeper activity towards correct
PKS chain length, but it is not known what controls the number of condensations the
iterative KS performs.
4.3.2 In vivo re-engineering of the MacpE tailoring steps to occur
on MmpB was successful
The long term ambition of in vivo generation of mupirocin NRPS hybrids, through
re-engineering of MmpB, requires the significant milestone of removing the C8-OH on
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MmpB. In the native mupirocin pathway, this is thought to occur on the freestanding
acyl carrier protein, MacpE. In this work, the C8-OH removal steps that would
normally occur on freestanding MacpE were successfully re-engineered to occur on
MmpB/TmpB hybrids in two different ways.
4.3.2.1 Conversion on MmpB/TmpB hybrid generation II mediated by thiomari-
nol enzymes
Firstly, conversion was re-engineered to occur on generation II hybrid JC58 with
thiomarinol tailoring enzymes TmlO, TmlP, TmlC, and TmlF. Chromosomal hybrid
mutant 10586 mmpB.JC58 ∆mupU produces only PA-B (Section 4.2.4.3), as without
MupU, PA-B is not loaded onto MacpE or converted to PA-A. When TmlO, P, C, and
F were provided on a plasmid to this strain, 12% of pseudomonic acid production
shifted to PA-A, despite the absence of MupU (Figure 4.51). In this scenario, MupO, P,
C, F and V are all also present, so it is not clear which combination of these enzymes
is required for conversion on hybrid II. However, at least one of TmlO, P, C or
F is required, as no PA-A was produced by 10586 mmpB.JC58 ∆mupU without the
four-gene expression plasmid.
This method of conversion proved inefficient, with a ratio of 88:12, PA-B:PA-A,
near the inverse of WT 10586. This could be explained by the lack of TE specificity,
as summarised in Figure 4.51. In normal mupirocin biosynthesis, the MmpB TE
domain is thought to release PA-B. This means that after KS0 mediated transfer of
PA-B from the MmpB ACP triplet to the module 2 ACP, the MmpB TE could catalyse
immediate release of PA-B. In addition to this, we can predict that the skipping effect
described previously will occur, and approximately 10% of PA-B will be putatively
released from the MmpB ACP triplet before transfer by the KS0 domain. There are
also further alternative possible release mechanisms that cannot be ruled out: an AT
domain in pederin biosynthesis has been reported to have editing activity (Jensen
et al., 2012), as has thioesterase II in pikromycin biosynthesis (Kim et al., 2002). Any
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PA-B released by either mechanism should not be converted to PA-A due to the
absence of MupU.
As the TE domain cannot demonstrate any gatekeeping activity towards PA-A,
there could be a competition between the thiomarinol or mupirocin tailoring enzymes
and the TE domain. The low efficiency of conversion may be due to the majority of
PA-B being released by the TE domain before tailoring enzyme mediated conversion
on the second module ACP can occur.
To continue this work, there are multiple further scenarios that could be tested.
Firstly, if the presented model is correct, then the observed conversion phenotype
should not require MacpE. 10586 mmpB.JC58 ∆mupU ∆macpE could be generated
by further mutagensis of the double mutant, and should still produce 10% PA-A.
Secondly, insertion of the KS0 mutant JC.58.C1824A into the chromosome should
abolish any conversion. These models predict that 10586 mmpB.JC58.C1824A ∆mupU
would produce only a small amount of PA-B mediated by ”skipping” release from
the ACP triplet, and no PA-A.
If the hypothesis that the low efficiency of PA-A production is due to premature
offloading of PA-B by the TE domain is correct, then partially disruptive point mu-
tation to the TE domain could increase the relative proportion of PA-A. A range
of point mutations could be introduced into JC58 TE domain amino acids in 10586
mmpB.JC58 ∆mupU. TE mutants that were defective in release of PA-B, but still func-
tional, could be identified by HPLC of SSM culture supernatants. If TmlOPCF were
provided to such a strain, then the model would predict an increase in PA-A produc-
tion relative to PA-B, as the TE turnover of PA-B would be lower allowing more time
for conversion to occur. However, this would likely only increase the proportion of
PA-A, and not the yield, as the tailoring process should still occur at the same rate.
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MacpENo tailoring to PA-A via the 
mup pathway as no MupU, 
no loading to MacpE
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Figure 4.51: Proposed model of thiomarinol enzyme mediated conversion on MmpB/TmpB hybrid II.
Any PA-B released from the hybrid will not be processed further as no MupU is present. As the MmpB TE domain will offload
PA-B or PA-A, thiomarinol enzyme mediated conversion needs to occur before TE catalysed release. This provides a putative
explanation for the 12:88 (PA-A:PA-B) proportion: the TE domain offloads the majority of PA-B before the tailoring enzymes
manage to convert it to PA-A.
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As mentioned previously, we can deduce that at least one of TmlO, P, C, or F is
required for this conversion. As MupO, P, C, F, and V are also present in the test,
they could still be functioning in this re-engineered conversion pathway. Experiments
could be performed where successive deletions were made of each of these domains
to determine which combination(s) are required.
These results represent the first evidence for the proposed hypothesis that some
or all of the TmlOPCF-catalysed C8-OH removal steps occur on TmpB module 2.
Ultimately, the alternative approach of re-purposing the native mupirocin tailor-
ing enzymes to generate PA-A on MmpB/TmpB hybrid generation III immediately
proved more efficient than using thiomarinol enzymes.
4.3.2.2 Conversion on MmpB/TmpB hybrid generation III through the re-purposing
of MacpE
As covered throughout Chapter 3, conversion of PA-B to PA-A is thought to occur
at least partially on the free-standing acyl carrier protein, MacpE. MmpB/TmpB
generation III consisted of three hybrid constructs with MacpE positioned behind the
KS0 domain. Hybrids JC119 (no TE domain) and JC120 (MmpB TE domain) were
both observed to restore PA-A production in 10586 ∆mmpB ∆macpE. The proposed
models outlining a mechanism for the hybrid III observations are outlined in Figure
4.52.
Hybrid JC120 proved an effective MmpB replacement, able to complement 10586
∆mmpB to 124 ±14% of WT bioassay zone, and 272 ±7% of WT PA-A HPLC peak
area. In the double mutant 10586 ∆mmpB ∆macpE, JC120 was observed to restore
both PA-B and PA-A to more than WT PA-A levels (Figure 4.48). Complementation
of the double mutant was also observed by plate bioassay, to 156 ±12% of WT area.
These data demonstrate that JC120 can effectively perform the native MmpB function
of 9-HN and therefore PA-B biosynthesis, but also act as the site of the PA-B to PA-A
tailoring steps that natively occur on MacpE. It is possible that each step catalysed
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by MupO, P, C and F occurs on MacpE, this hypothesis is explored in Section 5.2.1.1.
10586 ∆mmpB ∆macpE [pJC120] was observed to produce approximately equal
proportions of PA-B and PA-A. If the TE skipping hypothesis (Figure 4.50) were
correct, then a proportion of this PA-B could be attributed to direct offloading from
the MmpB ACP triplet by the TE. However, in generation II hybrid JC58, 10% of the
PA-B produced appears to be offloaded before KS0 processing. This therefore does
not explain the large production of both PA-B and PA-A by JC120. Instead, it seems
most likely that TE catalysed release of PA-B could also occur from MacpE on JC120
(Figure 4.52). This model corresponds with the previous tml enzyme model (Section
4.3.2.1), that C8-OH removal must occur quickly on the second module ACP or the
TE will release PA-B. Conversion appears to occur much more efficiently on JC120
through the relocated native pathway than on JC58 in the thiomarinol style, which is
perhaps not suprising.
In 10586 ∆mmpB ∆macpE, JC119 was observed to only offload PA-A, albeit at a
much lower throughput than JC120. This supports the proposed models: no PA-
B is released prematurely as the TE domain is not present. Without the PKS TE
domain, the most likely candidate for release of the observed PA-A is MupV (SDR
and TE). In the putative native PA-B to PA-A tailoring pathway, MupV is thought to
catalyse release from MacpE. It would make sense if MupV had evolved a specificity
towards releasing PA-A (or mupirocin C/F) and not releasing unprocessed PA-B, to
avoid leakage of PA-B from the pathway. This agrees with the 10586 ∆mmpB ∆macpE
[pJC119] phenotype of only PA-A production, but is contradicted by 10586 ∆mmpB
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Figure 4.52: Proposed model of PA-A production by MmpB/TmpB generation III hybrids JC119 and JC120.
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That JC119 releases less PA-A and PA-B than JC120 suggests that regardless of the
release mechanism in the absence of the TE domain, it occurs at a slower rate. An
alternative explanation for 10586 ∆mmpB ∆macpE [pJC119] only producing PA-A is
that this slower release allows full conversion of PA-B to PA-A on the in-line MacpE.
These hypotheses could be tested by deletion of mupV in 10586 ∆mmpB ∆macpE. If
MupV were responsible for release from JC119, then its deletion should abolish the
observed PA-A production. Further to this, the MupV point mutations described in
Section 3.2.1.2 could be used, and this may yield insights into the function of the two
domains.
4.3.3 Insights from the lack of activity of MmpB/TmpB hybrid I
Although the objective of re-engineering C8-OH tailoring was only achieved in
later hybrid iterations, the non-functional MmpB/TmpB hybrid I, in particular its
TmpB TE domain, yielded some interesting insights.
4.3.3.1 The MmpB and TmpB thioesterase domains may have different substrate
specificity
MmpB/TmpB hybrid I (JC50), incorporating the TmpB TE, failed to complement
10586 mmpB∆TE and ∆mmpB (Section 4.2.2.2). The protein hybrid must be correctly
expressed, as it was observed to complement ∆ACP567. MmpB/TmpB generation II
hybrids (JC58 and JC59), with the MmpB TE instead, were able to complement both
mmpB∆TE and ∆mmpB. These results suggest the TmpB TE was not functional in the
hybrids.
One explanation could be failure of the TmpB TE domain to recognise the pre-
ceding ACP in the PKS. However, the hybrid has been constructed with the TmpB
module 2 ACP preceding the TE domain, exactly as it is in TmpB. Therefore, the TE
domain should be able to interact with its native ACP, and it seems unlikely this is the
issue. The experiments with MmpB/TmpB hybrid generation II and III indicated that
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the MmpB TE can interact and offload from the TmpB module 2 ACP, also suggesting
this explanation is unlikely.
A more likely explanation is that the TmpB TE domain is demonstrating substrate
specificity. The erythromycin TE has been reported to demonstrate some sterochemi-
cal specificity towards hydrolysis of different chain length linear polyketides (Gokhale
et al., 1999). Conversely, in similar experiments with the same DEBS TE and the pi-
maricin TE, with a more diverse range of N-acetyl-cysteamine (SNAC) substrates,
very little substrate specificity was observed (Sharma and Boddy, 2007). In biosynthe-
sis of the NRPS-synthesised β-lactam nocardicin, the TE domain was demonstrated to
have stringent specificity for β-lactam-containing substrates (Gaudelli and Townsend,
2014). It therefore seems possible that TE domains could vary in substrate specificity
(Horsman et al., 2016), particularly in a scenario like TmpB, where there could be
evolutionary pressure on selectivity. Assuming the proposed model of C8-OH re-
moval on TmpB is correct, it would make sense if the TE domain was specific to C8-H
intermediates, thereby only releasing after conversion to the A form.
The TmpB TE domain could also be demonstrating substrate specificity towards
other parts of the molecule. One hypothesis, that the TmpB TE demonstrates speci-
ficity towards des-epoxy intermediates as would be seen in thiomarinol, was tested
and rejected in Section 4.2.4.2, as it was unable to offload PA-C.
In the future, it would be interesting and potentially impactful to the polyketide
field in general, to both determine if the TmpB TE domain is demonstrating specificity,
and if so what the structural basis for it is. This investigation could begin with the
cloning, expression and affinity purification of the TmpB TE domain from a suitable
vector such as pET28a. Then, its ability to catalyse the release of different mupirocin
and thiomarinol related compounds as N-acetylcysteamine (SNAC) thioesters could
be tested.
There are no close homologs to the either the MmpB or TmpB TE domains in the
PDB of solved structures. HHPRED searches of the PDB identified the best structures
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as NRPS thioesterase domains from tyrocidine synthetase 3 (4ZXI) and enterobactin
synthase F (3TEJ), at 16 and 17% amino acid similarity. This similarity is too low
for homology modelling to give any useful insight into the specificity differences.
However, it makes the solving of the X-ray structures of these thioesterase domains a
useful and impactful objective.
4.3.3.2 MmpB/TmpB hybrid I may form a heterodimer with MmpB
It is well established that PKS enzymes form homodimers, and attempts have
been made to identify the regions responsible for this dimerisation. NMR analysis
of DEBS enzymes revealed regions of hydrophobicity thought to be responsible for
stabilising dimerisation (Broadhurst et al., 2003), whereas a dimersation motif before
the KR domain has been reported in spinosyn (Zheng et al., 2013).
The results with MmpB/TmpB hybrid I provide evidence for heterodimer forma-
tion with WT MmpB (Figure 4.53). The TmpB TE in hybrid I proved non-functional,
and was unable to complement a chromosomal TE in-frame deletion mutant. How-
ever, hybrid I was observed to complement mmpB∆ACP567. In this scenario, the in
trans hybrid I lacks a functional TE domain, whereas the chromosomal MmpB lacks
ACP domains. To generate PA-A as observed, domains from both the plasmid and
chromosome must function on the same molecule. One explanation is the TE domain
is able to function in trans on the chromosomal copy lacking ACPs. Another possibil-
ity is that these form a heterodimer, using the ACP domains from the chromosomal
copy and the TE from the hybrid.
This seems the most likely explanation, as PKS enzymes are known to form
homodimers. Similar heterodimers have been reported in pikromycin PKS, PikAIV,
where a chromosomal TE deletion was complemented by inactive hybrids carrying
a functional TE, with the conclusion that the ketosynthase domain is responsible for
dimerisation (Chen et al., 2000).





Plasmid: MmpB/TmpB hybrid II (JC58)
Chromosome: MmpBΔACP567
Chromosome: MmpBΔACP567
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Figure 4.53: Evidence of heterodimer formation between MmpB variants.
MmpB domains are shown in blue, TmpB in red.
(c) Hybrid I is unable to complement a chromosomal MmpB TE deletion, which sug-
gests the TmpB TE domain is not functional.
(d) Hybrid I is able to complement a chromosomal ACP deletion, yet neither pep-
tide has all the domains required for function. This could be due to formation of
heterodimers between the ACP mutant MmpB and hybrid I.
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providing differing truncations in cis and in trans. A series of chromosomal MmpB N-
terminal truncations could be constructed alongside a series of C-terminal truncations
on pJH10. The ability of these to complement each other would yield insight into
regions responsible for dimerisation. Similar experiments have been performed in
fungal type I PKS ATX (Moriguchi et al., 2006).
4.3.4 Induction of MmpB expression by IPTG is inhibitory to pro-
duction of mupirocin
Throughout all the experiments reported in this chapter, induction of expression
of MmpB and its hybrid derivatives have proven inhibitory to mupirocin production.
IPTG is used to induce the tac promoter in pJH10 derivatives, where it relieves LacI
repression at the lac operator. This effect is not observed with empty pJH10 under
IPTG induction, and therefore must be due to the MmpB expression.
The effect was best characterised in Section 4.2.1.3, where MmpB was expressed
from pJH10/mmpB in P. fluorescens WT. Induction at 50 µM IPTG was partially
inhibitory, whereas 500 µM IPTG was observed completely inhibitory to detectable
mupirocin production.
One possible explanation is that MmpB needs to be expressed to a specific level
relative to the later tailoring enzymes, assuming MmpB interacts with these enzymes.
In such a scenario, the majority of MmpB enzymes would not carry intermediates,
and these unloaded proteins could interact with MupU, effectively sequestering the
loaded MmpB from interacting with its downstream partners. However, this would
presumably generate PA-B, with a phenotype similar to P. fluorescens ∆mupU. Induc-
tion of MmpB expression in 10586 WT yielded less PA-A with more IPTG, but no
increase in PA-B as detected by HPLC analysis.
A more likely explanation is that overexpression of MmpB sequesters MmpC,
therefore inhibiting the activity of MmpA and MmpD. MmpC holds the trans acting
AT domains, without which no extender units should be loaded. This hypothesis
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would predict no pseudomonic acid production with MmpB overexpression, and
as such seems the most likely explanation for this effect. This could be tested by
increasing MmpC expression together with MmpB.
Finally, the transition from no inhibition to significant inhibition occurred over
the range of 10 to 50 µM IPTG (Figure 4.10b). Whilst there is no guarantee this
will hold true for all genes expressed from pJH10, it is a useful starting point for
other experiments. Typically, most experiments involving expression from pJH10
have been performed with no IPTG induction, 0.1 mM or 0.5 mM (Hothersall et al.,
2007; Omer-Bali, 2013; Gurney and Thomas, 2011; Alsammarraie, 2016). These results







There is a well-established current need for new clinical antibiotics, and in par-
ticular new compound scaffolds for drug discovery. Historically, natural products
have proven a major source of clinical antibiotics, often with chemical modification
to improve the drugs in various ways. One pathway to the identification of new
antibiotics is the modification of existing clinical antibiotics such as mupirocin.
The work reported in this thesis was undertaken with the aim of contributing to a
wider goal of the Thomas group, the generation of in vivo mupirocin non ribosomal
peptide (NRP) derivatives. These derivatives would be generated on MmpB, which in
the mupirocin biosynthesis pathway is proposed to carry the inactive PA-B. Therefore,
the main goal of this work arose: in vivo re-engineering of late-stage mupirocin
biosynthesis so that conversion to active PA-A occurs on MmpB. This could facilitate
the in vivo generation of NRP-conjugated derivatives of the active PA-A in the future.
5.2 Key conclusions and future work
5.2.1 All mupirocin biosynthetic cluster genes required for conver-
sion of PA-B to PA-A have been identified
In the work described in Chapter 3, experiments were performed with the aim of
characterising the surprisingly convoluted conversion pathway between PA-B and PA-
A. A systematic screen was developed for the ability of P. fluorescens NCIMB10586
mutants to convert PA-B to PA-A. This screen identified 11 genes which, when
mutated, were deficient in conversion (Figure 3.12). A series of multi-gene expression
plasmids were developed, culminating in pJC133, which carried the 10 mupirocin
biosynthesis genes identified by the screen (transcriptional regulator mupR was not
included). This plasmid encoded all functions necessary for conversion of PA-B to
PA-A in 10586 ∆mup-cluster, and this represented the first evidence that all mupirocin
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biosynthetic cluster genes responsible for conversion of PA-B to PA-A have been
identified. However, as discussed in Section 3.3.1.2, no conversion was observed in P.
fluorescens SBW25 with pJC133.
In the screening experiments, a reproducibly variable defect in PA-B conversion
was observed in 10586 ∆mupL. Inactivation of mupL in pJC133 by point mutation
demonstrated its enzymatic activity is not required for conversion of PA-B to PA-A.
However, no conversion was observed without mupL in the multi-gene expression
plasmid. Fortunately, the gene downstream of mupL is the self-resistance encoding
mupM, which allowed for assay of expression levels by determination of mupirocin
resistance. These experiments supported the presence of a non-MupR regulated
promoter within mupL, which increases expression of mupM and mupN.
The results of both the systematic screen and pJC133-encoded conversion sup-
ported the current proposed PA-B to PA-A conversion pathway (Figure 3.41) (Gao
et al., 2017). These results provided evidence of a novel requirement for conversion
for MupM (IleRS, self-resistance) and MupN (phosphopantetheinyl transferase). As
the only ACP required is MacpE, this also represents the first evidence that MacpE is
completely reliant on MupN for activation, whereas other mupirocin ACPs are not
all reliant on MupN (Shields et al., 2010).
Historically, MupV has been annotated as a single domain enzyme (SDR), thought
responsible for catalysing release of late-stage mupirocin intermediates from MacpE
(Thomas et al., 2010; Gurney and Thomas, 2011; Gao et al., 2014; Cooper et al.,
2005; El-Sayed et al., 2003). However, bioinformatic re-analysis revealed a second
domain (TE). In this work, inactivation of either of these domains by point mutation
demonstrated the enzymatic activity of both is required for conversion of PA-B to
PA-A. It is not clear what additional function MupV could perform, or whether both
domains are required for its proposed role in release from MacpE.
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5.2.1.1 Proposed model: Tailoring from PA-B to PA-A could occur entirely on
MacpE
The Thomas-Simpson partnership have previously hypothesised that conversion
to mupirocin P occurs on MacpE, after which MupV catalysed release occurs. MupP,
MupC and MupF are then proposed to act on free standing intermediates (Gao et al.,
2017). This is supported by the conversion of fed mupirocin C1 to PA-A observed in
10586 ∆macpE. However, this author believes it is more likely all tailoring from PA-B
to PA-A occurs on MacpE; a comparison of these hypotheses is presented in Figure
5.1. In 10586 WT, PA-A (90%) and PA-B (5-8%) are produced but not mupirocin C1,
P or F. If mupirocin P, C1 or F were released from MacpE, as proposed in Gao et al.
(2017), then there should be evidence of production of mupirocin P, C1 or F at a
readily detectable scale in 10586 WT, as PA-B is. It is possible, and would be more
functionally efficient that MupV has a gatekeeping function, specifically catalysing
the release of PA-A from MacpE. Indeed, this would explain the production of
only PA-A and no PA-B by generation III MmpB/TmpB hybrid JC119, which lacks a
thioesterase domain (Section 4.2.5.3).
It is important to note that in this proposed model, PA-B generated on MmpB
would be converted to the final PA-A on MacpE, but not obligately so for all steps.
The conversion of PA-B to mupirocin P obligately requires MacpE, but externally fed
Mupirocin C1 has been observed to be processed to PA-A in the absence of MacpE
(Gao et al., 2014).
In Thomas et al. (2010), published before the MupP function was uncovered,
the MupC- and MupF-catalysed steps are pictured occurring on an unknown ACP,
labelled ACPX. This hypothesis follows a similar logic to B), that these steps would
occur on a carrier protein to facilitate efficient conversion. We have now putatively
assigned all the ACPs in the mupirocin pathway to functions, so it seems the best
candidate is for MacpE to perform all the conversion steps.
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Figure 5.1: Proposed models of PA-B to PA-A conversion on MacpE.
A) Our recent publications on this part of the pathway have depicted conversion from mupirocin P onwards occuring after
release from MacpE (Gao et al., 2014, 2017). However no detectable mupirocin P, C or F is produced by 10586 WT.
B) In this work, an alernative hypothesis is proposed where all tailoring steps from PA-B to PA-A occur whilst the intermediates
are still on MacpE.
The key evidence in support of model B) instead of A) is lack of mupirocin P, C or F produced by 10586 WT, whereas PA-B and
PA-A are produced at significant scales. Further to this, it is possible the tailoring enzymes could form a complex with MacpE
as shown, although there is no direct evidence for or against this.
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A further prediction: MupU could interact with the TE of MmpB
The thiomarinol homolog of MupU, TmlU, has been demonstrated to bind the
MmpB thioesterase domain by the bacterial two hybrid system (Alsammarraie, 2016).
Furthermore, expression of tmlU in 10586 caused a switch to C8-OH intermediates
with truncated fatty acids, which indirectly also supports a TmlU-MmpB interaction
(Omer-Bali, 2013; Alsammarraie, 2016). In mupirocin biosynthesis, 90% of all pseu-
domonic acid produced by the endogenous pathway is converted to PA-A, whereas
only around 40% of exogenous fed PA-B is converted to PA-A (Section 3.2.2.2). It
is possible MupU also interacts with MmpB, which would tether PA-B production
and conversion to PA-A in physical space in the cell. In this model a complex of
these tailoring enzymes would form, allowing for the efficient production of PA-A
observed in the cell to occur. This is supported by the need for MupU for PA-A
conversion on generation III MmpB/TmpB hybrid JC120, where the normal MupU
function should be provided by the KS0 domain (Section 4.2.5.3).
5.2.1.2 Future work: In vitro investigation of the mupirocin PA-B to PA-A tailor-
ing pathway
In vitro analysis of this tailoring pathway is an attractive prospect that could
answer the remaining questions and appraise the current model. Each of MupO,
MupP, MacpE, MupC, MupF, MupU, MupV, and MupN could be cloned individually
to a suitable protein expression vector such as pET28a. In this example vector, each
protein would be expressed from E. coli BL21, and nickel affinity purified using
terminal His tags.
The logical starting objective would be the generation of holo-MacpE followed
by its loading with PA-B. The expressed apo-MacpE is inactive as it lacks the phos-
phopantetheine arm on which it holds substrates. Activation could be achieved by
co-incubation of apo-MacpE, MupN (or Sfp), and coenzyme A. MupN (phosphopan-
tetheinyl transferase) should catalyse the transfer of 4’-phosphopantetheine from CoA
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to MacpE, generating the active holo form. Co-incubation of holo-MacpE, MupU, PA-B
and ATP would hopefully result in MupU-catalysed loading of PA-B onto MacpE,
which could be monitored by HPLC or LC-MS.
Once MacpE carrying PA-B had been generated, co-incubation with each of the
other enzymes could be performed to confirm the pathway proposed in Gao et al.
(2017), generating mupirocin P, C, F then PA-A successively. In Chapter 4, conversion
was observed to occur with MmpB/TmpB hybrid generation III only when MupU
was present, although the MupU function should be performed by the KS0. Therefore,
it would be intriguing to test whether conversion of PA-B on MacpE to PA-A could
proceed without MupU present.
The proposed MupV role of catalysing release from MacpE could also be investi-
gated. MacpE loaded with either PA-B, mupirocin P, mupirocin C, mupirocin F and
PA-A could be co-incubated with MupV to test its role and determine any specificity.
Furthermore, expression of the mupV point mutants could determine the role of each
domain.
Finally, protein-protein interaction experiments, such as co-immunoprecipitation,
could be used to test for interactions between these enzymes. For example, MupU
could be generated with a FLAG affinity tag, and mixed with His-tagged MacpE.
Nickel bead purification of MacpE should also capture MupU if there is an interaction,
and this could be detected by Western blots using FLAG antibodies conjugated to a
reporter.
5.2.2 Re-engineering of late-stage mupirocin biosynthesis has been
achieved
In Chapter 4, successive generations of hybrids between MmpB and TmpB were
generated with the aim of achieving the key goal of this work: re-engineering of
mupirocin biosynthesis such that C8-OH removal occurs on MmpB. In the PA-B pro-
ducer 10586 ∆mupU, restoration of 12% PA-A as a proportion of total pseudomonic
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acids was achieved with generation II hybrid, JC58, with tmlO, tmlP, tmlC and tmlF
expressed in trans (Section 4.2.4.3). MmpB/TmpB hybrid generation II has the TmpB
module 2 ACP positioned behind the KS0 domain as it is in TmpB. Without MupU, no
PA-B should be loaded onto MacpE, and no MupO-catalysed conversion to mupirocin
P should occur. Instead, it seems likely that the equivalent steps have been achieved
on the module 2 ACP using the thiomarinol enzymes. This represents the first exper-
imental evidence supporting the proposed hypothesis of C8-OH removal occurring
on TmpB in thiomarinol biosynthesis.
Restoration of conversion was also achieved with MmpB/TmpB hybrid generation
III, which have MacpE in the second module. In 10586 ∆mmpB ∆macpE, generation III
hybrids JC119 (no TE) and JC120 (MmpB TE) were observed to restore 40% and 124%
PA-A respectively as a proportion of 10586 WT PA-A (Section 4.2.5.3). Without a
chromosomal copy of macpE, all PA-B to PA-A conversion steps that would normally
occur on MacpE have been successfully re-engineered to occur on the generation III
hybrids. As proposed in Section 5.2.1.1, it is possible all conversion to PA-A occurs on
MacpE, and that PA-A is released from hybrid generation III. However, release of an
earlier intermediate, such as mupirocin P, and subsequent tailoring off of the hybrid
cannot be ruled out. Regardless, these results represent promising progress towards
the longer term goal of generation of a PA-A NRP derivative through coupling of
NRPS domains to MmpB.
5.2.2.1 The thiomarinol KS0 proved a useful tool for re-engineering mupirocin
biosynthesis
The TmpB KS0 domain from thiomarinol biosynthesis has proven an effective tool
for the transfer of mupirocin intermediates to an extra ACP. KS0-mediated transfer
was demonstrated when the inactivation of the KS0 by point mutation decreased
the PA-B throughput on JC58 to 10% (Section 4.2.3.4). Furthermore, the successful
re-engineering of tailoring steps to occur on the TmpB ACP in generation II hybrids,
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and MacpE in generation III hybrids, indirectly demonstrates the KS0 function in
loading these ACPs.
























Figure 5.2: Substrates putatively accepted by the TmpB KS0 domain.
The KS0 appears to have sufficiently relaxed substrate specificity to accept PA-B,
although PA-B is fairly similar to its thiomarinol equivalent, marinolic acid B. The
structure of marinolic acid B can be logically predicted from the proposed thiomarinol
biosynthesis pathway (Figure 5.2). Marinolic acid B has C10,11-alkene, whereas PA-B
has C10,11-epoxide, and the fatty acid chain is one carbon longer in PA-B. Marinolic
acid B may also have C4-OH, although the timing of installation of this hydroxyl by
TmuB is not yet known (Mohammad, 2017).
The TmpB KS0 does not seems to demonstrate specificity towards the ACPs with
which it interacts. In generation II hybrid JC58, the KS0 is proposed to transfer
intermediates from MmpB ACPs to the TmpB ACP that the KS0 would natively load
in thiomarinol biosynthesis. However, in generation III hybrids JC119 and JC120, the
KS0 may transfer from MmpB ACPs to MacpE, neither of which the KS0 domain has
co-evolved with. This KS0 domain therefore demonstrates some promise as a useful
tool for manipulating PKS pathways in vivo.
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5.2.2.2 Ongoing and Future work on coupling NRPS biosynthesis to MmpB/TmpB
hybrids
Now that conversion to PA-A has seemingly been achieved on MmpB/TmpB
hybrids, the next step towards coupling to NRPS biosynthesis is to install a third
module. We decided to generate an MmpB/TmpB hybrid generation IV, where
module 1 synthesises 9-HN, module 2 is the site of C8-OH removal, and module
3 would later be the coupling point to NRPS biosynthesis (Figure 5.3). Hybrid
generation IV was designed primarily by Amber Wilson1, and re-used the thiomarinol
KS0-ACP module amino acid sequence, whilst taking advantage of degeneracy to
change the DNA sequence.
(a) JC150
Module 2 Module 3
(b) JC151
Module 2 Module 3
Figure 5.3: Domain overview of MmpB/TmpB hybrid generation IV.
Preliminary results with these hybrids have been promising, both are able to
complement MmpB function, and conversion to PA-A was observed in 10586 ∆macpE
with JC150. These new generation IV hybrids now need to be thoroughly tested
as generations II and III were. If the model of competing rates of reaction between
tailoring enzymes and the TE proposed in Section 4.3.2.1 is correct, then addition
of the third module could increase the proportion of PA-A conversion before TE-
catalysed release. A point mutation could be introduced to the KS0 of either module
2 or 3. With an inactivated module 2 KS0, the TE-skipping hypothesis (Figure 4.50)
would predict a more severe decrease in PA-B release than seen in the generation II
1MmpB/TmpB hybrid generation IV was designed primarily by Amber Wilson, in collaboration
with this author, Chris Thomas and Anthony Haines. Molecular construction was performed by both
Amber Wilson and this author.
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mutants.
Next a point mutation could be introduced to the active site serine of the module
3 ACP, and this would hopefully cause a decrease in PA-B release from the hybrid. If
this mutant did generate a phenotype, then the module 3 ACP could be replaced with
a variety of ACPs from other systems, and their functionality in the hybrids assayed
by PA-B production. The ACPs used would be taken from PKS-NRPS junctions in
nature, such as DptF from daptomycin (fatty acid-NRPS) (Wittmann et al., 2008). Of
particular interest would be NRPS pathways that generate chromogenic products,
such as indigoidine (Reverchon et al., 2002).
Significant challenges remain before a successful in vivo mupirocin-NRP is gen-
erated, such as the manner of release from hybrids with NRPS components. Con-
structions need to be designed in such a manner that the function, or lack of function,
of any components added can be appraised. The NRPS C domain used will need
to accept pseudomonic acid as a substrate, and be able to interact with its native
ACP fused to MmpB/TmpB. It is also even possible that generation of a new deriva-
tive compound with alternate mode of action would be self-inhibitory to the 10586
host, which would lack evolved resistance. Generation of in vivo mupirocin-NRP
derivatives remains an ambitious goal, although the work reported in this thesis
demonstrates there is some scope for modifying mupirocin biosynthesis in vivo.
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